data_2zaj_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2zaj _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.457 ' CD2' ' ND2' ' A' ' 42' ' ' ASN . 13.3 mt . . . . . 0 C--O 1.23 0.071 0 CA-C-O 121.557 0.694 . . . . 0.0 110.953 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.6 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.85 -175.55 1.22 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.611 2.208 . . . . 0.0 112.313 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.26 146.76 53.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.09 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.402 ' CA ' ' CD1' ' A' ' 34' ' ' ILE . . . 89.5 -44.26 3.05 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.497 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.6 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -69.7 142.32 53.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.735 0.302 . . . . 0.0 110.904 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -153.29 114.67 4.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.922 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.71 144.26 47.74 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.919 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.57 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 41.9 mm -128.17 130.62 69.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.177 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -104.97 117.86 35.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.859 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -137.84 139.78 27.52 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.624 0.726 . . . . 0.0 110.878 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.415 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.2 Cg_endo -69.83 -7.96 22.39 Favored 'Trans proline' 0 C--O 1.233 0.237 0 C-N-CA 122.646 2.231 . . . . 0.0 112.302 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 96.4 t -113.83 -38.01 2.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.081 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.8 m-85 -98.08 -30.79 12.47 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.941 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.26 -142.91 18.43 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.527 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.557 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.8 mp -99.64 111.46 29.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.848 0.356 . . . . 0.0 111.116 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.57 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 39.2 p90 -137.2 131.54 32.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.978 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.43 ' CD2' HD11 ' A' ' 14' ' ' LEU . 5.5 m-30 -88.98 123.6 33.47 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.925 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.415 ' CG2' ' CE2' ' A' ' 29' ' ' TYR . 10.8 t -110.2 116.57 52.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.148 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.407 ' OD2' ' NE1' ' A' ' 18' ' ' TRP . 51.5 t0 -95.77 106.09 18.17 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.929 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -71.36 -14.27 62.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.819 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.555 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 0.9 OUTLIER -85.98 -62.34 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.158 179.971 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.424 ' C ' ' HD3' ' A' ' 36' ' ' ARG . 28.0 m-80 -80.65 -13.81 58.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.852 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.424 ' HD3' ' C ' ' A' ' 35' ' ' ASN . 1.8 mpp_? 63.09 46.25 4.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -128.03 154.75 45.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.855 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.7 p -129.45 117.95 21.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.133 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.472 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.1 pt20 -149.66 141.86 24.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.956 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . 0.557 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.81 -25.99 59.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.922 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 -63.06 160.77 14.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.94 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.457 ' ND2' ' CD2' ' A' ' 14' ' ' LEU . 9.9 t-20 -115.48 102.02 54.33 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.589 0.709 . . . . 0.0 110.849 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.472 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.4 Cg_endo . . . . . 0 C--N 1.341 0.16 0 C-N-CA 122.705 2.27 . . . . 0.0 112.322 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.494 HD13 ' CD2' ' A' ' 30' ' ' TYR . 11.0 mt . . . . . 0 C--O 1.23 0.052 0 CA-C-O 121.603 0.716 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.616 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.2 Cg_endo -69.7 -172.74 0.6 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.668 2.245 . . . . 0.0 112.349 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.58 148.62 51.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.093 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.91 -41.39 3.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.492 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.616 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.0 m95 -71.3 143.68 50.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.65 0.262 . . . . 0.0 110.956 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 30.3 tp10 -154.3 113.49 3.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.847 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.95 139.8 46.99 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.934 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.57 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 34.7 mm -122.76 129.12 75.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.164 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -101.97 117.92 35.82 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.896 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.447 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.7 t70 -139.01 139.16 22.57 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.614 0.721 . . . . 0.0 110.836 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -9.81 27.01 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.72 2.28 . . . . 0.0 112.372 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.4 t -111.54 -37.94 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.123 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.413 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -97.79 -32.1 11.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.967 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.27 -144.67 18.66 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.455 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.485 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.0 mp -98.62 109.81 24.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.781 0.325 . . . . 0.0 111.105 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.57 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 36.9 p90 -136.16 130.75 33.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.494 ' CD2' HD13 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.78 124.35 34.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.914 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.0 t -110.91 115.93 51.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.114 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.408 ' O ' ' N ' ' A' ' 36' ' ' ARG . 13.5 t0 -94.45 101.93 13.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.895 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -67.46 -18.38 65.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.504 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.1 mp -80.7 -63.35 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.15 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -81.14 -16.72 52.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.818 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.408 ' N ' ' O ' ' A' ' 32' ' ' ASP . 17.7 mmt180 64.89 47.98 2.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.544 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.0 OUTLIER -132.47 129.03 38.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.869 179.976 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.3 p -104.59 120.19 40.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.167 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.439 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.8 pt20 -150.11 140.91 22.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.932 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . 0.485 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.41 -23.77 59.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.908 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 55.7 mm-40 -64.86 158.28 25.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.909 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.445 ' ND2' ' HG ' ' A' ' 14' ' ' LEU . 12.0 t-20 -115.32 102.0 54.46 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.665 0.745 . . . . 0.0 110.896 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.439 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.1 Cg_endo . . . . . 0 C--N 1.342 0.209 0 C-N-CA 122.713 2.276 . . . . 0.0 112.335 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.422 ' CD2' ' ND2' ' A' ' 42' ' ' ASN . 15.1 mt . . . . . 0 C--O 1.231 0.111 0 CA-C-O 121.586 0.708 . . . . 0.0 110.923 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.621 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.3 Cg_endo -69.74 -172.19 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.605 2.203 . . . . 0.0 112.376 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.19 146.63 54.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.071 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.418 ' CA ' ' CD1' ' A' ' 34' ' ' ILE . . . 88.54 -40.7 3.06 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.467 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.621 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -72.64 142.66 48.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.733 0.301 . . . . 0.0 110.895 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -153.4 115.51 4.34 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.882 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -74.22 140.99 45.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.553 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 38.1 mm -123.87 129.73 74.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.163 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.2 mt-10 -103.79 117.88 35.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.871 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.449 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.1 t70 -139.12 139.67 24.0 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.568 0.699 . . . . 0.0 110.905 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.421 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.6 Cg_endo -69.77 -9.48 26.2 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.627 2.218 . . . . 0.0 112.38 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 95.6 t -111.78 -38.04 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.13 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -97.91 -31.49 12.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.959 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.3 -145.73 19.86 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.456 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.598 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.7 mp -97.1 110.01 24.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.821 0.343 . . . . 0.0 111.198 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.553 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 34.9 p90 -137.37 130.62 30.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.901 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.451 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 3.0 m-30 -89.02 126.85 35.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.931 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.6 t -112.67 116.13 51.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.115 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.463 ' O ' ' N ' ' A' ' 36' ' ' ARG . 10.4 t0 -93.56 102.16 14.35 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.821 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 -68.0 -17.14 64.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.889 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.516 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.1 mp -82.46 -58.17 3.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.127 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -87.34 -14.29 41.16 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.887 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.463 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.2 mpt_? 62.59 47.99 4.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.79 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.45 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.0 OUTLIER -130.93 126.94 37.4 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.941 179.952 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.6 p -102.35 119.34 38.65 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.107 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.456 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.0 pt20 -149.65 141.83 24.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.961 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . 0.598 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 3.0 m-85 -76.02 -24.6 55.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.89 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 25.7 mm-40 -62.93 161.25 13.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.422 ' ND2' ' CD2' ' A' ' 14' ' ' LEU . 8.8 t-20 -116.36 102.1 53.61 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.616 0.722 . . . . 0.0 110.867 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.456 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.3 Cg_endo . . . . . 0 C--N 1.341 0.179 0 C-N-CA 122.655 2.237 . . . . 0.0 112.316 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.461 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 11.9 mt . . . . . 0 C--O 1.231 0.119 0 CA-C-O 121.619 0.723 . . . . 0.0 110.937 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.617 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.71 -175.82 1.27 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.677 2.251 . . . . 0.0 112.361 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.31 143.37 57.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.113 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.445 ' CA ' HD12 ' A' ' 34' ' ' ILE . . . 93.21 -41.49 2.69 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.543 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.617 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 60.4 m95 -72.69 137.75 46.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.721 0.296 . . . . 0.0 110.932 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -151.1 114.46 4.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.92 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.92 145.12 48.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.879 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.563 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 44.6 mm -129.13 131.76 67.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -106.57 117.99 35.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.851 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.424 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.6 t70 -138.54 139.65 25.36 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.608 0.718 . . . . 0.0 110.884 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.414 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.5 Cg_endo -69.74 -7.22 20.48 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.609 2.206 . . . . 0.0 112.362 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 95.2 t -114.49 -38.01 2.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.404 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.9 m-85 -98.29 -31.08 12.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.867 -179.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.02 -144.27 19.29 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.416 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 1.8 mp -97.15 111.29 26.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.783 0.325 . . . . 0.0 111.145 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.563 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 32.0 p90 -139.18 131.35 28.13 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.935 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.481 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.05 128.25 35.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.947 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.9 t -113.06 115.86 50.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -95.62 102.41 14.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.883 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 60.6 m-70 -69.51 -14.4 62.85 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.86 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.574 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.0 OUTLIER -87.16 -60.94 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.132 -179.981 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 21.0 m-20 -82.63 -15.19 53.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 13.1 mmm180 62.38 47.58 5.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.79 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.566 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 4.8 ptpp? -130.48 129.11 42.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.897 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -107.64 121.58 44.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.181 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.472 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.9 pt20 -150.05 141.86 23.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.881 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.2 m-85 -72.33 -26.99 62.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.903 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.435 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 6.1 mm-40 -68.99 162.99 25.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.946 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.468 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 1.9 t-20 -122.13 108.66 34.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.661 0.744 . . . . 0.0 110.862 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.472 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.1 Cg_endo . . . . . 0 C--N 1.341 0.179 0 C-N-CA 122.698 2.265 . . . . 0.0 112.35 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.428 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 11.8 mt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 121.63 0.729 . . . . 0.0 110.899 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.617 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.3 Cg_endo -69.77 -174.58 0.94 Allowed 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.663 2.242 . . . . 0.0 112.314 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.23 143.74 57.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.071 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.437 ' CA ' HD11 ' A' ' 34' ' ' ILE . . . 93.15 -41.64 2.68 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.617 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 60.6 m95 -72.42 137.76 46.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.73 0.3 . . . . 0.0 110.955 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -151.35 117.06 5.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.835 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.53 143.55 42.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.916 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.561 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 45.0 mm -127.09 131.89 70.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.121 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -104.94 117.69 34.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.848 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.418 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -137.99 138.5 23.62 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.652 0.739 . . . . 0.0 110.899 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -6.62 19.04 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.689 2.259 . . . . 0.0 112.267 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 90.7 t -115.2 -38.02 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.133 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.42 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.8 m-85 -98.1 -31.23 12.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.925 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.04 -145.45 19.23 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.45 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.407 HD12 ' N ' ' A' ' 28' ' ' ILE . 2.0 mp -97.41 111.6 27.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 111.086 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.561 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.7 p90 -138.57 132.83 31.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.896 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.481 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.84 128.52 36.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.945 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.8 t -113.43 115.82 50.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.116 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -94.54 102.12 14.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.892 179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 70.2 m-70 -68.99 -12.86 62.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.599 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 0.9 OUTLIER -89.0 -60.39 2.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.134 179.958 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -83.01 -18.6 39.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.809 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.6 mmm180 65.67 48.05 2.03 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.565 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 14.9 ptpt -130.53 131.16 44.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -109.25 120.29 42.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.118 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.467 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 6.9 pt20 -149.43 140.89 23.32 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.965 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -71.19 -24.6 62.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.941 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.405 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 8.0 mt-10 -69.76 161.1 30.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.458 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 1.9 t-20 -122.75 105.45 35.4 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.637 0.732 . . . . 0.0 110.913 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.467 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.5 Cg_endo . . . . . 0 C--N 1.341 0.18 0 C-N-CA 122.73 2.286 . . . . 0.0 112.391 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.481 HD13 ' CD2' ' A' ' 30' ' ' TYR . 14.5 mt . . . . . 0 C--O 1.232 0.138 0 CA-C-O 121.59 0.71 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.615 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.1 Cg_endo -69.7 -173.85 0.79 Allowed 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.683 2.255 . . . . 0.0 112.392 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.73 149.29 49.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.098 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.412 ' CA ' ' CD1' ' A' ' 34' ' ' ILE . . . 86.05 -42.4 3.15 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.503 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.615 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.2 m95 -70.39 139.19 51.82 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.685 0.279 . . . . 0.0 110.916 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 29.4 tp10 -149.49 113.87 5.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.846 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.85 144.79 50.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.896 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.569 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 33.9 mm -128.27 130.97 69.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.126 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -105.6 118.59 36.97 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.91 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.432 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.14 139.56 21.47 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.669 0.747 . . . . 0.0 110.845 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.41 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.6 Cg_endo -69.74 -8.65 24.14 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.751 2.301 . . . . 0.0 112.336 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 91.3 t -112.68 -38.04 2.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.113 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.417 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.22 -32.45 11.56 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.927 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.4 -144.62 18.55 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.505 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.6 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.9 mp -97.99 109.59 23.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.811 0.338 . . . . 0.0 111.195 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.569 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 38.4 p90 -135.34 130.96 35.81 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.95 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.481 ' CD2' HD13 ' A' ' 14' ' ' LEU . 3.9 m-30 -88.65 121.44 31.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.981 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.7 t -107.96 116.36 51.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.151 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -96.03 102.59 14.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 60.6 m-70 -68.26 -18.14 64.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.902 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.503 ' CD1' ' N ' ' A' ' 34' ' ' ILE . 1.1 mp -81.39 -63.42 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -79.22 -18.46 52.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.902 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.474 ' NE ' ' HA ' ' A' ' 36' ' ' ARG . 0.1 OUTLIER 66.61 47.77 1.56 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 -179.971 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.485 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 6.3 ptpt -134.5 130.72 37.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.876 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.8 p -106.05 119.99 40.63 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.19 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.4 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.7 pt20 -149.99 141.76 23.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.926 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . 0.6 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -75.05 -25.42 58.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.914 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -62.74 158.18 19.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.834 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.444 ' ND2' ' CD2' ' A' ' 14' ' ' LEU . 9.2 t-20 -114.28 101.9 54.45 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.522 0.677 . . . . 0.0 110.915 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.4 ' HD2' ' CD2' ' A' ' 14' ' ' LEU . 53.9 Cg_endo . . . . . 0 N--CA 1.465 -0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.376 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.57 HD13 ' CD2' ' A' ' 30' ' ' TYR . 11.5 mt . . . . . 0 C--O 1.232 0.139 0 CA-C-O 121.569 0.699 . . . . 0.0 110.887 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.613 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.7 -171.73 0.5 Allowed 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.69 2.26 . . . . 0.0 112.368 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.23 147.32 52.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.106 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.429 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 88.58 -40.39 3.08 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.483 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.613 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 57.3 m95 -73.3 130.55 40.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.674 0.273 . . . . 0.0 110.887 -179.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -137.28 113.29 9.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.883 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.58 144.56 41.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.843 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.531 ' HB ' ' CZ ' ' A' ' 29' ' ' TYR . 29.9 mm -130.62 132.8 64.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.181 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -104.38 120.28 40.87 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.899 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.43 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.69 137.54 17.47 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.668 0.747 . . . . 0.0 110.876 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -7.68 21.66 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.654 2.236 . . . . 0.0 112.416 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.9 t -113.47 -37.95 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.218 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.417 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.14 -31.69 11.98 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.893 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.48 -148.19 20.43 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.435 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.446 HD12 ' N ' ' A' ' 28' ' ' ILE . 1.9 mp -96.39 109.17 22.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.862 0.363 . . . . 0.0 111.122 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.531 ' CZ ' ' HB ' ' A' ' 21' ' ' ILE . 37.9 p90 -133.31 131.07 39.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.57 ' CD2' HD13 ' A' ' 14' ' ' LEU . 4.7 m-30 -88.21 123.59 33.0 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.935 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.6 t -109.44 115.77 50.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.067 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.449 ' O ' ' N ' ' A' ' 36' ' ' ARG . 9.8 t0 -94.64 102.03 13.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 76.1 m-70 -68.55 -16.15 63.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.856 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.502 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.1 mp -83.27 -58.6 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.176 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -87.42 -14.12 41.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.853 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 32' ' ' ASP . 4.1 mpt_? 62.73 47.47 4.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.919 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.561 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 5.6 ptpt -128.77 130.02 46.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.4 p -107.34 118.56 37.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.136 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.419 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 6.2 pt20 -150.07 142.99 24.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.889 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -75.12 -26.44 59.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.904 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 23.7 mm-40 -62.01 161.17 11.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.426 ' ND2' ' CD2' ' A' ' 14' ' ' LEU . 12.7 t-20 -116.77 102.28 53.19 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.657 0.741 . . . . 0.0 110.891 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.436 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.154 0 C-N-CA 122.706 2.271 . . . . 0.0 112.34 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.44 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 14.5 mt . . . . . 0 C--O 1.232 0.139 0 CA-C-O 121.577 0.703 . . . . 0.0 110.926 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.63 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.0 Cg_endo -69.72 -175.78 1.26 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.702 2.268 . . . . 0.0 112.321 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.46 144.26 57.16 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.415 ' CA ' ' CD1' ' A' ' 34' ' ' ILE . . . 92.03 -40.82 2.86 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.501 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.63 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 63.8 m95 -73.04 135.27 44.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.769 0.319 . . . . 0.0 110.908 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -149.52 114.98 5.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.889 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.41 143.68 48.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.901 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.538 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 45.8 mm -127.02 131.67 70.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.125 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -104.84 117.74 34.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.92 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.417 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.9 t70 -139.15 139.13 22.2 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.591 0.71 . . . . 0.0 110.901 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -7.03 20.03 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.659 2.239 . . . . 0.0 112.372 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.6 t -114.5 -37.99 2.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.126 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.412 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.17 -31.81 11.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.94 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.57 -145.85 19.75 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.467 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.463 HD11 ' N ' ' A' ' 28' ' ' ILE . 2.0 mp -96.63 108.57 21.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.792 0.33 . . . . 0.0 111.123 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.538 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.3 p90 -135.97 132.1 35.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.476 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.06 125.05 34.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.93 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.9 t -110.5 115.78 50.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.176 179.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -95.44 102.04 13.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 66.9 m-70 -68.93 -14.15 62.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.534 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.1 mp -84.41 -63.26 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.169 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.403 ' CB ' ' HZ3' ' A' ' 37' ' ' LYS . 19.2 m-20 -82.6 -17.24 45.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.916 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 33.4 mmm-85 65.81 47.42 2.08 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.836 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.578 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 4.1 ptpp? -129.81 126.75 38.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.952 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.3 p -104.92 122.11 45.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.185 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.48 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 8.5 pt20 -150.01 140.02 21.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.88 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.2 m-85 -71.1 -26.11 62.9 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.908 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -69.05 160.27 31.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.849 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.454 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 2.0 t-20 -120.23 106.8 40.21 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.618 0.723 . . . . 0.0 110.887 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.48 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.4 Cg_endo . . . . . 0 C--O 1.231 0.173 0 C-N-CA 122.743 2.295 . . . . 0.0 112.347 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.567 HD12 ' CD2' ' A' ' 30' ' ' TYR . 13.3 mt . . . . . 0 C--O 1.231 0.09 0 CA-C-O 121.643 0.735 . . . . 0.0 110.879 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.636 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.68 -173.96 0.8 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.683 2.256 . . . . 0.0 112.367 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.42 149.64 48.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.122 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.417 ' CA ' ' CD1' ' A' ' 34' ' ' ILE . . . 84.52 -41.3 3.01 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.458 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.636 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 57.7 m95 -70.41 140.44 52.05 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.827 0.346 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -152.81 117.96 5.18 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.941 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.05 147.12 40.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.851 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.498 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 31.6 mm -131.01 132.04 63.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.161 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -105.16 117.8 34.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.883 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.405 ' O ' ' N ' ' A' ' 27' ' ' GLY . 8.9 t70 -138.05 137.47 21.22 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.606 0.717 . . . . 0.0 110.858 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.79 -4.04 13.24 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.651 2.234 . . . . 0.0 112.392 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.6 t -117.19 -38.03 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.123 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.425 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.56 -31.0 12.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.85 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.0 -146.08 18.94 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.436 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.582 ' O ' ' CE2' ' A' ' 40' ' ' TYR . 1.7 mp -98.43 108.3 21.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.849 0.357 . . . . 0.0 111.159 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.498 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 28.8 p90 -134.41 132.2 39.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.912 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.567 ' CD2' HD12 ' A' ' 14' ' ' LEU . 3.0 m-30 -88.65 122.53 32.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.925 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 t -107.78 115.89 49.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.129 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.462 ' O ' ' N ' ' A' ' 36' ' ' ARG . 57.6 t0 -95.15 101.95 13.73 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.861 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -68.57 -18.52 64.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.498 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.1 mp -82.14 -57.16 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.125 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -87.18 -14.88 39.94 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.874 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.462 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.3 mpt_? 62.23 47.73 5.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.853 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.559 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 5.0 ptpp? -131.5 132.49 44.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.854 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 7.1 p -108.05 118.35 36.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.12 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -150.05 139.14 21.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.919 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . 0.582 ' CE2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -74.26 -21.04 59.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.967 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 34.1 mp0 -65.99 156.9 32.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.888 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.409 HD21 ' CD2' ' A' ' 14' ' ' LEU . 7.4 t-20 -115.52 101.98 54.3 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.644 0.735 . . . . 0.0 110.968 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--N 1.342 0.208 0 C-N-CA 122.642 2.228 . . . . 0.0 112.339 -179.956 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 12.8 mt . . . . . 0 C--O 1.232 0.173 0 CA-C-O 121.579 0.704 . . . . 0.0 110.921 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.629 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.6 Cg_endo -69.77 -169.36 0.32 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.7 2.267 . . . . 0.0 112.326 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.98 153.74 41.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.443 ' CA ' HD11 ' A' ' 34' ' ' ILE . . . 82.24 -45.89 3.43 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.418 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.629 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 71.3 m95 -67.67 134.66 51.52 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.732 0.301 . . . . 0.0 110.896 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -149.92 113.99 5.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.02 142.72 43.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.917 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.532 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 19.0 mm -128.36 130.78 69.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.094 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -102.51 119.88 39.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.895 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.432 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.69 139.7 20.58 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 121.576 0.703 . . . . 0.0 110.896 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.42 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.9 Cg_endo -69.77 -7.8 21.99 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.692 2.261 . . . . 0.0 112.342 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.9 t -113.92 -37.92 2.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.179 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.436 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.5 m-85 -98.51 -31.61 11.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 86.78 -143.74 19.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.423 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.537 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -97.94 108.8 22.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.878 0.37 . . . . 0.0 111.162 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.532 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 39.7 p90 -135.11 131.95 37.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.905 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.442 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 3.3 m-30 -88.77 124.92 34.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.916 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -111.38 116.41 52.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.095 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.627 ' OD1' ' CE3' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -100.12 103.3 14.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 179.903 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 48.3 m-70 -68.83 -8.44 43.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.851 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.604 ' CD1' ' N ' ' A' ' 34' ' ' ILE . 0.9 OUTLIER -90.22 -62.81 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.156 179.995 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 7.4 m-80 -82.44 -19.91 38.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.915 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 19.6 mmm-85 66.28 47.39 1.82 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.901 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.406 ' HG3' ' OD2' ' A' ' 32' ' ' ASP . 0.1 OUTLIER -129.76 122.2 28.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.847 179.988 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.3 p -100.2 118.34 36.32 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.42 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 6.7 pt20 -148.98 141.34 24.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.95 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . 0.537 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -75.26 -24.45 57.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 -62.62 161.24 12.52 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 -120.3 102.02 46.17 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.625 0.726 . . . . 0.0 110.883 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.42 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.2 Cg_endo . . . . . 0 C--O 1.231 0.148 0 C-N-CA 122.709 2.273 . . . . 0.0 112.363 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.54 HD13 ' CD2' ' A' ' 30' ' ' TYR . 10.7 mt . . . . . 0 C--O 1.231 0.108 0 CA-C-O 121.603 0.716 . . . . 0.0 110.879 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.61 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.67 -171.71 0.49 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.606 2.204 . . . . 0.0 112.371 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.46 150.52 48.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.072 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.31 -43.92 3.31 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.755 -0.735 . . . . 0.0 112.46 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.61 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -68.66 141.62 55.31 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.751 0.31 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 23.2 tp10 -153.14 113.58 4.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.907 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.47 142.57 48.58 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.898 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.566 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 32.3 mm -127.38 130.76 70.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.105 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -103.81 117.88 35.38 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.928 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.42 ' O ' ' N ' ' A' ' 27' ' ' GLY . 9.8 t70 -138.17 139.36 25.39 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.511 0.672 . . . . 0.0 110.956 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.406 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 54.2 Cg_endo -69.77 -6.92 19.75 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.614 2.21 . . . . 0.0 112.367 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.2 t -114.21 -37.91 2.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.18 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.427 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.66 -32.31 11.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.47 -144.19 18.26 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.425 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.451 HD13 ' N ' ' A' ' 28' ' ' ILE . 1.9 mp -97.86 108.82 22.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.827 0.346 . . . . 0.0 111.128 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.566 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.3 p90 -135.78 131.19 35.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.933 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.54 ' CD2' HD13 ' A' ' 14' ' ' LEU . 2.9 m-30 -88.88 125.55 34.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.92 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.9 t -111.35 116.72 53.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.098 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.412 ' O ' ' N ' ' A' ' 36' ' ' ARG . 19.4 t0 -95.55 102.58 14.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 72.8 m-70 -67.93 -15.13 63.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.564 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.0 OUTLIER -85.02 -61.4 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 -179.998 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 21.4 m-20 -83.49 -15.41 49.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.902 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.412 ' N ' ' O ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER 62.9 47.99 4.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.848 179.957 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.559 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.1 OUTLIER -130.38 130.89 44.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.833 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 3.0 p -108.13 120.26 41.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.151 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.474 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 8.2 pt20 -150.01 140.71 22.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . 0.411 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -74.38 -21.75 59.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.89 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 21.6 mt-10 -67.94 161.41 26.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.844 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.439 ' ND2' ' CD2' ' A' ' 14' ' ' LEU . 12.0 t-20 -117.62 102.07 51.95 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.631 0.729 . . . . 0.0 110.839 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.474 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.0 Cg_endo . . . . . 0 C--N 1.342 0.228 0 C-N-CA 122.64 2.226 . . . . 0.0 112.363 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.565 HD11 ' CD2' ' A' ' 30' ' ' TYR . 12.5 mt . . . . . 0 C--O 1.232 0.151 0 CA-C-O 121.554 0.692 . . . . 0.0 110.938 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.627 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.71 -173.67 0.75 Allowed 'Trans proline' 0 C--N 1.34 0.094 0 C-N-CA 122.689 2.259 . . . . 0.0 112.373 179.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.4 148.77 51.14 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.063 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.413 ' CA ' ' CD1' ' A' ' 34' ' ' ILE . . . 86.64 -43.04 3.19 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.524 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.627 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.7 m95 -68.22 143.88 55.13 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.691 0.281 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -155.45 116.23 3.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.848 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.8 144.25 45.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.891 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.568 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 43.7 mm -128.11 130.69 69.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.151 179.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -104.74 117.82 35.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.0 t70 -138.15 139.69 26.48 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 121.589 0.709 . . . . 0.0 110.878 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.1 Cg_endo -69.82 -7.36 20.88 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.689 2.259 . . . . 0.0 112.38 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 86.4 t -114.12 -37.95 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.104 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.43 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.45 -31.54 11.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.913 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.84 -143.78 18.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.449 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.598 ' O ' ' CE2' ' A' ' 40' ' ' TYR . 1.7 mp -98.41 110.17 25.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.855 0.359 . . . . 0.0 111.151 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.568 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.1 p90 -136.93 131.69 33.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.98 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.565 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.84 124.34 34.09 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.885 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 t -110.3 115.97 51.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.116 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -95.33 102.72 14.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.813 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -69.16 -17.31 63.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.507 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.1 mp -82.2 -62.67 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.185 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 18.9 m-20 -81.2 -18.25 46.85 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.931 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.0 mmt85 66.08 47.75 1.86 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.839 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.573 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 5.0 ptpp? -131.95 131.74 42.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.9 p -106.55 118.35 36.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.16 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.46 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 9.0 pt20 -149.81 139.61 21.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . 0.598 ' CE2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.65 -24.99 58.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.911 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -64.1 158.7 22.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.901 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.445 ' ND2' ' HG ' ' A' ' 14' ' ' LEU . 12.7 t-20 -115.87 102.01 54.02 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.627 0.727 . . . . 0.0 110.854 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.46 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.6 Cg_endo . . . . . 0 C--N 1.342 0.209 0 C-N-CA 122.747 2.298 . . . . 0.0 112.288 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.452 HD13 ' CD2' ' A' ' 30' ' ' TYR . 13.5 mt . . . . . 0 C--O 1.231 0.109 0 CA-C-O 121.578 0.704 . . . . 0.0 110.915 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.665 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.84 -173.45 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.693 2.262 . . . . 0.0 112.285 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.43 149.92 47.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.123 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 83.88 -39.25 2.84 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.387 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.665 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 72.6 m95 -74.94 131.91 41.03 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.707 0.289 . . . . 0.0 110.926 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -145.46 112.91 6.23 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.896 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.2 145.65 47.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.908 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.561 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 18.7 mm -130.06 132.05 65.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.126 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -104.24 118.59 37.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.873 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.429 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.0 t70 -139.73 139.86 23.17 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.576 0.703 . . . . 0.0 110.877 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.428 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.5 Cg_endo -69.79 -8.85 24.65 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.687 2.258 . . . . 0.0 112.312 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.5 t -112.92 -37.91 2.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.157 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.8 m-85 -98.28 -32.06 11.74 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.939 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.08 -143.63 18.93 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.588 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.544 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -98.37 108.06 21.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.82 0.343 . . . . 0.0 111.115 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.561 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 27.4 p90 -135.13 131.83 37.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.895 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.458 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.9 m-30 -88.64 120.1 29.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.915 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.408 ' CG2' ' CE2' ' A' ' 29' ' ' TYR . 21.9 t -102.79 123.17 55.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.122 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.618 ' OD2' ' CZ3' ' A' ' 18' ' ' TRP . 5.0 m-20 -97.9 118.73 35.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.852 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 81.1 m-70 -92.31 -4.97 53.16 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.8 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.591 ' CD1' ' N ' ' A' ' 34' ' ' ILE . 0.8 OUTLIER -96.39 -49.98 11.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.122 -179.994 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.459 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 14.9 m-80 -98.36 -12.36 21.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.9 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 44.0 mmm-85 64.3 46.29 3.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.858 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.459 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 22.8 pttt -126.09 127.48 45.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.941 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -107.63 121.01 43.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.164 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.459 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 8.7 pt20 -150.29 144.92 25.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.885 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . 0.544 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 5.1 m-85 -79.12 -28.76 42.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -60.4 159.33 10.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.842 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.409 ' ND2' HD23 ' A' ' 14' ' ' LEU . 14.7 t-20 -114.73 102.01 54.65 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.632 0.729 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.459 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.0 Cg_endo . . . . . 0 C--O 1.232 0.19 0 C-N-CA 122.72 2.28 . . . . 0.0 112.33 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.574 HD12 ' CD2' ' A' ' 30' ' ' TYR . 9.2 mt . . . . . 0 C--O 1.231 0.085 0 CA-C-O 121.577 0.704 . . . . 0.0 110.917 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.652 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.8 Cg_endo -69.83 -177.41 1.89 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.626 2.217 . . . . 0.0 112.375 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.38 144.78 56.92 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.053 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.409 ' CA ' HD12 ' A' ' 34' ' ' ILE . . . 90.75 -35.87 3.76 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.44 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.652 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 70.5 m95 -78.74 132.73 37.06 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.758 0.313 . . . . 0.0 110.938 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -139.23 111.76 7.67 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.11 146.52 47.44 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.47 ' HB ' ' CZ ' ' A' ' 29' ' ' TYR . 29.9 mm -132.86 133.55 58.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.178 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -106.45 118.93 37.94 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.868 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.444 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -138.57 137.98 21.26 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.577 0.703 . . . . 0.0 110.85 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -8.38 23.46 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.657 2.238 . . . . 0.0 112.372 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.7 t -112.83 -38.02 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.095 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.412 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.04 -31.89 11.91 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.16 -147.63 19.72 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.486 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.423 HD13 ' N ' ' A' ' 28' ' ' ILE . 1.8 mp -97.07 108.88 22.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.873 0.368 . . . . 0.0 111.065 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.47 ' CZ ' ' HB ' ' A' ' 21' ' ' ILE . 42.4 p90 -133.41 131.83 40.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.574 ' CD2' HD12 ' A' ' 14' ' ' LEU . 5.7 m-30 -88.6 124.22 33.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.895 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.2 t -106.06 114.9 46.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.148 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.53 ' OD2' ' CE2' ' A' ' 18' ' ' TRP . 35.9 t0 -91.96 102.25 14.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.836 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -71.53 -10.37 59.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.849 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.516 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 0.8 OUTLIER -92.32 -60.26 2.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.113 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.466 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 5.9 m-80 -81.29 -21.7 39.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.778 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 10.6 mmt85 67.89 47.63 1.09 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.879 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.466 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 16.9 pttt -139.65 121.86 15.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.879 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 3.3 p -93.07 125.67 37.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.166 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.437 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 5.7 pt20 -150.58 140.15 21.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.89 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -73.5 -21.15 60.48 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.923 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 52.8 mm-40 -66.03 157.71 30.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.881 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -115.76 101.98 54.11 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.603 0.716 . . . . 0.0 110.875 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.437 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.1 Cg_endo . . . . . 0 C--O 1.232 0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.396 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.582 HD12 ' CD2' ' A' ' 30' ' ' TYR . 13.7 mt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 121.661 0.743 . . . . 0.0 110.908 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.655 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.73 -175.87 1.29 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.66 2.24 . . . . 0.0 112.347 179.842 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.87 145.24 56.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.083 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.464 ' CA ' HD12 ' A' ' 34' ' ' ILE . . . 89.52 -41.09 3.01 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.531 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.655 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 69.8 m95 -73.18 129.92 39.11 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.763 0.316 . . . . 0.0 110.916 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -138.45 112.36 8.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.917 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -74.57 145.49 43.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.909 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.572 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 26.2 mm -132.12 133.43 60.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.123 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -105.36 119.39 38.96 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.873 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.456 ' O ' ' N ' ' A' ' 27' ' ' GLY . 10.5 t70 -140.06 138.45 19.48 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.567 0.699 . . . . 0.0 110.883 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -9.78 26.95 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.677 2.251 . . . . 0.0 112.341 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.9 t -111.27 -38.0 3.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.095 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.402 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.8 m-85 -98.05 -33.0 11.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.89 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.41 -146.79 19.16 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.479 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.468 HD13 ' N ' ' A' ' 28' ' ' ILE . 2.0 mp -97.68 109.76 24.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.845 0.355 . . . . 0.0 111.152 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.572 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 27.1 p90 -134.53 131.63 38.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.582 ' CD2' HD12 ' A' ' 14' ' ' LEU . 4.9 m-30 -88.51 120.77 30.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.942 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.9 t -106.13 115.69 48.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.143 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.414 ' O ' ' N ' ' A' ' 36' ' ' ARG . 8.8 t0 -94.2 101.99 13.99 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.85 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 76.5 m-70 -67.39 -13.92 62.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.878 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.511 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.1 mp -85.35 -62.86 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.101 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.478 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 5.8 m-80 -83.56 -15.83 47.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.421 ' HB3' ' NH1' ' A' ' 36' ' ' ARG . 4.8 mmm180 64.25 47.68 3.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.852 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.478 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 21.1 pttt -129.75 136.79 50.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.835 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 22.6 p -113.44 123.04 49.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.108 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.47 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 8.1 pt20 -149.96 138.54 20.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.948 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -72.59 -16.22 61.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.948 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -73.54 159.97 32.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.857 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 -116.43 101.93 53.6 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.646 0.736 . . . . 0.0 110.926 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.47 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.5 Cg_endo . . . . . 0 C--N 1.342 0.236 0 C-N-CA 122.687 2.258 . . . . 0.0 112.354 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.542 HD12 ' CG ' ' A' ' 30' ' ' TYR . 10.8 mt . . . . . 0 C--O 1.23 0.072 0 CA-C-O 121.65 0.738 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.645 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.8 Cg_endo -69.77 -173.61 0.75 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.707 2.271 . . . . 0.0 112.323 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.86 144.52 55.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.102 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.48 ' CA ' HD11 ' A' ' 34' ' ' ILE . . . 92.14 -39.14 3.06 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.479 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.645 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 69.1 m95 -74.68 131.31 40.77 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.669 0.271 . . . . 0.0 110.916 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.4 tt0 -135.82 111.82 9.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.891 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.11 146.65 39.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.859 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.543 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 31.5 mm -133.56 135.52 55.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.137 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 -107.33 117.66 34.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.905 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.43 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.4 t70 -137.71 137.9 22.85 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.638 0.733 . . . . 0.0 110.796 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -8.12 22.8 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.68 2.253 . . . . 0.0 112.333 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 86.5 t -113.17 -38.03 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.182 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.435 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.5 m-85 -97.46 -31.72 12.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.942 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.44 -148.28 20.51 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.459 HD11 ' N ' ' A' ' 28' ' ' ILE . 2.0 mp -96.6 108.97 22.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.778 0.323 . . . . 0.0 111.17 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.543 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 37.9 p90 -132.84 131.38 40.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.928 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.542 ' CG ' HD12 ' A' ' 14' ' ' LEU . 4.9 m-30 -88.38 123.6 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.865 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.8 t -107.94 115.08 48.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.146 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 28.3 t0 -91.63 102.02 14.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.844 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -68.22 -16.52 64.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.817 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.517 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.0 OUTLIER -86.87 -61.11 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.117 -179.988 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 -79.74 -16.97 54.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.902 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 64.47 45.78 3.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.848 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 1.4 pttm -131.68 146.2 52.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.881 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.7 p -120.5 122.94 41.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.112 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.435 ' NE2' ' HB2' ' A' ' 41' ' ' GLU . 6.7 pt20 -150.53 140.1 21.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.934 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -72.57 -20.75 61.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.901 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.435 ' HB2' ' NE2' ' A' ' 39' ' ' GLN . 35.0 mp0 -68.36 157.39 35.8 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.866 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.473 ' ND2' ' CD2' ' A' ' 14' ' ' LEU . 8.9 t-20 -115.36 102.15 54.45 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.659 0.742 . . . . 0.0 110.844 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.431 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.5 Cg_endo . . . . . 0 C--N 1.341 0.178 0 C-N-CA 122.677 2.251 . . . . 0.0 112.332 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.455 HD23 ' ND2' ' A' ' 42' ' ' ASN . 17.4 mt . . . . . 0 C--O 1.232 0.15 0 CA-C-O 121.579 0.704 . . . . 0.0 110.954 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.628 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.74 -171.21 0.45 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.719 2.28 . . . . 0.0 112.417 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.95 147.35 53.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.084 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.481 ' CA ' HD11 ' A' ' 34' ' ' ILE . . . 88.2 -44.66 3.22 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.47 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.628 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 63.2 m95 -68.38 135.92 52.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.779 0.323 . . . . 0.0 110.903 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -149.52 115.61 5.72 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.79 142.0 42.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.566 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 38.4 mm -125.34 131.52 72.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.134 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -102.65 117.78 35.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.0 t70 -139.12 139.48 23.37 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.578 0.704 . . . . 0.0 110.884 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.409 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 54.6 Cg_endo -69.69 -11.31 30.67 Favored 'Trans proline' 0 N--CA 1.465 -0.183 0 C-N-CA 122.668 2.245 . . . . 0.0 112.437 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.3 t -109.93 -37.98 3.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.155 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.36 -32.85 11.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.9 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.48 -140.78 15.82 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.472 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.605 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.9 mp -102.08 109.4 26.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.808 0.337 . . . . 0.0 111.132 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.566 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 32.6 p90 -135.54 133.96 38.94 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.882 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.478 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.4 m-30 -90.18 126.8 35.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.927 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.2 t -113.21 117.24 54.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.125 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.459 ' O ' ' N ' ' A' ' 36' ' ' ARG . 62.4 t0 -95.14 103.31 15.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 47.7 m-70 -68.6 -16.38 63.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.645 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 0.6 OUTLIER -83.39 -55.49 7.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.121 -179.993 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . 0.405 ' CB ' ' HZ2' ' A' ' 37' ' ' LYS . 63.1 m-20 -93.33 -2.39 54.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.854 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.459 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.5 mpt_? 54.62 47.94 21.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.405 ' HZ2' ' CB ' ' A' ' 35' ' ' ASN . 8.7 mtmm -113.54 160.8 18.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -145.12 108.3 4.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.14 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.454 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 9.4 pt20 -147.88 144.19 27.93 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.919 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . 0.605 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.6 m-85 -76.29 -26.54 55.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -63.6 161.42 14.8 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.854 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.455 ' ND2' HD23 ' A' ' 14' ' ' LEU . 18.7 t-20 -116.62 101.93 53.44 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.614 0.721 . . . . 0.0 110.933 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.459 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 54.2 Cg_endo . . . . . 0 C--N 1.342 0.198 0 C-N-CA 122.637 2.225 . . . . 0.0 112.377 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.53 HD13 ' CG ' ' A' ' 30' ' ' TYR . 9.6 mt . . . . . 0 C--O 1.231 0.085 0 CA-C-O 121.614 0.721 . . . . 0.0 110.874 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.651 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.79 -170.38 0.39 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.614 2.209 . . . . 0.0 112.311 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.62 140.91 48.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.12 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 94.62 -32.19 6.24 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.505 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.651 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 67.4 m95 -81.89 147.72 29.15 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.703 0.287 . . . . 0.0 110.896 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.486 ' CG ' ' O ' ' A' ' 19' ' ' GLU . 2.3 pt-20 -152.71 119.57 5.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.888 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.59 141.47 36.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.95 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.571 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 18.2 mm -129.41 132.4 66.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.097 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -106.02 120.6 42.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.933 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.451 ' O ' ' N ' ' A' ' 27' ' ' GLY . 10.8 t70 -140.37 139.66 21.21 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.561 0.696 . . . . 0.0 110.888 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.425 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.9 Cg_endo -69.67 -8.18 22.94 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.696 2.264 . . . . 0.0 112.376 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 99.5 t -114.89 -37.9 2.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.123 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.31 -29.2 13.3 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.905 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 82.51 -151.73 29.82 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.508 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.445 HD12 ' N ' ' A' ' 28' ' ' ILE . 1.9 mp -89.81 110.88 22.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.824 0.345 . . . . 0.0 111.05 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.571 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 46.3 p90 -136.03 130.88 34.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.913 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.53 ' CG ' HD13 ' A' ' 14' ' ' LEU . 5.3 m-30 -88.48 132.79 34.34 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.963 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.4 t -114.62 116.47 52.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.138 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.478 ' OD1' ' CD1' ' A' ' 18' ' ' TRP . 13.3 t0 -98.59 102.03 13.64 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.898 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 -72.07 -11.24 60.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.84 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.508 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 0.8 OUTLIER -85.83 -57.2 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.129 179.947 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -87.65 -18.36 29.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.895 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 68.02 47.88 1.02 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.87 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.413 ' HE2' ' CH2' ' A' ' 18' ' ' TRP . 8.5 pttm -139.35 130.96 27.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.1 p -104.19 126.15 51.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 5.3 pt20 -150.63 141.82 23.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.956 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -73.78 -21.63 60.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 30.0 mm-40 -66.41 154.1 41.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.924 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.417 ' ND2' ' CD2' ' A' ' 14' ' ' LEU . 9.0 t-20 -112.3 101.99 53.22 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.597 0.713 . . . . 0.0 110.911 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.402 ' HD2' ' CD2' ' A' ' 14' ' ' LEU . 53.1 Cg_endo . . . . . 0 C--N 1.34 0.13 0 C-N-CA 122.672 2.248 . . . . 0.0 112.31 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.568 HD11 ' CD2' ' A' ' 30' ' ' TYR . 11.6 mt . . . . . 0 C--O 1.23 0.053 0 CA-C-O 121.609 0.719 . . . . 0.0 110.956 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.623 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.6 Cg_endo -69.76 -171.78 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.647 2.232 . . . . 0.0 112.368 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.73 149.98 49.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.077 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.412 ' CA ' ' CD1' ' A' ' 34' ' ' ILE . . . 84.94 -40.46 3.0 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.539 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.623 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 58.4 m95 -72.51 140.44 48.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.712 0.291 . . . . 0.0 110.995 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -152.24 115.04 4.6 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.406 ' O ' ' HG3' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -74.35 138.6 43.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.568 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 34.9 mm -121.13 131.21 73.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.166 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -103.54 117.94 35.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.854 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.44 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.7 t70 -138.91 137.98 20.55 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.578 0.704 . . . . 0.0 110.88 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 -8.26 23.14 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.665 2.244 . . . . 0.0 112.291 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.5 t -112.86 -37.97 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.169 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . 0.418 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -97.94 -31.98 11.9 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.959 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.4 -145.49 18.47 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.561 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.596 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -98.99 108.57 22.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.813 0.339 . . . . 0.0 111.081 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.568 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 31.5 p90 -134.42 131.58 38.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.568 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.6 m-30 -88.75 122.4 32.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.912 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.0 t -108.11 115.62 49.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.146 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 57.1 t0 -94.77 101.99 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.828 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 65.9 m-70 -68.74 -18.76 64.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.862 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.497 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.1 mp -81.67 -62.73 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.109 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.2 m-80 -80.34 -16.37 54.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.867 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 27.5 mmm180 64.11 47.69 3.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.53 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 11.1 ptpt -133.11 129.44 37.95 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.7 p -105.34 119.46 39.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.198 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.425 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.4 pt20 -150.29 140.5 22.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.91 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . 0.596 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.55 -25.08 59.08 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.884 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -62.06 161.84 10.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.872 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.404 ' ND2' ' CD2' ' A' ' 14' ' ' LEU . 10.8 t-20 -118.44 101.93 50.59 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.581 0.705 . . . . 0.0 110.937 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.425 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.7 Cg_endo . . . . . 0 C--N 1.341 0.148 0 C-N-CA 122.677 2.251 . . . . 0.0 112.346 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' LEU . . . . . 0.573 HD12 ' CD2' ' A' ' 30' ' ' TYR . 14.3 mt . . . . . 0 C--O 1.231 0.124 0 CA-C-O 121.556 0.693 . . . . 0.0 110.947 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.651 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.5 Cg_endo -69.77 -173.49 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.721 2.281 . . . . 0.0 112.292 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.52 146.91 54.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.035 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.458 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 87.9 -42.14 3.1 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.456 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' TRP . . . . . 0.651 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 70.8 m95 -71.78 122.3 20.45 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.834 0.35 . . . . 0.0 110.911 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -128.3 111.43 13.36 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.17 145.2 40.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.854 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.562 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 32.8 mm -132.68 133.58 59.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.127 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -106.06 117.99 35.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.912 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.474 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.1 t70 -138.36 139.67 25.87 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.64 0.733 . . . . 0.0 110.891 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.421 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.7 Cg_endo -69.71 -11.8 31.67 Favored 'Trans proline' 0 C--O 1.232 0.225 0 C-N-CA 122.704 2.269 . . . . 0.0 112.33 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 94.0 t -109.36 -37.95 3.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.162 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.28 -32.27 11.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.846 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.13 -140.95 16.0 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.439 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.448 HD13 ' N ' ' A' ' 28' ' ' ILE . 1.9 mp -102.91 108.87 25.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 0.0 111.179 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' TYR . . . . . 0.562 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 25.0 p90 -133.39 131.14 39.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.922 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' TYR . . . . . 0.573 ' CD2' HD12 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.27 119.65 28.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.916 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.4 t -101.88 115.57 43.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.098 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.615 ' OD2' ' CZ3' ' A' ' 18' ' ' TRP . 3.8 m-20 -88.87 112.96 23.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 -86.37 -7.07 58.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.946 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.59 ' CD1' ' N ' ' A' ' 34' ' ' ILE . 0.7 OUTLIER -97.11 -49.13 12.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.097 179.99 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 -96.06 -13.66 23.53 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.85 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ARG . . . . . 0.401 ' HA ' ' O ' ' A' ' 32' ' ' ASP . 25.3 mmt180 65.32 42.49 3.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.851 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . 0.546 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 0.1 OUTLIER -121.51 129.86 53.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.877 -179.986 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -111.21 116.1 30.48 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.149 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . 0.451 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 6.8 pt20 -145.96 146.39 31.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.935 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -77.96 -30.9 50.59 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.939 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLU . . . . . 0.409 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 4.1 mt-10 -58.25 166.75 1.53 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.845 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.466 ' ND2' HD21 ' A' ' 14' ' ' LEU . 12.5 t-20 -120.81 102.0 44.87 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.663 0.744 . . . . 0.0 110.906 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' PRO . . . . . 0.539 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 53.1 Cg_endo . . . . . 0 C--N 1.342 0.223 0 C-N-CA 122.682 2.255 . . . . 0.0 112.271 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 112.588 -0.205 . . . . 0.0 112.588 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 73.8 m -138.31 151.41 47.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.845 0.355 . . . . 0.0 110.904 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.8 m -124.09 154.32 40.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.784 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 123.63 -155.51 17.68 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.529 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.9 t -122.63 161.92 22.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.943 0.401 . . . . 0.0 110.787 -179.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 73.2 m -149.35 173.41 13.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.8 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 56.19 60.5 8.82 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.439 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 58.4 mt -83.43 -47.73 11.09 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.745 0.307 . . . . 0.0 110.856 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.95 117.66 35.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.88 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.2 t -109.42 16.28 22.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.884 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -108.69 13.17 25.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.883 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 37.5 mt -114.4 154.18 28.55 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.875 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -75.69 171.87 13.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.892 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.457 ' CD2' ' ND2' ' A' ' 42' ' ' ASN . 13.3 mt -89.41 153.15 48.25 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.557 0.694 . . . . 0.0 110.953 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.6 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.85 -175.55 1.22 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.611 2.208 . . . . 0.0 112.313 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.26 146.76 53.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.09 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.402 ' CA ' ' CD1' ' A' ' 34' ' ' ILE . . . 89.5 -44.26 3.05 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.497 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.6 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -69.7 142.32 53.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.735 0.302 . . . . 0.0 110.904 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -153.29 114.67 4.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.922 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.71 144.26 47.74 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.919 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.57 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 41.9 mm -128.17 130.62 69.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.177 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -104.97 117.86 35.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.859 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -137.84 139.78 27.52 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.624 0.726 . . . . 0.0 110.878 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.415 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.2 Cg_endo -69.83 -7.96 22.39 Favored 'Trans proline' 0 C--O 1.233 0.237 0 C-N-CA 122.646 2.231 . . . . 0.0 112.302 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 96.4 t -113.83 -38.01 2.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.081 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.8 m-85 -98.08 -30.79 12.47 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.941 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.26 -142.91 18.43 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.527 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.557 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.8 mp -99.64 111.46 29.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.848 0.356 . . . . 0.0 111.116 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.57 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 39.2 p90 -137.2 131.54 32.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.978 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.43 ' CD2' HD11 ' A' ' 14' ' ' LEU . 5.5 m-30 -88.98 123.6 33.47 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.925 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.415 ' CG2' ' CE2' ' A' ' 29' ' ' TYR . 10.8 t -110.2 116.57 52.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.148 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.407 ' OD2' ' NE1' ' A' ' 18' ' ' TRP . 51.5 t0 -95.77 106.09 18.17 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.929 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -71.36 -14.27 62.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.819 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.555 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 0.9 OUTLIER -85.98 -62.34 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.158 179.971 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.424 ' C ' ' HD3' ' A' ' 36' ' ' ARG . 28.0 m-80 -80.65 -13.81 58.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.852 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.424 ' HD3' ' C ' ' A' ' 35' ' ' ASN . 1.8 mpp_? 63.09 46.25 4.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -128.03 154.75 45.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.855 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.7 p -129.45 117.95 21.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.133 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.472 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.1 pt20 -149.66 141.86 24.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.956 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . 0.557 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.81 -25.99 59.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.922 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 -63.06 160.77 14.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.94 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.457 ' ND2' ' CD2' ' A' ' 14' ' ' LEU . 9.9 t-20 -115.48 102.02 54.33 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.589 0.709 . . . . 0.0 110.849 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.472 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.4 Cg_endo -69.8 3.13 2.97 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.705 2.27 . . . . 0.0 112.322 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 7.5 p -52.05 148.2 6.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 124.73 177.94 15.14 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.495 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 85.08 0.63 Allowed 'Trans proline' 0 N--CA 1.466 -0.14 0 C-N-CA 122.684 2.256 . . . . 0.0 112.388 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 27.9 p -143.85 107.45 4.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.861 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 50.8 p -96.37 164.29 12.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.835 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.478 179.989 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.282 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 40.5 p -58.68 -52.02 67.48 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.892 0.377 . . . . 0.0 110.823 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.6 p -74.68 -44.42 50.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.805 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.66 157.14 20.31 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.457 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 91.5 p -111.98 147.45 35.89 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.926 0.393 . . . . 0.0 110.861 -179.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.9 m 56.38 42.02 28.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.83 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -126.0 -75.69 0.24 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.464 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.1 mp -86.75 105.72 17.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.851 0.358 . . . . 0.0 110.925 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -130.93 127.55 38.68 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.85 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.7 t -99.97 17.02 22.03 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.91 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 20.7 pt-20 -107.48 15.56 24.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.89 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 50.4 mt -107.1 173.26 6.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.915 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 77.2 mt-10 -107.65 169.36 8.64 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.879 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.494 HD13 ' CD2' ' A' ' 30' ' ' TYR . 11.0 mt -91.09 154.49 45.01 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.603 0.716 . . . . 0.0 110.924 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.616 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.2 Cg_endo -69.7 -172.74 0.6 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.668 2.245 . . . . 0.0 112.349 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.58 148.62 51.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.093 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.91 -41.39 3.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.492 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.616 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.0 m95 -71.3 143.68 50.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.65 0.262 . . . . 0.0 110.956 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 30.3 tp10 -154.3 113.49 3.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.847 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.95 139.8 46.99 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.934 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.57 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 34.7 mm -122.76 129.12 75.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.164 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -101.97 117.92 35.82 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.896 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.447 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.7 t70 -139.01 139.16 22.57 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.614 0.721 . . . . 0.0 110.836 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -9.81 27.01 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.72 2.28 . . . . 0.0 112.372 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.4 t -111.54 -37.94 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.123 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.413 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -97.79 -32.1 11.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.967 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.27 -144.67 18.66 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.455 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.485 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.0 mp -98.62 109.81 24.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.781 0.325 . . . . 0.0 111.105 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.57 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 36.9 p90 -136.16 130.75 33.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.494 ' CD2' HD13 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.78 124.35 34.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.914 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.0 t -110.91 115.93 51.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.114 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.408 ' O ' ' N ' ' A' ' 36' ' ' ARG . 13.5 t0 -94.45 101.93 13.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.895 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -67.46 -18.38 65.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.504 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.1 mp -80.7 -63.35 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.15 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -81.14 -16.72 52.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.818 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.408 ' N ' ' O ' ' A' ' 32' ' ' ASP . 17.7 mmt180 64.89 47.98 2.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.544 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.0 OUTLIER -132.47 129.03 38.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.869 179.976 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.3 p -104.59 120.19 40.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.167 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.439 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.8 pt20 -150.11 140.91 22.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.932 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . 0.485 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.41 -23.77 59.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.908 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 55.7 mm-40 -64.86 158.28 25.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.909 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.445 ' ND2' ' HG ' ' A' ' 14' ' ' LEU . 12.0 t-20 -115.32 102.0 54.46 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.665 0.745 . . . . 0.0 110.896 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.439 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.1 Cg_endo -69.7 0.77 5.12 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.713 2.276 . . . . 0.0 112.335 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.2 t -53.33 167.89 0.18 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.828 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 122.43 161.47 11.26 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.46 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 -5.2 15.64 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.717 2.278 . . . . 0.0 112.343 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.9 m -70.22 -55.63 8.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.889 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 30.7 t -60.59 120.39 9.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.868 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.473 179.988 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.5 t -65.59 147.82 52.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.869 0.366 . . . . 0.0 110.889 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.9 t 64.33 42.39 5.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.885 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -83.98 -84.5 0.92 Allowed Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.415 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 94.3 p -58.23 105.99 0.33 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.821 0.343 . . . . 0.0 110.909 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 26.1 p -73.34 126.98 31.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.19 -69.62 1.35 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.5 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 23.6 mt 58.89 41.18 21.72 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.841 0.353 . . . . 0.0 110.899 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -87.63 17.97 4.3 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.86 179.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 27.7 p -75.47 5.31 6.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -109.26 17.25 21.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.84 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 17.6 mt -129.45 176.88 7.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.945 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -111.67 170.97 7.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.422 ' CD2' ' ND2' ' A' ' 42' ' ' ASN . 15.1 mt -90.61 151.93 44.52 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.586 0.708 . . . . 0.0 110.923 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.621 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.3 Cg_endo -69.74 -172.19 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.605 2.203 . . . . 0.0 112.376 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.19 146.63 54.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.071 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.418 ' CA ' ' CD1' ' A' ' 34' ' ' ILE . . . 88.54 -40.7 3.06 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.467 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.621 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -72.64 142.66 48.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.733 0.301 . . . . 0.0 110.895 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -153.4 115.51 4.34 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.882 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -74.22 140.99 45.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.553 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 38.1 mm -123.87 129.73 74.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.163 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.2 mt-10 -103.79 117.88 35.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.871 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.449 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.1 t70 -139.12 139.67 24.0 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.568 0.699 . . . . 0.0 110.905 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.421 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.6 Cg_endo -69.77 -9.48 26.2 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.627 2.218 . . . . 0.0 112.38 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 95.6 t -111.78 -38.04 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.13 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -97.91 -31.49 12.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.959 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.3 -145.73 19.86 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.456 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.598 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.7 mp -97.1 110.01 24.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.821 0.343 . . . . 0.0 111.198 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.553 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 34.9 p90 -137.37 130.62 30.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.901 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.451 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 3.0 m-30 -89.02 126.85 35.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.931 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.6 t -112.67 116.13 51.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.115 179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.463 ' O ' ' N ' ' A' ' 36' ' ' ARG . 10.4 t0 -93.56 102.16 14.35 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.821 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 -68.0 -17.14 64.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.889 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.516 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.1 mp -82.46 -58.17 3.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.127 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -87.34 -14.29 41.16 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.887 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.463 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.2 mpt_? 62.59 47.99 4.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.79 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.45 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.0 OUTLIER -130.93 126.94 37.4 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.941 179.952 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.6 p -102.35 119.34 38.65 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.107 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.456 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.0 pt20 -149.65 141.83 24.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.961 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . 0.598 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 3.0 m-85 -76.02 -24.6 55.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.89 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 25.7 mm-40 -62.93 161.25 13.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.422 ' ND2' ' CD2' ' A' ' 14' ' ' LEU . 8.8 t-20 -116.36 102.1 53.61 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.616 0.722 . . . . 0.0 110.867 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.456 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.3 Cg_endo -69.88 3.95 2.53 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.655 2.237 . . . . 0.0 112.316 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.3 p -52.06 147.35 7.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.88 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 134.19 170.81 12.39 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.489 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 95.53 0.56 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.7 2.267 . . . . 0.0 112.349 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.3 m -76.34 -47.17 24.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.842 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.1 t -51.63 -52.42 47.86 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.834 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.43 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.509 179.954 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.9 m -78.46 114.22 17.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.85 0.357 . . . . 0.0 110.852 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.4 m 57.94 42.12 23.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.822 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -88.92 -166.66 42.4 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.504 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 16.3 m -136.03 155.68 49.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.896 0.379 . . . . 0.0 110.828 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.1 t -52.16 -56.74 12.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.898 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 179.12 -174.58 46.58 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.437 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 28.1 mt -135.24 148.21 49.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.863 0.363 . . . . 0.0 110.875 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -121.76 103.35 8.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.892 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 61.0 m -100.94 16.66 24.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.871 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -113.21 16.2 19.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.891 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 34.3 mt -128.73 159.91 34.18 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.919 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -112.9 172.27 7.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.921 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.461 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 11.9 mt -88.71 155.45 50.52 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.619 0.723 . . . . 0.0 110.937 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.617 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.71 -175.82 1.27 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.677 2.251 . . . . 0.0 112.361 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.31 143.37 57.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.113 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.445 ' CA ' HD12 ' A' ' 34' ' ' ILE . . . 93.21 -41.49 2.69 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.543 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.617 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 60.4 m95 -72.69 137.75 46.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.721 0.296 . . . . 0.0 110.932 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -151.1 114.46 4.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.92 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.92 145.12 48.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.879 179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.563 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 44.6 mm -129.13 131.76 67.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -106.57 117.99 35.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.851 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.424 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.6 t70 -138.54 139.65 25.36 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.608 0.718 . . . . 0.0 110.884 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.414 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.5 Cg_endo -69.74 -7.22 20.48 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.609 2.206 . . . . 0.0 112.362 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 95.2 t -114.49 -38.01 2.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.404 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.9 m-85 -98.29 -31.08 12.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.867 -179.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.02 -144.27 19.29 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.416 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 1.8 mp -97.15 111.29 26.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.783 0.325 . . . . 0.0 111.145 -179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.563 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 32.0 p90 -139.18 131.35 28.13 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.935 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.481 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.05 128.25 35.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.947 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.9 t -113.06 115.86 50.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -95.62 102.41 14.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.883 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 60.6 m-70 -69.51 -14.4 62.85 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.86 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.574 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.0 OUTLIER -87.16 -60.94 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.132 -179.981 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 21.0 m-20 -82.63 -15.19 53.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 13.1 mmm180 62.38 47.58 5.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.79 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.566 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 4.8 ptpp? -130.48 129.11 42.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.897 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -107.64 121.58 44.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.181 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.472 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.9 pt20 -150.05 141.86 23.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.881 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.2 m-85 -72.33 -26.99 62.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.903 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.435 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 6.1 mm-40 -68.99 162.99 25.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.946 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.468 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 1.9 t-20 -122.13 108.66 34.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.661 0.744 . . . . 0.0 110.862 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.472 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.1 Cg_endo -69.78 1.73 4.18 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.698 2.265 . . . . 0.0 112.35 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 83.0 p -51.97 171.06 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.843 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 88.12 -176.4 45.43 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.491 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.86 -17.05 37.34 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.63 2.22 . . . . 0.0 112.335 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 44.5 m 61.16 41.85 13.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.863 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.4 t -71.07 137.66 49.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.844 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.224 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.491 -179.99 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.433 -0.267 . . . . 0.0 112.433 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 42.7 m -90.7 173.31 8.1 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.879 0.371 . . . . 0.0 110.811 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.417 ' HG ' ' N ' ' A' ' 4' ' ' GLY . 46.3 t -60.39 153.2 23.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.858 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.417 ' N ' ' HG ' ' A' ' 3' ' ' SER . . . 71.4 71.63 1.02 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.527 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 60.3 p -70.78 -47.15 61.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.853 0.358 . . . . 0.0 110.872 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.9 m -107.2 141.46 38.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.788 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -134.13 88.14 0.25 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.46 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.1 tp -118.32 142.64 47.31 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.819 0.342 . . . . 0.0 110.917 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -91.55 110.78 22.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 34.7 t -103.9 16.35 26.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.836 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -114.84 16.38 17.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.905 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 24.7 mt -127.58 156.19 42.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.885 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 21.9 mt-10 -89.35 171.21 9.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.846 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.428 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 11.8 mt -93.94 154.77 40.72 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.63 0.729 . . . . 0.0 110.899 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.617 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.3 Cg_endo -69.77 -174.58 0.94 Allowed 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.663 2.242 . . . . 0.0 112.314 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.23 143.74 57.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.071 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.437 ' CA ' HD11 ' A' ' 34' ' ' ILE . . . 93.15 -41.64 2.68 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.617 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 60.6 m95 -72.42 137.76 46.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.73 0.3 . . . . 0.0 110.955 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -151.35 117.06 5.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.835 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.53 143.55 42.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.916 179.907 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.561 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 45.0 mm -127.09 131.89 70.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.121 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -104.94 117.69 34.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.848 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.418 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -137.99 138.5 23.62 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.652 0.739 . . . . 0.0 110.899 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -6.62 19.04 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.689 2.259 . . . . 0.0 112.267 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 90.7 t -115.2 -38.02 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.133 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.42 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.8 m-85 -98.1 -31.23 12.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.925 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.04 -145.45 19.23 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.45 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.407 HD12 ' N ' ' A' ' 28' ' ' ILE . 2.0 mp -97.41 111.6 27.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 111.086 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.561 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.7 p90 -138.57 132.83 31.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.896 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.481 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.84 128.52 36.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.945 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.8 t -113.43 115.82 50.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.116 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -94.54 102.12 14.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.892 179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 70.2 m-70 -68.99 -12.86 62.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.599 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 0.9 OUTLIER -89.0 -60.39 2.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.134 179.958 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -83.01 -18.6 39.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.809 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.6 mmm180 65.67 48.05 2.03 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.565 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 14.9 ptpt -130.53 131.16 44.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -109.25 120.29 42.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.118 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.467 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 6.9 pt20 -149.43 140.89 23.32 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.965 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -71.19 -24.6 62.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.941 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.405 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 8.0 mt-10 -69.76 161.1 30.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.458 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 1.9 t-20 -122.75 105.45 35.4 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.637 0.732 . . . . 0.0 110.913 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.467 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.5 Cg_endo -69.7 3.25 2.85 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.73 2.286 . . . . 0.0 112.391 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 64.9 p -52.41 142.11 18.2 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.896 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -151.54 168.07 30.96 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.478 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 0.02 6.27 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.692 2.261 . . . . 0.0 112.319 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 21.0 m -81.09 -59.08 2.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.892 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.6 t -130.05 116.37 18.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.822 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.473 179.997 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 89.8 p -147.74 106.86 3.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.978 0.418 . . . . 0.0 110.849 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.6 m -72.03 -50.29 29.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.909 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -165.35 117.02 0.73 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.509 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 79.2 p -63.38 104.4 0.61 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.869 0.366 . . . . 0.0 110.854 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.8 p -39.8 -58.05 1.44 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.906 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.66 67.19 0.98 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.47 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 tp -71.46 128.9 37.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.798 0.333 . . . . 0.0 110.935 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 43.0 m-20 -137.71 123.07 19.46 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.879 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.3 p -102.27 16.8 25.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.874 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -117.42 15.48 14.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.939 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 35.0 mt -129.07 160.29 33.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.979 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 -108.73 168.91 9.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.896 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.481 HD13 ' CD2' ' A' ' 30' ' ' TYR . 14.5 mt -83.71 152.62 63.52 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.59 0.71 . . . . 0.0 110.924 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.615 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.1 Cg_endo -69.7 -173.85 0.79 Allowed 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.683 2.255 . . . . 0.0 112.392 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.73 149.29 49.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.098 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.412 ' CA ' ' CD1' ' A' ' 34' ' ' ILE . . . 86.05 -42.4 3.15 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.503 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.615 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.2 m95 -70.39 139.19 51.82 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.685 0.279 . . . . 0.0 110.916 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 29.4 tp10 -149.49 113.87 5.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.846 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.85 144.79 50.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.896 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.569 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 33.9 mm -128.27 130.97 69.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.126 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -105.6 118.59 36.97 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.91 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.432 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.14 139.56 21.47 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.669 0.747 . . . . 0.0 110.845 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.41 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.6 Cg_endo -69.74 -8.65 24.14 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.751 2.301 . . . . 0.0 112.336 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 91.3 t -112.68 -38.04 2.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.113 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.417 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.22 -32.45 11.56 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.927 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.4 -144.62 18.55 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.505 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.6 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.9 mp -97.99 109.59 23.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.811 0.338 . . . . 0.0 111.195 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.569 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 38.4 p90 -135.34 130.96 35.81 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.95 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.481 ' CD2' HD13 ' A' ' 14' ' ' LEU . 3.9 m-30 -88.65 121.44 31.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.981 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.7 t -107.96 116.36 51.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.151 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -96.03 102.59 14.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 60.6 m-70 -68.26 -18.14 64.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.902 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.503 ' CD1' ' N ' ' A' ' 34' ' ' ILE . 1.1 mp -81.39 -63.42 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -79.22 -18.46 52.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.902 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.474 ' NE ' ' HA ' ' A' ' 36' ' ' ARG . 0.1 OUTLIER 66.61 47.77 1.56 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 -179.971 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.485 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 6.3 ptpt -134.5 130.72 37.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.876 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.8 p -106.05 119.99 40.63 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.19 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.4 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.7 pt20 -149.99 141.76 23.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.926 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . 0.6 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -75.05 -25.42 58.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.914 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -62.74 158.18 19.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.834 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.444 ' ND2' ' CD2' ' A' ' 14' ' ' LEU . 9.2 t-20 -114.28 101.9 54.45 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.522 0.677 . . . . 0.0 110.915 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.4 ' HD2' ' CD2' ' A' ' 14' ' ' LEU . 53.9 Cg_endo -69.72 3.39 2.78 Favored 'Trans proline' 0 N--CA 1.465 -0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.376 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 14.0 p -51.92 168.61 0.08 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.894 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 120.16 174.8 15.45 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.442 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 102.42 1.02 Allowed 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.736 2.291 . . . . 0.0 112.371 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 98.4 p -63.04 120.75 12.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.837 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 25.2 p -103.96 134.04 47.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.855 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.479 179.985 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.536 -0.226 . . . . 0.0 112.536 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 99.3 p -130.24 122.51 28.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.921 0.391 . . . . 0.0 110.833 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.1 t -140.92 160.27 40.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.88 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -101.0 66.96 0.48 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.46 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.0 m -133.35 114.32 13.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.908 0.385 . . . . 0.0 110.834 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.8 t -60.67 -46.66 89.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.9 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.55 -152.76 5.75 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.536 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 13.2 tp -91.36 125.95 36.28 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.838 0.351 . . . . 0.0 110.923 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -104.93 17.82 23.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.906 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.5 m -77.39 7.97 4.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.837 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -107.25 15.83 24.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.878 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 45.1 mt -116.7 146.86 42.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.87 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -64.24 171.06 3.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.8 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.57 HD13 ' CD2' ' A' ' 30' ' ' TYR . 11.5 mt -98.97 153.42 37.82 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.569 0.699 . . . . 0.0 110.887 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.613 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.7 -171.73 0.5 Allowed 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.69 2.26 . . . . 0.0 112.368 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.23 147.32 52.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.106 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.429 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 88.58 -40.39 3.08 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.483 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.613 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 57.3 m95 -73.3 130.55 40.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.674 0.273 . . . . 0.0 110.887 -179.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -137.28 113.29 9.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.883 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.58 144.56 41.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.843 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.531 ' HB ' ' CZ ' ' A' ' 29' ' ' TYR . 29.9 mm -130.62 132.8 64.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.181 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -104.38 120.28 40.87 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.899 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.43 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.69 137.54 17.47 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.668 0.747 . . . . 0.0 110.876 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -7.68 21.66 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.654 2.236 . . . . 0.0 112.416 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.9 t -113.47 -37.95 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.218 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.417 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.14 -31.69 11.98 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.893 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.48 -148.19 20.43 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.435 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.446 HD12 ' N ' ' A' ' 28' ' ' ILE . 1.9 mp -96.39 109.17 22.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.862 0.363 . . . . 0.0 111.122 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.531 ' CZ ' ' HB ' ' A' ' 21' ' ' ILE . 37.9 p90 -133.31 131.07 39.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.57 ' CD2' HD13 ' A' ' 14' ' ' LEU . 4.7 m-30 -88.21 123.59 33.0 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.935 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.6 t -109.44 115.77 50.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.067 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.449 ' O ' ' N ' ' A' ' 36' ' ' ARG . 9.8 t0 -94.64 102.03 13.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 76.1 m-70 -68.55 -16.15 63.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.856 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.502 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.1 mp -83.27 -58.6 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.176 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -87.42 -14.12 41.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.853 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 32' ' ' ASP . 4.1 mpt_? 62.73 47.47 4.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.919 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.561 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 5.6 ptpt -128.77 130.02 46.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.4 p -107.34 118.56 37.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.136 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.419 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 6.2 pt20 -150.07 142.99 24.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.889 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -75.12 -26.44 59.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.904 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 23.7 mm-40 -62.01 161.17 11.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.426 ' ND2' ' CD2' ' A' ' 14' ' ' LEU . 12.7 t-20 -116.77 102.28 53.19 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.657 0.741 . . . . 0.0 110.891 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.436 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 53.9 Cg_endo -69.68 -3.27 11.63 Favored 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.706 2.271 . . . . 0.0 112.34 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 6.6 t -52.3 157.91 1.31 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 139.94 164.2 9.8 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.475 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.7 -34.63 14.38 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.725 2.283 . . . . 0.0 112.322 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 86.3 p -119.7 159.32 24.71 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.856 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 22.1 t 66.75 42.1 2.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.828 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.228 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.485 179.986 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.384 0 N-CA-C 112.52 -0.232 . . . . 0.0 112.52 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.7 t -45.89 -57.31 4.46 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.891 0.377 . . . . 0.0 110.842 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 69.3 m -90.6 162.21 15.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.875 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 151.59 56.7 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.516 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 70.2 m -45.85 -54.19 8.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.877 0.37 . . . . 0.0 110.838 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.8 t 53.28 42.03 32.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.869 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -119.86 74.55 0.32 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.471 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -91.89 140.61 29.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.829 0.347 . . . . 0.0 110.914 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -122.44 154.22 38.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.841 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.1 t -85.68 17.23 3.43 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.852 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -111.95 17.67 19.49 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.823 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 30.1 mt -113.31 157.88 21.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.862 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -109.34 173.29 6.39 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.86 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.44 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 14.5 mt -96.68 154.94 38.27 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.577 0.703 . . . . 0.0 110.926 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.63 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.0 Cg_endo -69.72 -175.78 1.26 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.702 2.268 . . . . 0.0 112.321 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.46 144.26 57.16 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.415 ' CA ' ' CD1' ' A' ' 34' ' ' ILE . . . 92.03 -40.82 2.86 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.501 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.63 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 63.8 m95 -73.04 135.27 44.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.769 0.319 . . . . 0.0 110.908 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -149.52 114.98 5.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.889 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.41 143.68 48.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.901 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.538 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 45.8 mm -127.02 131.67 70.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.125 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -104.84 117.74 34.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.92 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.417 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.9 t70 -139.15 139.13 22.2 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.591 0.71 . . . . 0.0 110.901 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -7.03 20.03 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.659 2.239 . . . . 0.0 112.372 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.6 t -114.5 -37.99 2.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.126 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.412 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.17 -31.81 11.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.94 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.57 -145.85 19.75 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.467 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.463 HD11 ' N ' ' A' ' 28' ' ' ILE . 2.0 mp -96.63 108.57 21.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.792 0.33 . . . . 0.0 111.123 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.538 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.3 p90 -135.97 132.1 35.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.476 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.06 125.05 34.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.93 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.9 t -110.5 115.78 50.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.176 179.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -95.44 102.04 13.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 66.9 m-70 -68.93 -14.15 62.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.534 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.1 mp -84.41 -63.26 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.169 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.403 ' CB ' ' HZ3' ' A' ' 37' ' ' LYS . 19.2 m-20 -82.6 -17.24 45.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.916 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 33.4 mmm-85 65.81 47.42 2.08 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.836 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.578 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 4.1 ptpp? -129.81 126.75 38.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.952 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.3 p -104.92 122.11 45.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.185 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.48 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 8.5 pt20 -150.01 140.02 21.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.88 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.2 m-85 -71.1 -26.11 62.9 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.908 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -69.05 160.27 31.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.849 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.454 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 2.0 t-20 -120.23 106.8 40.21 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.618 0.723 . . . . 0.0 110.887 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.48 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.4 Cg_endo -69.81 3.23 2.92 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.743 2.295 . . . . 0.0 112.347 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 42.5 t -52.28 152.62 3.27 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.817 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 148.83 -177.59 26.97 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.454 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 168.46 21.4 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.673 2.249 . . . . 0.0 112.336 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 27.0 t 57.29 42.23 25.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.848 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.4 m -74.79 -44.65 48.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.852 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.505 -179.988 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.427 -0.269 . . . . 0.0 112.427 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.7 p -103.17 155.82 18.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.908 0.385 . . . . 0.0 110.847 -179.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 70.0 m -87.82 148.81 24.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.834 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 162.42 -90.27 0.11 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.516 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.5 m -73.91 -37.93 64.49 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.868 0.366 . . . . 0.0 110.881 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.5 m -55.11 156.69 3.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.872 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -45.88 -92.91 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.512 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 26.7 mt 60.25 42.62 14.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.737 0.303 . . . . 0.0 110.959 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -91.95 117.68 30.04 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 38.9 m -100.13 17.61 20.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.824 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -113.71 17.35 18.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.881 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 25.1 mt -128.03 147.53 50.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.881 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -85.9 163.64 17.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.567 HD12 ' CD2' ' A' ' 30' ' ' TYR . 13.3 mt -82.77 153.54 67.54 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-O 121.643 0.735 . . . . 0.0 110.879 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.636 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.68 -173.96 0.8 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.683 2.256 . . . . 0.0 112.367 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.42 149.64 48.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.122 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.417 ' CA ' ' CD1' ' A' ' 34' ' ' ILE . . . 84.52 -41.3 3.01 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.458 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.636 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 57.7 m95 -70.41 140.44 52.05 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.827 0.346 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -152.81 117.96 5.18 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.941 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.05 147.12 40.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.851 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.498 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 31.6 mm -131.01 132.04 63.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.161 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -105.16 117.8 34.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.883 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.405 ' O ' ' N ' ' A' ' 27' ' ' GLY . 8.9 t70 -138.05 137.47 21.22 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.606 0.717 . . . . 0.0 110.858 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.79 -4.04 13.24 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.651 2.234 . . . . 0.0 112.392 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.6 t -117.19 -38.03 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.123 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.425 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.56 -31.0 12.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.85 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.0 -146.08 18.94 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.436 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.582 ' O ' ' CE2' ' A' ' 40' ' ' TYR . 1.7 mp -98.43 108.3 21.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.849 0.357 . . . . 0.0 111.159 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.498 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 28.8 p90 -134.41 132.2 39.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.912 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.567 ' CD2' HD12 ' A' ' 14' ' ' LEU . 3.0 m-30 -88.65 122.53 32.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.925 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 t -107.78 115.89 49.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.129 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.462 ' O ' ' N ' ' A' ' 36' ' ' ARG . 57.6 t0 -95.15 101.95 13.73 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.861 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -68.57 -18.52 64.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.498 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.1 mp -82.14 -57.16 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.125 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -87.18 -14.88 39.94 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.874 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.462 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.3 mpt_? 62.23 47.73 5.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.853 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.559 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 5.0 ptpp? -131.5 132.49 44.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.854 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 7.1 p -108.05 118.35 36.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.12 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -150.05 139.14 21.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.919 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . 0.582 ' CE2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -74.26 -21.04 59.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.967 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 34.1 mp0 -65.99 156.9 32.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.888 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.409 HD21 ' CD2' ' A' ' 14' ' ' LEU . 7.4 t-20 -115.52 101.98 54.3 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.644 0.735 . . . . 0.0 110.968 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 -13.03 34.15 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.642 2.228 . . . . 0.0 112.339 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 34.9 t -52.05 155.76 1.78 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.832 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 126.07 -172.75 17.86 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.469 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 2.49 3.49 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.679 2.252 . . . . 0.0 112.344 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 93.2 p -71.06 172.56 8.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.894 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 49.5 m -38.82 -49.67 1.64 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.918 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.449 179.985 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 N-CA-C 112.457 -0.257 . . . . 0.0 112.457 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.2 t -62.95 121.73 14.26 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.855 0.36 . . . . 0.0 110.9 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.4 t -157.68 104.54 1.97 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.895 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -65.18 -124.49 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.527 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 70.6 m -77.44 152.27 34.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.891 0.377 . . . . 0.0 110.855 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.4 m -114.15 175.84 5.3 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.784 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -169.26 122.17 0.99 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.538 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 7.0 mp -121.69 168.34 11.91 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.829 0.347 . . . . 0.0 110.956 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -82.41 17.04 1.83 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.842 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 70.4 m -78.13 8.66 4.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -104.49 10.73 35.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.886 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.401 ' CD1' ' C ' ' A' ' 45' ' ' GLY . 46.3 mt -116.27 148.62 40.31 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.943 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -84.68 164.78 18.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.886 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 12.8 mt -79.93 151.94 73.93 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.579 0.704 . . . . 0.0 110.921 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.629 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.6 Cg_endo -69.77 -169.36 0.32 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.7 2.267 . . . . 0.0 112.326 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.98 153.74 41.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.443 ' CA ' HD11 ' A' ' 34' ' ' ILE . . . 82.24 -45.89 3.43 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.418 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.629 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 71.3 m95 -67.67 134.66 51.52 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.732 0.301 . . . . 0.0 110.896 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -149.92 113.99 5.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.02 142.72 43.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.917 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.532 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 19.0 mm -128.36 130.78 69.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.094 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -102.51 119.88 39.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.895 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.432 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.69 139.7 20.58 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 121.576 0.703 . . . . 0.0 110.896 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.42 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.9 Cg_endo -69.77 -7.8 21.99 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.692 2.261 . . . . 0.0 112.342 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.9 t -113.92 -37.92 2.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.179 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.436 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.5 m-85 -98.51 -31.61 11.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 86.78 -143.74 19.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.423 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.537 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -97.94 108.8 22.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.878 0.37 . . . . 0.0 111.162 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.532 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 39.7 p90 -135.11 131.95 37.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.905 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.442 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 3.3 m-30 -88.77 124.92 34.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.916 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -111.38 116.41 52.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.095 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.627 ' OD1' ' CE3' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -100.12 103.3 14.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 179.903 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 48.3 m-70 -68.83 -8.44 43.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.851 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.604 ' CD1' ' N ' ' A' ' 34' ' ' ILE . 0.9 OUTLIER -90.22 -62.81 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.156 179.995 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 7.4 m-80 -82.44 -19.91 38.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.915 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 19.6 mmm-85 66.28 47.39 1.82 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.901 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.406 ' HG3' ' OD2' ' A' ' 32' ' ' ASP . 0.1 OUTLIER -129.76 122.2 28.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.847 179.988 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.3 p -100.2 118.34 36.32 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.42 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 6.7 pt20 -148.98 141.34 24.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.95 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . 0.537 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -75.26 -24.45 57.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 -62.62 161.24 12.52 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 -120.3 102.02 46.17 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.625 0.726 . . . . 0.0 110.883 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.42 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.2 Cg_endo -69.74 -9.37 25.95 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.709 2.273 . . . . 0.0 112.363 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 6.6 m -59.35 146.4 39.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.854 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . 0.401 ' C ' ' CD1' ' A' ' 12' ' ' LEU . . . -168.36 165.57 38.9 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.496 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.83 113.28 3.33 Favored 'Trans proline' 0 N--CA 1.465 -0.205 0 C-N-CA 122.688 2.258 . . . . 0.0 112.346 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 58.0 m -59.86 112.22 1.76 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.802 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.9 m -76.32 -56.43 4.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.849 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.515 -179.982 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.474 -0.25 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 58.3 m -56.64 -41.85 77.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.836 0.351 . . . . 0.0 110.841 -179.686 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.9 t -95.93 -44.46 7.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.851 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -46.85 -87.01 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.501 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 m -60.35 -47.62 85.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.859 0.361 . . . . 0.0 110.806 -179.684 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.6 t 60.48 42.39 14.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.826 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -49.04 134.73 22.64 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.467 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -144.11 118.51 9.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.883 0.373 . . . . 0.0 110.875 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 p-10 -69.26 105.19 2.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.9 t -106.93 13.8 27.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.846 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -109.28 16.9 22.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.964 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 20.2 mt -128.93 146.91 50.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.892 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -78.19 173.67 12.01 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.833 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.54 HD13 ' CD2' ' A' ' 30' ' ' TYR . 10.7 mt -99.78 155.06 36.9 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 121.603 0.716 . . . . 0.0 110.879 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.61 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.67 -171.71 0.49 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.606 2.204 . . . . 0.0 112.371 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.46 150.52 48.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.072 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.31 -43.92 3.31 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.755 -0.735 . . . . 0.0 112.46 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.61 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -68.66 141.62 55.31 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.751 0.31 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 23.2 tp10 -153.14 113.58 4.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.907 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.47 142.57 48.58 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.898 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.566 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 32.3 mm -127.38 130.76 70.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.105 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -103.81 117.88 35.38 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.928 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.42 ' O ' ' N ' ' A' ' 27' ' ' GLY . 9.8 t70 -138.17 139.36 25.39 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.511 0.672 . . . . 0.0 110.956 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.406 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 54.2 Cg_endo -69.77 -6.92 19.75 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.614 2.21 . . . . 0.0 112.367 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.2 t -114.21 -37.91 2.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.18 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.427 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.66 -32.31 11.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.47 -144.19 18.26 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.425 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.451 HD13 ' N ' ' A' ' 28' ' ' ILE . 1.9 mp -97.86 108.82 22.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.827 0.346 . . . . 0.0 111.128 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.566 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.3 p90 -135.78 131.19 35.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.933 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.54 ' CD2' HD13 ' A' ' 14' ' ' LEU . 2.9 m-30 -88.88 125.55 34.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.92 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.9 t -111.35 116.72 53.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.098 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.412 ' O ' ' N ' ' A' ' 36' ' ' ARG . 19.4 t0 -95.55 102.58 14.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 72.8 m-70 -67.93 -15.13 63.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.564 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.0 OUTLIER -85.02 -61.4 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 -179.998 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 21.4 m-20 -83.49 -15.41 49.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.902 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.412 ' N ' ' O ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER 62.9 47.99 4.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.848 179.957 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.559 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.1 OUTLIER -130.38 130.89 44.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.833 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 3.0 p -108.13 120.26 41.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.151 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.474 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 8.2 pt20 -150.01 140.71 22.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . 0.411 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -74.38 -21.75 59.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.89 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 21.6 mt-10 -67.94 161.41 26.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.844 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.439 ' ND2' ' CD2' ' A' ' 14' ' ' LEU . 12.0 t-20 -117.62 102.07 51.95 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.631 0.729 . . . . 0.0 110.839 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.474 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.0 Cg_endo -69.84 -12.57 33.01 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.64 2.226 . . . . 0.0 112.363 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 43' ' ' PRO . 24.1 t -34.76 -59.44 0.48 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.92 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -52.12 -173.4 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.433 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 2.45 3.54 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.623 2.215 . . . . 0.0 112.308 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 74.7 p -106.58 135.19 48.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.7 t -121.91 152.51 39.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.839 -179.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.525 -179.941 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.448 -0.261 . . . . 0.0 112.448 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.7 t -83.64 -51.78 6.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.856 0.36 . . . . 0.0 110.884 -179.736 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.7 p -83.99 169.89 14.52 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.856 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -171.77 157.63 27.96 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.471 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.0 m -112.06 133.34 54.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.822 0.344 . . . . 0.0 110.898 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.2 t -82.56 147.72 28.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.905 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.94 132.37 11.16 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.492 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 7.5 mp -86.13 -59.34 2.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.854 0.359 . . . . 0.0 110.934 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.458 ' CB ' HD12 ' A' ' 12' ' ' LEU . 6.9 m-20 -148.14 108.39 4.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.875 179.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.9 p -97.06 16.36 19.84 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.767 -179.658 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -117.49 17.7 14.47 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.92 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.458 HD12 ' CB ' ' A' ' 9' ' ' ASP . 32.6 mt -124.81 151.07 45.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.956 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -76.21 171.22 14.88 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.892 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.565 HD11 ' CD2' ' A' ' 30' ' ' TYR . 12.5 mt -94.19 155.19 40.23 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.554 0.692 . . . . 0.0 110.938 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.627 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.71 -173.67 0.75 Allowed 'Trans proline' 0 C--N 1.34 0.094 0 C-N-CA 122.689 2.259 . . . . 0.0 112.373 179.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.4 148.77 51.14 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.063 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.413 ' CA ' ' CD1' ' A' ' 34' ' ' ILE . . . 86.64 -43.04 3.19 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.524 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.627 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.7 m95 -68.22 143.88 55.13 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.691 0.281 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -155.45 116.23 3.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.848 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.8 144.25 45.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.891 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.568 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 43.7 mm -128.11 130.69 69.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.151 179.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -104.74 117.82 35.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.0 t70 -138.15 139.69 26.48 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 121.589 0.709 . . . . 0.0 110.878 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.1 Cg_endo -69.82 -7.36 20.88 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.689 2.259 . . . . 0.0 112.38 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 86.4 t -114.12 -37.95 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.104 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.43 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.45 -31.54 11.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.913 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.84 -143.78 18.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.449 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.598 ' O ' ' CE2' ' A' ' 40' ' ' TYR . 1.7 mp -98.41 110.17 25.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.855 0.359 . . . . 0.0 111.151 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.568 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.1 p90 -136.93 131.69 33.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.98 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.565 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.84 124.34 34.09 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.885 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 t -110.3 115.97 51.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.116 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -95.33 102.72 14.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.813 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -69.16 -17.31 63.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.507 ' CD1' ' N ' ' A' ' 34' ' ' ILE . 1.1 mp -82.2 -62.67 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.185 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 18.9 m-20 -81.2 -18.25 46.85 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.931 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.0 mmt85 66.08 47.75 1.86 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.839 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.573 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 5.0 ptpp? -131.95 131.74 42.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.9 p -106.55 118.35 36.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.16 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.46 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 9.0 pt20 -149.81 139.61 21.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . 0.598 ' CE2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.65 -24.99 58.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.911 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -64.1 158.7 22.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.901 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.445 ' ND2' ' HG ' ' A' ' 14' ' ' LEU . 12.7 t-20 -115.87 102.01 54.02 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.627 0.727 . . . . 0.0 110.854 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.46 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.6 Cg_endo -69.8 0.0 6.31 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.747 2.298 . . . . 0.0 112.288 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 7.6 t -52.09 161.69 0.57 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.875 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.61 175.07 25.33 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.432 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 -178.92 2.54 Favored 'Trans proline' 0 C--O 1.231 0.158 0 C-N-CA 122.663 2.242 . . . . 0.0 112.397 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.3 p 52.63 39.03 27.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.884 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.2 t -57.4 161.09 3.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.916 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.492 -179.945 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.371 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.3 p -48.42 -32.95 8.41 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.864 0.364 . . . . 0.0 110.808 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.8 p -62.43 -50.34 71.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.856 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -40.16 139.66 1.11 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.452 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.1 m -58.46 -46.51 86.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.894 0.378 . . . . 0.0 110.879 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 74.6 m -100.93 109.12 21.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.909 -179.854 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.43 -174.07 46.03 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.453 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.1 mp -70.22 -48.54 56.59 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.785 0.326 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -98.65 17.96 17.95 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.857 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 26.5 t -82.32 16.78 1.9 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.855 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -104.33 16.24 26.59 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.894 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 38.8 mt -105.5 146.04 30.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -92.59 168.49 11.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.851 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.452 HD13 ' CD2' ' A' ' 30' ' ' TYR . 13.5 mt -94.61 153.77 40.17 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.578 0.704 . . . . 0.0 110.915 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.665 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.84 -173.45 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.693 2.262 . . . . 0.0 112.285 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.43 149.92 47.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.123 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 83.88 -39.25 2.84 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.387 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.665 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 72.6 m95 -74.94 131.91 41.03 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.707 0.289 . . . . 0.0 110.926 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -145.46 112.91 6.23 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.896 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.2 145.65 47.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.908 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.561 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 18.7 mm -130.06 132.05 65.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.126 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -104.24 118.59 37.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.873 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.429 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.0 t70 -139.73 139.86 23.17 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.576 0.703 . . . . 0.0 110.877 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.428 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.5 Cg_endo -69.79 -8.85 24.65 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.687 2.258 . . . . 0.0 112.312 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.5 t -112.92 -37.91 2.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.157 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.8 m-85 -98.28 -32.06 11.74 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.939 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.08 -143.63 18.93 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.588 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.544 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -98.37 108.06 21.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.82 0.343 . . . . 0.0 111.115 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.561 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 27.4 p90 -135.13 131.83 37.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.895 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.458 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.9 m-30 -88.64 120.1 29.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.915 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.408 ' CG2' ' CE2' ' A' ' 29' ' ' TYR . 21.9 t -102.79 123.17 55.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.122 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.618 ' OD2' ' CZ3' ' A' ' 18' ' ' TRP . 5.0 m-20 -97.9 118.73 35.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.852 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 81.1 m-70 -92.31 -4.97 53.16 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.8 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.591 ' CD1' ' N ' ' A' ' 34' ' ' ILE . 0.8 OUTLIER -96.39 -49.98 11.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.122 -179.994 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.459 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 14.9 m-80 -98.36 -12.36 21.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.9 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 44.0 mmm-85 64.3 46.29 3.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.858 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.459 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 22.8 pttt -126.09 127.48 45.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.941 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -107.63 121.01 43.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.164 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.459 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 8.7 pt20 -150.29 144.92 25.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.885 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . 0.544 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 5.1 m-85 -79.12 -28.76 42.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -60.4 159.33 10.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.842 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.461 ' OD1' ' CB ' ' A' ' 44' ' ' SER . 14.7 t-20 -114.73 102.01 54.65 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.632 0.729 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.459 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.0 Cg_endo -69.79 3.57 2.71 Favored 'Trans proline' 0 C--O 1.232 0.19 0 C-N-CA 122.72 2.28 . . . . 0.0 112.33 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.461 ' CB ' ' OD1' ' A' ' 42' ' ' ASN . 8.3 t -52.01 168.73 0.08 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.856 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 156.02 160.09 9.79 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.499 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 127.58 14.83 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.699 2.266 . . . . 0.0 112.4 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.1 t -66.17 -53.67 34.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.854 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' SER . . . . . 0.42 ' O ' ' C ' ' A' ' 49' ' ' GLY . 35.0 p -159.64 157.24 29.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.844 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' A' ' 48' ' ' SER . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.459 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.465 -0.254 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.5 t -156.52 145.71 20.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.947 0.403 . . . . 0.0 110.813 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 76.7 p -77.84 -45.8 23.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.81 -179.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 105.26 61.72 0.64 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.507 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.6 m 57.06 42.1 26.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.868 0.366 . . . . 0.0 110.837 -179.701 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.4 m -74.4 -49.86 20.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.896 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 43.33 -112.92 0.6 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.502 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -94.42 149.45 21.23 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.817 0.342 . . . . 0.0 110.955 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -117.78 103.01 9.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.855 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 73.9 m -92.98 16.04 13.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.895 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -114.65 15.33 17.66 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.886 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 36.5 mt -125.55 161.84 26.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.916 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -90.33 171.43 9.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.919 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.574 HD12 ' CD2' ' A' ' 30' ' ' TYR . 9.2 mt -92.96 154.51 41.82 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.577 0.704 . . . . 0.0 110.917 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.652 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.8 Cg_endo -69.83 -177.41 1.89 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.626 2.217 . . . . 0.0 112.375 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.38 144.78 56.92 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.053 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.409 ' CA ' HD12 ' A' ' 34' ' ' ILE . . . 90.75 -35.87 3.76 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.44 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.652 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 70.5 m95 -78.74 132.73 37.06 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.758 0.313 . . . . 0.0 110.938 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -139.23 111.76 7.67 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.11 146.52 47.44 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.47 ' HB ' ' CZ ' ' A' ' 29' ' ' TYR . 29.9 mm -132.86 133.55 58.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.178 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -106.45 118.93 37.94 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.868 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.444 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -138.57 137.98 21.26 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.577 0.703 . . . . 0.0 110.85 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -8.38 23.46 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.657 2.238 . . . . 0.0 112.372 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.7 t -112.83 -38.02 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.095 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.412 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.04 -31.89 11.91 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.16 -147.63 19.72 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.486 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.423 HD13 ' N ' ' A' ' 28' ' ' ILE . 1.8 mp -97.07 108.88 22.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.873 0.368 . . . . 0.0 111.065 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.47 ' CZ ' ' HB ' ' A' ' 21' ' ' ILE . 42.4 p90 -133.41 131.83 40.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.574 ' CD2' HD12 ' A' ' 14' ' ' LEU . 5.7 m-30 -88.6 124.22 33.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.895 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.2 t -106.06 114.9 46.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.148 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.53 ' OD2' ' CE2' ' A' ' 18' ' ' TRP . 35.9 t0 -91.96 102.25 14.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.836 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -71.53 -10.37 59.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.849 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.516 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 0.8 OUTLIER -92.32 -60.26 2.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.113 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.466 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 5.9 m-80 -81.29 -21.7 39.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.778 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 10.6 mmt85 67.89 47.63 1.09 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.879 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.466 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 16.9 pttt -139.65 121.86 15.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.879 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 3.3 p -93.07 125.67 37.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.166 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.437 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 5.7 pt20 -150.58 140.15 21.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.89 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -73.5 -21.15 60.48 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.923 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 52.8 mm-40 -66.03 157.71 30.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.881 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -115.76 101.98 54.11 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.603 0.716 . . . . 0.0 110.875 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.437 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.1 Cg_endo -69.75 2.87 3.13 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.396 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.2 p -52.62 146.46 10.09 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.86 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 131.55 176.83 14.57 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.485 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 -177.59 1.93 Allowed 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.726 2.284 . . . . 0.0 112.298 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 13.3 t -94.42 146.51 24.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 14.9 t -89.65 113.35 24.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.882 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.527 -179.996 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.273 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.2 t -120.17 112.34 18.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.865 0.364 . . . . 0.0 110.897 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 80.2 p -160.5 153.1 20.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.806 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -96.21 -119.39 3.59 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.5 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 82.6 p -163.49 167.44 21.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.941 0.4 . . . . 0.0 110.846 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 17.1 m -92.68 176.43 6.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.795 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -43.23 119.9 2.56 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.516 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.458 ' HG ' ' N ' ' A' ' 9' ' ' ASP . 1.3 pt? -39.24 -39.38 0.61 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.804 0.335 . . . . 0.0 110.951 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.458 ' N ' ' HG ' ' A' ' 8' ' ' LEU . 4.6 m-20 -128.37 129.34 46.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.87 179.798 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.7 m -94.19 17.02 13.38 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.893 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -108.55 15.68 23.61 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.894 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 25.1 mt -112.71 146.0 39.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.897 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 27.0 mt-10 -85.98 173.34 10.0 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.867 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.582 HD12 ' CD2' ' A' ' 30' ' ' TYR . 13.7 mt -100.63 153.47 37.72 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.661 0.743 . . . . 0.0 110.908 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.655 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.73 -175.87 1.29 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.66 2.24 . . . . 0.0 112.347 179.842 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.87 145.24 56.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.083 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.464 ' CA ' HD12 ' A' ' 34' ' ' ILE . . . 89.52 -41.09 3.01 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.531 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.655 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 69.8 m95 -73.18 129.92 39.11 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.763 0.316 . . . . 0.0 110.916 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -138.45 112.36 8.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.917 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -74.57 145.49 43.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.909 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.572 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 26.2 mm -132.12 133.43 60.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.123 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -105.36 119.39 38.96 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.873 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.456 ' O ' ' N ' ' A' ' 27' ' ' GLY . 10.5 t70 -140.06 138.45 19.48 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.567 0.699 . . . . 0.0 110.883 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -9.78 26.95 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.677 2.251 . . . . 0.0 112.341 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.9 t -111.27 -38.0 3.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.095 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.402 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.8 m-85 -98.05 -33.0 11.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.89 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.41 -146.79 19.16 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.479 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.468 HD13 ' N ' ' A' ' 28' ' ' ILE . 2.0 mp -97.68 109.76 24.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.845 0.355 . . . . 0.0 111.152 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.572 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 27.1 p90 -134.53 131.63 38.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.582 ' CD2' HD12 ' A' ' 14' ' ' LEU . 4.9 m-30 -88.51 120.77 30.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.942 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.9 t -106.13 115.69 48.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.143 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.414 ' O ' ' N ' ' A' ' 36' ' ' ARG . 8.8 t0 -94.2 101.99 13.99 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.85 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 76.5 m-70 -67.39 -13.92 62.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.878 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.511 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.1 mp -85.35 -62.86 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.101 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.478 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 5.8 m-80 -83.56 -15.83 47.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.421 ' HB3' ' NH1' ' A' ' 36' ' ' ARG . 4.8 mmm180 64.25 47.68 3.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.852 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.478 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 21.1 pttt -129.75 136.79 50.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.835 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 22.6 p -113.44 123.04 49.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.108 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.47 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 8.1 pt20 -149.96 138.54 20.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.948 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -72.59 -16.22 61.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.948 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -73.54 159.97 32.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.857 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.407 ' OD1' ' CB ' ' A' ' 44' ' ' SER . 11.9 t-20 -116.43 101.93 53.6 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.646 0.736 . . . . 0.0 110.926 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.47 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.5 Cg_endo -69.72 3.56 2.68 Favored 'Trans proline' 0 C--N 1.342 0.236 0 C-N-CA 122.687 2.258 . . . . 0.0 112.354 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.407 ' CB ' ' OD1' ' A' ' 42' ' ' ASN . 19.5 t -52.1 156.96 1.44 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.855 -179.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 129.68 160.21 10.09 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.502 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.62 115.74 4.21 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.71 2.273 . . . . 0.0 112.4 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 64.7 m -81.03 -58.9 2.87 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.905 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.8 m 54.33 42.17 31.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.921 -179.796 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.41 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.441 -179.918 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.453 -0.259 . . . . 0.0 112.453 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 30.0 t -42.46 -44.86 4.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.877 0.37 . . . . 0.0 110.796 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.7 m -79.11 148.88 32.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.862 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -146.93 -153.85 6.02 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.463 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 28.9 t -58.37 151.04 20.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.865 0.364 . . . . 0.0 110.849 -179.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 8.9 t -154.97 159.26 40.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.891 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 133.97 158.17 8.49 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.446 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.9 mp -85.06 153.67 22.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.863 0.363 . . . . 0.0 110.865 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -93.3 116.61 29.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.798 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.1 p -81.42 13.37 3.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.855 -179.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -112.97 16.48 19.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.832 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 30.0 mt -110.72 154.17 24.25 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.895 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -104.12 166.78 10.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.819 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.542 HD12 ' CG ' ' A' ' 30' ' ' TYR . 10.8 mt -85.06 154.94 60.89 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.65 0.738 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.645 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.8 Cg_endo -69.77 -173.61 0.75 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.707 2.271 . . . . 0.0 112.323 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.86 144.52 55.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.102 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.48 ' CA ' HD11 ' A' ' 34' ' ' ILE . . . 92.14 -39.14 3.06 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.479 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.645 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 69.1 m95 -74.68 131.31 40.77 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.669 0.271 . . . . 0.0 110.916 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.4 tt0 -135.82 111.82 9.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.891 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.11 146.65 39.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.859 -179.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.543 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 31.5 mm -133.56 135.52 55.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.137 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 -107.33 117.66 34.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.905 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.43 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.4 t70 -137.71 137.9 22.85 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.638 0.733 . . . . 0.0 110.796 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -8.12 22.8 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.68 2.253 . . . . 0.0 112.333 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 86.5 t -113.17 -38.03 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.182 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.435 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.5 m-85 -97.46 -31.72 12.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.942 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.44 -148.28 20.51 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.459 HD11 ' N ' ' A' ' 28' ' ' ILE . 2.0 mp -96.6 108.97 22.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.778 0.323 . . . . 0.0 111.17 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.543 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 37.9 p90 -132.84 131.38 40.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.928 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.542 ' CG ' HD12 ' A' ' 14' ' ' LEU . 4.9 m-30 -88.38 123.6 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.865 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.8 t -107.94 115.08 48.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.146 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 28.3 t0 -91.63 102.02 14.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.844 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -68.22 -16.52 64.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.817 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.517 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 1.0 OUTLIER -86.87 -61.11 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.117 -179.988 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 -79.74 -16.97 54.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.902 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 64.47 45.78 3.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.848 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 1.4 pttm -131.68 146.2 52.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.881 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.7 p -120.5 122.94 41.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.112 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.435 ' NE2' ' HB2' ' A' ' 41' ' ' GLU . 6.7 pt20 -150.53 140.1 21.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.934 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -72.57 -20.75 61.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.901 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.435 ' HB2' ' NE2' ' A' ' 39' ' ' GLN . 35.0 mp0 -68.36 157.39 35.8 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.866 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.473 ' ND2' ' CD2' ' A' ' 14' ' ' LEU . 8.9 t-20 -115.36 102.15 54.45 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.659 0.742 . . . . 0.0 110.844 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.431 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.5 Cg_endo -69.87 3.37 2.86 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.677 2.251 . . . . 0.0 112.332 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 34.2 t -52.16 142.67 15.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.838 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 129.22 162.77 11.02 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.474 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -16.34 37.65 Favored 'Trans proline' 0 C--O 1.23 0.095 0 C-N-CA 122.702 2.268 . . . . 0.0 112.375 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 67.9 m -46.8 -45.36 19.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.833 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 99.3 p -44.16 -46.84 8.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.785 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.48 -179.939 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.546 -0.222 . . . . 0.0 112.546 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 43.7 t -105.32 149.2 26.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.884 0.374 . . . . 0.0 110.888 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.4 t -75.49 138.11 41.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.815 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.47 104.98 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.526 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 78.6 p -71.98 -49.05 40.53 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.828 0.346 . . . . 0.0 110.885 -179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 77.9 p -128.55 160.61 31.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.879 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -69.45 112.72 4.67 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.478 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -87.31 -53.68 4.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.72 0.295 . . . . 0.0 110.866 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -85.61 17.69 3.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.855 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.3 t -76.98 7.32 4.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.824 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -107.57 15.53 24.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.844 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 30.6 mt -125.16 158.01 35.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.914 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -92.67 171.3 9.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.882 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.455 HD23 ' ND2' ' A' ' 42' ' ' ASN . 17.4 mt -98.73 152.29 37.79 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.579 0.704 . . . . 0.0 110.954 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.628 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.74 -171.21 0.45 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.719 2.28 . . . . 0.0 112.417 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.95 147.35 53.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.084 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.481 ' CA ' HD11 ' A' ' 34' ' ' ILE . . . 88.2 -44.66 3.22 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.47 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.628 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 63.2 m95 -68.38 135.92 52.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.779 0.323 . . . . 0.0 110.903 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -149.52 115.61 5.72 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.79 142.0 42.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.566 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 38.4 mm -125.34 131.52 72.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.134 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -102.65 117.78 35.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.0 t70 -139.12 139.48 23.37 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.578 0.704 . . . . 0.0 110.884 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.409 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 54.6 Cg_endo -69.69 -11.31 30.67 Favored 'Trans proline' 0 N--CA 1.465 -0.183 0 C-N-CA 122.668 2.245 . . . . 0.0 112.437 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.3 t -109.93 -37.98 3.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.155 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.36 -32.85 11.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.9 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.48 -140.78 15.82 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.472 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.605 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.9 mp -102.08 109.4 26.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.808 0.337 . . . . 0.0 111.132 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.566 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 32.6 p90 -135.54 133.96 38.94 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.882 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.478 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.4 m-30 -90.18 126.8 35.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.927 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.2 t -113.21 117.24 54.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.125 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.459 ' O ' ' N ' ' A' ' 36' ' ' ARG . 62.4 t0 -95.14 103.31 15.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 47.7 m-70 -68.6 -16.38 63.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.645 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 0.6 OUTLIER -83.39 -55.49 7.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.121 -179.993 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . 0.405 ' CB ' ' HZ2' ' A' ' 37' ' ' LYS . 63.1 m-20 -93.33 -2.39 54.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.854 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.459 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.5 mpt_? 54.62 47.94 21.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.405 ' HZ2' ' CB ' ' A' ' 35' ' ' ASN . 8.7 mtmm -113.54 160.8 18.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -145.12 108.3 4.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.14 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.454 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 9.4 pt20 -147.88 144.19 27.93 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.919 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . 0.605 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.6 m-85 -76.29 -26.54 55.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -63.6 161.42 14.8 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.854 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.455 ' ND2' HD23 ' A' ' 14' ' ' LEU . 18.7 t-20 -116.62 101.93 53.44 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.614 0.721 . . . . 0.0 110.933 -179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.463 ' O ' ' C ' ' A' ' 44' ' ' SER . 54.2 Cg_endo -69.74 -11.26 30.5 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.637 2.225 . . . . 0.0 112.377 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.463 ' C ' ' O ' ' A' ' 43' ' ' PRO . 8.4 t -33.56 -65.77 0.17 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.85 -179.865 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -63.61 173.1 12.89 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.521 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 83.24 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.69 2.26 . . . . 0.0 112.338 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 28.2 p -108.5 124.8 51.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.84 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 48.9 m -114.89 175.81 5.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.953 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.498 -179.973 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.407 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . 0.4 ' O ' ' C ' ' A' ' 3' ' ' SER . 34.0 t 64.86 42.37 4.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.841 0.353 . . . . 0.0 110.829 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . 0.422 ' HG ' ' N ' ' A' ' 4' ' ' GLY . 86.3 p -37.48 -41.18 0.43 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.882 -179.787 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.422 ' N ' ' HG ' ' A' ' 3' ' ' SER . . . 152.61 161.49 10.28 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.546 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 29.6 t -92.83 142.41 27.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.806 0.336 . . . . 0.0 110.924 -179.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.4 m -43.41 -50.72 6.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.857 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 132.95 121.03 2.18 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.503 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 54.0 mt -91.2 -45.82 8.43 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.769 0.319 . . . . 0.0 110.907 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.06 17.98 14.41 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.904 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.0 m -82.02 16.27 1.98 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.908 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -112.93 16.36 19.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.899 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 30.5 mt -115.61 167.67 10.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -97.26 168.31 10.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.859 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.53 HD13 ' CG ' ' A' ' 30' ' ' TYR . 9.6 mt -89.19 156.67 48.68 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.614 0.721 . . . . 0.0 110.874 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.651 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.79 -170.38 0.39 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.614 2.209 . . . . 0.0 112.311 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.62 140.91 48.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.12 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 94.62 -32.19 6.24 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.505 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.651 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 67.4 m95 -81.89 147.72 29.15 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.703 0.287 . . . . 0.0 110.896 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.486 ' CG ' ' O ' ' A' ' 19' ' ' GLU . 2.3 pt-20 -152.71 119.57 5.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.888 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.59 141.47 36.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.95 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.571 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 18.2 mm -129.41 132.4 66.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.097 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -106.02 120.6 42.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.933 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.451 ' O ' ' N ' ' A' ' 27' ' ' GLY . 10.8 t70 -140.37 139.66 21.21 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.561 0.696 . . . . 0.0 110.888 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.425 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.9 Cg_endo -69.67 -8.18 22.94 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.696 2.264 . . . . 0.0 112.376 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 99.5 t -114.89 -37.9 2.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.123 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.31 -29.2 13.3 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.905 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.451 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 82.51 -151.73 29.82 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.508 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.445 HD12 ' N ' ' A' ' 28' ' ' ILE . 1.9 mp -89.81 110.88 22.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.824 0.345 . . . . 0.0 111.05 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.571 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 46.3 p90 -136.03 130.88 34.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.913 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.53 ' CG ' HD13 ' A' ' 14' ' ' LEU . 5.3 m-30 -88.48 132.79 34.34 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.963 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.4 t -114.62 116.47 52.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.138 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.478 ' OD1' ' CD1' ' A' ' 18' ' ' TRP . 13.3 t0 -98.59 102.03 13.64 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.898 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 -72.07 -11.24 60.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.84 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.508 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 0.8 OUTLIER -85.83 -57.2 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.129 179.947 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -87.65 -18.36 29.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.895 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 68.02 47.88 1.02 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.87 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.413 ' HE2' ' CH2' ' A' ' 18' ' ' TRP . 8.5 pttm -139.35 130.96 27.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.1 p -104.19 126.15 51.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 5.3 pt20 -150.63 141.82 23.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.956 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -73.78 -21.63 60.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 30.0 mm-40 -66.41 154.1 41.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.924 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.417 ' ND2' ' CD2' ' A' ' 14' ' ' LEU . 9.0 t-20 -112.3 101.99 53.22 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.597 0.713 . . . . 0.0 110.911 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.402 ' HD2' ' CD2' ' A' ' 14' ' ' LEU . 53.1 Cg_endo -69.79 2.2 3.77 Favored 'Trans proline' 0 C--N 1.34 0.13 0 C-N-CA 122.672 2.248 . . . . 0.0 112.31 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 30.3 t -52.1 148.49 6.18 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.868 -179.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 144.27 165.73 11.11 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.478 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.7 0.7 5.22 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.658 2.239 . . . . 0.0 112.376 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.0 t -108.27 131.68 54.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.834 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 t -109.63 127.74 54.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.905 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.459 179.985 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.521 -0.232 . . . . 0.0 112.521 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.6 m -87.26 -60.92 1.84 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.811 0.339 . . . . 0.0 110.8 -179.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.8 m -77.25 -54.95 5.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.33 87.06 1.11 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.512 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 42.4 t -83.11 -46.56 12.63 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.782 0.325 . . . . 0.0 110.796 -179.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.4 t -64.29 151.95 42.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.915 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -124.85 -89.19 0.8 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.493 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mt -119.76 121.53 39.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.788 0.328 . . . . 0.0 110.928 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.423 ' CG ' HD11 ' A' ' 12' ' ' LEU . 2.2 t70 -102.29 171.79 7.27 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.869 179.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.563 ' O ' ' CG ' ' A' ' 11' ' ' GLU . 1.7 t -147.82 178.0 8.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.826 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.563 ' CG ' ' O ' ' A' ' 10' ' ' SER . 2.8 pt-20 54.0 32.05 14.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.905 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.437 ' HG ' ' O ' ' A' ' 10' ' ' SER . 27.3 mt -117.48 162.64 17.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.989 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -111.14 173.99 6.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.919 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.568 HD11 ' CD2' ' A' ' 30' ' ' TYR . 11.6 mt -104.2 154.11 38.48 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.609 0.719 . . . . 0.0 110.956 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.623 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.6 Cg_endo -69.76 -171.78 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.647 2.232 . . . . 0.0 112.368 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.73 149.98 49.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.077 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.412 ' CA ' ' CD1' ' A' ' 34' ' ' ILE . . . 84.94 -40.46 3.0 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.539 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.623 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 58.4 m95 -72.51 140.44 48.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.712 0.291 . . . . 0.0 110.995 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -152.24 115.04 4.6 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.406 ' O ' ' HG3' ' A' ' 20' ' ' LYS . 0.0 OUTLIER -74.35 138.6 43.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.568 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 34.9 mm -121.13 131.21 73.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.166 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -103.54 117.94 35.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.854 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.44 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.7 t70 -138.91 137.98 20.55 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.578 0.704 . . . . 0.0 110.88 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 -8.26 23.14 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.665 2.244 . . . . 0.0 112.291 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.5 t -112.86 -37.97 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.169 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . 0.418 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.7 m-85 -97.94 -31.98 11.9 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.959 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.4 -145.49 18.47 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.561 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.596 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -98.99 108.57 22.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.813 0.339 . . . . 0.0 111.081 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.568 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 31.5 p90 -134.42 131.58 38.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.568 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.6 m-30 -88.75 122.4 32.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.912 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.0 t -108.11 115.62 49.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.146 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 57.1 t0 -94.77 101.99 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.828 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 65.9 m-70 -68.74 -18.76 64.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.862 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.497 ' CD1' ' N ' ' A' ' 34' ' ' ILE . 1.1 mp -81.67 -62.73 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.109 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.2 m-80 -80.34 -16.37 54.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.867 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 27.5 mmm180 64.11 47.69 3.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.53 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 11.1 ptpt -133.11 129.44 37.95 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.7 p -105.34 119.46 39.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.198 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.425 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.4 pt20 -150.29 140.5 22.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.91 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . 0.596 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.55 -25.08 59.08 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.884 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -62.06 161.84 10.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.872 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.404 ' ND2' ' CD2' ' A' ' 14' ' ' LEU . 10.8 t-20 -118.44 101.93 50.59 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.581 0.705 . . . . 0.0 110.937 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.425 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.7 Cg_endo -69.65 -11.68 31.51 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.677 2.251 . . . . 0.0 112.346 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 23.0 t -42.78 -49.61 5.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.832 -179.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -47.04 176.24 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.508 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 159.24 54.11 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.708 2.272 . . . . 0.0 112.277 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 69.7 m 62.64 42.68 8.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.88 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 22.6 t -54.24 -59.67 4.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.878 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.484 179.994 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.246 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.9 m -67.09 -46.88 72.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.889 0.376 . . . . 0.0 110.827 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.8 p -122.3 160.39 25.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.791 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -81.79 45.66 3.33 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.532 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 24.3 p -123.24 119.54 30.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.891 0.377 . . . . 0.0 110.835 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.8 m -151.41 150.26 30.25 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.84 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.12 64.18 1.24 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.545 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.8 mt -76.73 -52.62 9.25 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.818 0.342 . . . . 0.0 110.953 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 63.3 m-20 -87.57 130.91 34.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.948 179.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.7 p -106.22 14.64 27.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.846 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -116.88 16.52 15.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.863 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 32.2 mt -110.87 148.58 32.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.963 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 27.1 mt-10 -85.67 169.56 13.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.865 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' LEU . . . . . 0.573 HD12 ' CD2' ' A' ' 30' ' ' TYR . 14.3 mt -97.16 154.09 38.25 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.556 0.693 . . . . 0.0 110.947 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.651 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.5 Cg_endo -69.77 -173.49 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.721 2.281 . . . . 0.0 112.292 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.52 146.91 54.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.035 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.458 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 87.9 -42.14 3.1 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.456 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' TRP . . . . . 0.651 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 70.8 m95 -71.78 122.3 20.45 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.834 0.35 . . . . 0.0 110.911 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.5 tt0 -128.3 111.43 13.36 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 -179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.17 145.2 40.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.854 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.562 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 32.8 mm -132.68 133.58 59.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.127 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -106.06 117.99 35.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.912 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.474 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.1 t70 -138.36 139.67 25.87 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.64 0.733 . . . . 0.0 110.891 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.421 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.7 Cg_endo -69.71 -11.8 31.67 Favored 'Trans proline' 0 C--O 1.232 0.225 0 C-N-CA 122.704 2.269 . . . . 0.0 112.33 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 94.0 t -109.36 -37.95 3.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.162 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.28 -32.27 11.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.846 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.13 -140.95 16.0 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.439 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.448 HD13 ' N ' ' A' ' 28' ' ' ILE . 1.9 mp -102.91 108.87 25.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 0.0 111.179 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' TYR . . . . . 0.562 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 25.0 p90 -133.39 131.14 39.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.922 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' TYR . . . . . 0.573 ' CD2' HD12 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.27 119.65 28.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.916 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.4 t -101.88 115.57 43.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.098 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.615 ' OD2' ' CZ3' ' A' ' 18' ' ' TRP . 3.8 m-20 -88.87 112.96 23.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 87.6 m-70 -86.37 -7.07 58.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.946 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.59 ' CD1' ' N ' ' A' ' 34' ' ' ILE . 0.7 OUTLIER -97.11 -49.13 12.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.097 179.99 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 -96.06 -13.66 23.53 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.85 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ARG . . . . . 0.401 ' HA ' ' O ' ' A' ' 32' ' ' ASP . 25.3 mmt180 65.32 42.49 3.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.851 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . 0.546 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 0.1 OUTLIER -121.51 129.86 53.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.877 -179.986 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -111.21 116.1 30.48 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.149 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . 0.451 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 6.8 pt20 -145.96 146.39 31.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.935 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -77.96 -30.9 50.59 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.939 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLU . . . . . 0.409 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 4.1 mt-10 -58.25 166.75 1.53 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.845 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.466 ' ND2' HD21 ' A' ' 14' ' ' LEU . 12.5 t-20 -120.81 102.0 44.87 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.663 0.744 . . . . 0.0 110.906 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' PRO . . . . . 0.539 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.77 -1.58 8.73 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.682 2.255 . . . . 0.0 112.271 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 7.9 t -52.02 154.47 2.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.88 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 158.52 166.54 17.85 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.533 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.69 2.54 3.41 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.749 2.3 . . . . 0.0 112.345 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 2.5 m -112.77 107.34 15.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.793 -179.77 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 50.1 m -119.2 129.81 55.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.852 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.282 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.507 -179.996 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.471 HD11 ' CD2' ' A' ' 30' ' ' TYR . 13.3 mt . . . . . 0 C--O 1.23 0.071 0 CA-C-O 121.557 0.694 . . . . 0.0 110.953 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.611 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.85 -175.55 1.22 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.611 2.208 . . . . 0.0 112.313 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.26 146.76 53.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.09 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.665 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 89.5 -44.26 3.05 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.497 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.611 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -69.7 142.32 53.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.735 0.302 . . . . 0.0 110.904 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -153.29 114.67 4.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.922 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.441 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -72.71 144.26 47.74 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.919 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.576 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 41.9 mm -128.17 130.62 69.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.177 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -104.97 117.86 35.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.859 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -137.84 139.78 27.52 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.624 0.726 . . . . 0.0 110.878 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.415 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.2 Cg_endo -69.83 -7.96 22.39 Favored 'Trans proline' 0 C--O 1.233 0.237 0 C-N-CA 122.646 2.231 . . . . 0.0 112.302 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 96.4 t -113.83 -38.01 2.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.081 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.8 m-85 -98.08 -30.79 12.47 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.941 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.26 -142.91 18.43 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.527 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.557 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.8 mp -99.64 111.46 29.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.848 0.356 . . . . 0.0 111.116 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.576 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 39.2 p90 -137.2 131.54 32.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.978 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.471 ' CD2' HD11 ' A' ' 14' ' ' LEU . 5.5 m-30 -88.98 123.6 33.47 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.925 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.415 ' CG2' ' CE2' ' A' ' 29' ' ' TYR . 10.8 t -110.2 116.57 52.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.148 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.407 ' OD2' ' NE1' ' A' ' 18' ' ' TRP . 51.5 t0 -95.77 106.09 18.17 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.929 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -71.36 -14.27 62.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.819 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.665 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.9 OUTLIER -85.98 -62.34 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.158 179.971 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.425 ' C ' ' HD3' ' A' ' 36' ' ' ARG . 28.0 m-80 -80.65 -13.81 58.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.852 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.425 ' HD3' ' C ' ' A' ' 35' ' ' ASN . 1.8 mpp_? 63.09 46.25 4.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -128.03 154.75 45.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.855 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.7 p -129.45 117.95 21.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.133 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -149.66 141.86 24.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.956 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' TYR . . . . . 0.557 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.81 -25.99 59.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.922 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 -63.06 160.77 14.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.94 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -115.48 102.02 54.33 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.589 0.709 . . . . 0.0 110.849 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.442 ' HD2' HD21 ' A' ' 14' ' ' LEU . 53.4 Cg_endo . . . . . 0 C--N 1.341 0.16 0 C-N-CA 122.705 2.27 . . . . 0.0 112.322 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.613 HD11 ' CD2' ' A' ' 30' ' ' TYR . 11.0 mt . . . . . 0 C--O 1.23 0.052 0 CA-C-O 121.603 0.716 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.63 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.2 Cg_endo -69.7 -172.74 0.6 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.668 2.245 . . . . 0.0 112.349 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.58 148.62 51.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.093 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.695 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 86.91 -41.39 3.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.492 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.63 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.0 m95 -71.3 143.68 50.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.65 0.262 . . . . 0.0 110.956 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 30.3 tp10 -154.3 113.49 3.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.847 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.462 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -72.95 139.8 46.99 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.934 179.888 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.577 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 34.7 mm -122.76 129.12 75.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.164 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -101.97 117.92 35.82 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.896 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.447 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.7 t70 -139.01 139.16 22.57 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.614 0.721 . . . . 0.0 110.836 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -9.81 27.01 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.72 2.28 . . . . 0.0 112.372 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.4 t -111.54 -37.94 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.123 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.413 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -97.79 -32.1 11.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.967 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.27 -144.67 18.66 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.455 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.485 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.0 mp -98.62 109.81 24.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.781 0.325 . . . . 0.0 111.105 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.577 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 36.9 p90 -136.16 130.75 33.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.613 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.78 124.35 34.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.914 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.466 HG22 HG22 ' A' ' 38' ' ' THR . 12.0 t -110.91 115.93 51.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.114 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.406 ' O ' ' N ' ' A' ' 36' ' ' ARG . 13.5 t0 -94.45 101.93 13.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.895 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -67.46 -18.38 65.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.695 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -80.7 -63.35 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.15 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -81.14 -16.72 52.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.818 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.406 ' N ' ' O ' ' A' ' 32' ' ' ASP . 17.7 mmt180 64.89 47.98 2.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.565 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.0 OUTLIER -132.47 129.03 38.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.869 179.976 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.466 HG22 HG22 ' A' ' 31' ' ' VAL . 2.3 p -104.59 120.19 40.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.167 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -150.11 140.91 22.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.932 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' TYR . . . . . 0.485 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.41 -23.77 59.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.908 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 55.7 mm-40 -64.86 158.28 25.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.909 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 55.8 t30 -115.32 102.0 54.46 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.665 0.745 . . . . 0.0 110.896 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.409 ' HD2' HD21 ' A' ' 14' ' ' LEU . 53.1 Cg_endo . . . . . 0 C--N 1.342 0.209 0 C-N-CA 122.713 2.276 . . . . 0.0 112.335 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.505 HD11 ' CD2' ' A' ' 30' ' ' TYR . 15.1 mt . . . . . 0 C--O 1.231 0.111 0 CA-C-O 121.586 0.708 . . . . 0.0 110.923 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.632 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.3 Cg_endo -69.74 -172.19 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.605 2.203 . . . . 0.0 112.376 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.19 146.63 54.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.071 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.704 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 88.54 -40.7 3.06 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.467 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.632 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -72.64 142.66 48.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.733 0.301 . . . . 0.0 110.895 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -153.4 115.51 4.34 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.882 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.474 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.22 140.99 45.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 -179.967 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.559 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 38.1 mm -123.87 129.73 74.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.163 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.2 mt-10 -103.79 117.88 35.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.871 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.449 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.1 t70 -139.12 139.67 24.0 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.568 0.699 . . . . 0.0 110.905 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.42 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.6 Cg_endo -69.77 -9.48 26.2 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.627 2.218 . . . . 0.0 112.38 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 95.6 t -111.78 -38.04 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.13 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -97.91 -31.49 12.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.959 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.3 -145.73 19.86 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.456 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.598 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.7 mp -97.1 110.01 24.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.821 0.343 . . . . 0.0 111.198 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.559 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 34.9 p90 -137.37 130.62 30.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.901 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.505 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.0 m-30 -89.02 126.85 35.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.931 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.522 HG22 HG22 ' A' ' 38' ' ' THR . 10.6 t -112.67 116.13 51.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.115 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.463 ' O ' ' N ' ' A' ' 36' ' ' ARG . 10.4 t0 -93.56 102.16 14.35 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.821 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 -68.0 -17.14 64.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.889 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.704 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -82.46 -58.17 3.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.127 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -87.34 -14.29 41.16 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.887 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.463 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.2 mpt_? 62.59 47.99 4.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.79 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.469 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.0 OUTLIER -130.93 126.94 37.4 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.941 179.952 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.522 HG22 HG22 ' A' ' 31' ' ' VAL . 1.6 p -102.35 119.34 38.65 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.107 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -149.65 141.83 24.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.961 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' TYR . . . . . 0.598 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 3.0 m-85 -76.02 -24.6 55.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.89 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 25.7 mm-40 -62.93 161.25 13.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 61.2 t30 -116.36 102.1 53.61 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.616 0.722 . . . . 0.0 110.867 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo . . . . . 0 C--N 1.341 0.179 0 C-N-CA 122.655 2.237 . . . . 0.0 112.316 179.969 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.461 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 11.9 mt . . . . . 0 C--O 1.231 0.119 0 CA-C-O 121.619 0.723 . . . . 0.0 110.937 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.629 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.71 -175.82 1.27 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.677 2.251 . . . . 0.0 112.361 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.31 143.37 57.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.113 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.717 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 93.21 -41.49 2.69 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.543 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.629 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 60.4 m95 -72.69 137.75 46.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.721 0.296 . . . . 0.0 110.932 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -151.1 114.46 4.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.92 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.461 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -71.92 145.12 48.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.879 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.568 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 44.6 mm -129.13 131.76 67.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -106.57 117.99 35.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.851 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.424 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.6 t70 -138.54 139.65 25.36 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.608 0.718 . . . . 0.0 110.884 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.412 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.5 Cg_endo -69.74 -7.22 20.48 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.609 2.206 . . . . 0.0 112.362 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 95.2 t -114.49 -38.01 2.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.404 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.9 m-85 -98.29 -31.08 12.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.867 -179.856 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.02 -144.27 19.29 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.416 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.45 HD12 ' N ' ' A' ' 28' ' ' ILE . 1.8 mp -97.15 111.29 26.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.783 0.325 . . . . 0.0 111.145 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.568 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 32.0 p90 -139.18 131.35 28.13 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.935 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.481 ' CD1' ' N ' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.05 128.25 35.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.947 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.9 t -113.06 115.86 50.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -95.62 102.41 14.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.883 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 60.6 m-70 -69.51 -14.4 62.85 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.86 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.717 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.0 OUTLIER -87.16 -60.94 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.132 -179.981 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 21.0 m-20 -82.63 -15.19 53.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 13.1 mmm180 62.38 47.58 5.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.79 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.577 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 4.8 ptpp? -130.48 129.11 42.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.897 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -107.64 121.58 44.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.181 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.4 pt20 -150.05 141.86 23.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.881 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.2 m-85 -72.33 -26.99 62.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.903 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.435 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 6.1 mm-40 -68.99 162.99 25.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.946 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.468 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 1.9 t-20 -122.13 108.66 34.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.661 0.744 . . . . 0.0 110.862 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 42' ' ' ASN . 53.1 Cg_endo . . . . . 0 C--N 1.341 0.179 0 C-N-CA 122.698 2.265 . . . . 0.0 112.35 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.428 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 11.8 mt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 121.63 0.729 . . . . 0.0 110.899 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.629 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.3 Cg_endo -69.77 -174.58 0.94 Allowed 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.663 2.242 . . . . 0.0 112.314 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.23 143.74 57.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.071 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.683 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 93.15 -41.64 2.68 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.629 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 60.6 m95 -72.42 137.76 46.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.73 0.3 . . . . 0.0 110.955 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -151.35 117.06 5.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.835 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.525 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -75.53 143.55 42.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.916 179.907 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.567 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 45.0 mm -127.09 131.89 70.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.121 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -104.94 117.69 34.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.848 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.418 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -137.99 138.5 23.62 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.652 0.739 . . . . 0.0 110.899 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -6.62 19.04 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.689 2.259 . . . . 0.0 112.267 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 90.7 t -115.2 -38.02 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.133 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.42 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.8 m-85 -98.1 -31.23 12.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.925 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.04 -145.45 19.23 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.45 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.408 HD12 ' N ' ' A' ' 28' ' ' ILE . 2.0 mp -97.41 111.6 27.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 111.086 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.567 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.7 p90 -138.57 132.83 31.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.896 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.481 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.84 128.52 36.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.945 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.8 t -113.43 115.82 50.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.116 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -94.54 102.12 14.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.892 179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 70.2 m-70 -68.99 -12.86 62.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.683 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.9 OUTLIER -89.0 -60.39 2.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.134 179.958 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -83.01 -18.6 39.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.809 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.6 mmm180 65.67 48.05 2.03 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.577 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 14.9 ptpt -130.53 131.16 44.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -109.25 120.29 42.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.118 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 -149.43 140.89 23.32 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.965 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -71.19 -24.6 62.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.941 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.405 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 8.0 mt-10 -69.76 161.1 30.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.458 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 1.9 t-20 -122.75 105.45 35.4 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.637 0.732 . . . . 0.0 110.913 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.42 ' HD2' ' HA ' ' A' ' 42' ' ' ASN . 54.5 Cg_endo . . . . . 0 C--N 1.341 0.18 0 C-N-CA 122.73 2.286 . . . . 0.0 112.391 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.554 HD11 ' CD2' ' A' ' 30' ' ' TYR . 14.5 mt . . . . . 0 C--O 1.232 0.138 0 CA-C-O 121.59 0.71 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.629 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.1 Cg_endo -69.7 -173.85 0.79 Allowed 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.683 2.255 . . . . 0.0 112.392 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.73 149.29 49.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.098 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.724 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 86.05 -42.4 3.15 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.503 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.629 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.2 m95 -70.39 139.19 51.82 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.685 0.279 . . . . 0.0 110.916 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 29.4 tp10 -149.49 113.87 5.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.846 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.85 144.79 50.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.896 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.582 HG21 ' OH ' ' A' ' 29' ' ' TYR . 33.9 mm -128.27 130.97 69.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.126 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -105.6 118.59 36.97 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.91 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.432 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.14 139.56 21.47 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.669 0.747 . . . . 0.0 110.845 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.407 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.6 Cg_endo -69.74 -8.65 24.14 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.751 2.301 . . . . 0.0 112.336 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 91.3 t -112.68 -38.04 2.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.113 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.417 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.22 -32.45 11.56 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.927 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.4 -144.62 18.55 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.505 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.6 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.9 mp -97.99 109.59 23.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.811 0.338 . . . . 0.0 111.195 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.582 ' OH ' HG21 ' A' ' 21' ' ' ILE . 38.4 p90 -135.34 130.96 35.81 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.95 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.554 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.9 m-30 -88.65 121.44 31.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.981 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.465 HG22 HG22 ' A' ' 38' ' ' THR . 11.7 t -107.96 116.36 51.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.151 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -96.03 102.59 14.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 60.6 m-70 -68.26 -18.14 64.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.902 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.724 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -81.39 -63.42 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -79.22 -18.46 52.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.902 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.478 ' CZ ' ' HA ' ' A' ' 36' ' ' ARG . 0.1 OUTLIER 66.61 47.77 1.56 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 -179.971 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.502 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 6.3 ptpt -134.5 130.72 37.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.876 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.465 HG22 HG22 ' A' ' 31' ' ' VAL . 1.8 p -106.05 119.99 40.63 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.19 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -149.99 141.76 23.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.926 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' TYR . . . . . 0.6 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -75.05 -25.42 58.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.914 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -62.74 158.18 19.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.834 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 60.5 t30 -114.28 101.9 54.45 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.522 0.677 . . . . 0.0 110.915 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.426 ' HD2' HD21 ' A' ' 14' ' ' LEU . 53.9 Cg_endo . . . . . 0 N--CA 1.465 -0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.376 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.562 HD11 ' CD2' ' A' ' 30' ' ' TYR . 11.5 mt . . . . . 0 C--O 1.232 0.139 0 CA-C-O 121.569 0.699 . . . . 0.0 110.887 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.625 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.7 -171.73 0.5 Allowed 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.69 2.26 . . . . 0.0 112.368 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.23 147.32 52.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.106 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.744 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 88.58 -40.39 3.08 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.483 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.625 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 57.3 m95 -73.3 130.55 40.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.674 0.273 . . . . 0.0 110.887 -179.867 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -137.28 113.29 9.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.883 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.58 144.56 41.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.843 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.543 ' HB ' ' CZ ' ' A' ' 29' ' ' TYR . 29.9 mm -130.62 132.8 64.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.181 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -104.38 120.28 40.87 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.899 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.43 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.69 137.54 17.47 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.668 0.747 . . . . 0.0 110.876 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -7.68 21.66 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.654 2.236 . . . . 0.0 112.416 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.9 t -113.47 -37.95 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.218 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.417 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.14 -31.69 11.98 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.893 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.48 -148.19 20.43 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.435 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.414 HD12 ' N ' ' A' ' 28' ' ' ILE . 1.9 mp -96.39 109.17 22.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.862 0.363 . . . . 0.0 111.122 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.543 ' CZ ' ' HB ' ' A' ' 21' ' ' ILE . 37.9 p90 -133.31 131.07 39.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.562 ' CD2' HD11 ' A' ' 14' ' ' LEU . 4.7 m-30 -88.21 123.59 33.0 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.935 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.6 t -109.44 115.77 50.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.067 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.449 ' O ' ' N ' ' A' ' 36' ' ' ARG . 9.8 t0 -94.64 102.03 13.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 76.1 m-70 -68.55 -16.15 63.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.856 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.744 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -83.27 -58.6 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.176 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -87.42 -14.12 41.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.853 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 32' ' ' ASP . 4.1 mpt_? 62.73 47.47 4.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.919 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.58 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 5.6 ptpt -128.77 130.02 46.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.4 p -107.34 118.56 37.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.136 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.8 pt20 -150.07 142.99 24.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.889 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -75.12 -26.44 59.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.904 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 23.7 mm-40 -62.01 161.17 11.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 56.4 t30 -116.77 102.28 53.19 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.657 0.741 . . . . 0.0 110.891 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.448 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.154 0 C-N-CA 122.706 2.271 . . . . 0.0 112.34 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.44 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 14.5 mt . . . . . 0 C--O 1.232 0.139 0 CA-C-O 121.577 0.703 . . . . 0.0 110.926 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.643 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.0 Cg_endo -69.72 -175.78 1.26 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.702 2.268 . . . . 0.0 112.321 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.46 144.26 57.16 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.725 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 92.03 -40.82 2.86 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.501 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.643 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 63.8 m95 -73.04 135.27 44.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.769 0.319 . . . . 0.0 110.908 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -149.52 114.98 5.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.889 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.503 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -72.41 143.68 48.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.901 179.944 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.547 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 45.8 mm -127.02 131.67 70.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.125 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -104.84 117.74 34.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.92 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.417 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.9 t70 -139.15 139.13 22.2 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.591 0.71 . . . . 0.0 110.901 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -7.03 20.03 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.659 2.239 . . . . 0.0 112.372 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.6 t -114.5 -37.99 2.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.126 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.412 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.17 -31.81 11.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.94 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.57 -145.85 19.75 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.467 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.0 mp -96.63 108.57 21.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.792 0.33 . . . . 0.0 111.123 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.547 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.3 p90 -135.97 132.1 35.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.476 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.06 125.05 34.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.93 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.9 t -110.5 115.78 50.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.176 179.798 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -95.44 102.04 13.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 66.9 m-70 -68.93 -14.15 62.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.725 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -84.41 -63.26 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.169 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 19.2 m-20 -82.6 -17.24 45.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.916 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 33.4 mmm-85 65.81 47.42 2.08 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.836 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.58 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 4.1 ptpp? -129.81 126.75 38.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.952 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.3 p -104.92 122.11 45.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.185 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 -150.01 140.02 21.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.88 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.2 m-85 -71.1 -26.11 62.9 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.908 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -69.05 160.27 31.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.849 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.454 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 2.0 t-20 -120.23 106.8 40.21 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.618 0.723 . . . . 0.0 110.887 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 42' ' ' ASN . 53.4 Cg_endo . . . . . 0 C--O 1.231 0.173 0 C-N-CA 122.743 2.295 . . . . 0.0 112.347 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.588 HD11 ' CD2' ' A' ' 30' ' ' TYR . 13.3 mt . . . . . 0 C--O 1.231 0.09 0 CA-C-O 121.643 0.735 . . . . 0.0 110.879 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.651 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.68 -173.96 0.8 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.683 2.256 . . . . 0.0 112.367 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.42 149.64 48.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.122 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.756 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 84.52 -41.3 3.01 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.458 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.651 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 57.7 m95 -70.41 140.44 52.05 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.827 0.346 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -152.81 117.96 5.18 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.941 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.05 147.12 40.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.851 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.505 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 31.6 mm -131.01 132.04 63.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.161 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -105.16 117.8 34.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.883 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -138.05 137.47 21.22 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.606 0.717 . . . . 0.0 110.858 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.79 -4.04 13.24 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.651 2.234 . . . . 0.0 112.392 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.6 t -117.19 -38.03 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.123 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.425 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.56 -31.0 12.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.85 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.0 -146.08 18.94 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.436 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.582 ' O ' ' CE2' ' A' ' 40' ' ' TYR . 1.7 mp -98.43 108.3 21.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.849 0.357 . . . . 0.0 111.159 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.518 ' HB3' ' CE1' ' A' ' 40' ' ' TYR . 28.8 p90 -134.41 132.2 39.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.912 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.588 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.0 m-30 -88.65 122.53 32.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.925 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 t -107.78 115.89 49.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.129 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.459 ' O ' ' N ' ' A' ' 36' ' ' ARG . 57.6 t0 -95.15 101.95 13.73 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.861 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -68.57 -18.52 64.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.756 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -82.14 -57.16 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.125 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -87.18 -14.88 39.94 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.874 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.459 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.3 mpt_? 62.23 47.73 5.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.853 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.577 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 5.0 ptpp? -131.5 132.49 44.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.854 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 7.1 p -108.05 118.35 36.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.12 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -150.05 139.14 21.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.919 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' TYR . . . . . 0.582 ' CE2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -74.26 -21.04 59.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.967 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 34.1 mp0 -65.99 156.9 32.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.888 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -115.52 101.98 54.3 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.644 0.735 . . . . 0.0 110.968 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.41 ' HD2' HD21 ' A' ' 14' ' ' LEU . 53.6 Cg_endo . . . . . 0 C--N 1.342 0.208 0 C-N-CA 122.642 2.228 . . . . 0.0 112.339 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 12.8 mt . . . . . 0 C--O 1.232 0.173 0 CA-C-O 121.579 0.704 . . . . 0.0 110.921 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.644 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.6 Cg_endo -69.77 -169.36 0.32 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.7 2.267 . . . . 0.0 112.326 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.98 153.74 41.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.683 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 82.24 -45.89 3.43 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.418 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.644 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 71.3 m95 -67.67 134.66 51.52 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.732 0.301 . . . . 0.0 110.896 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -149.92 113.99 5.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.02 142.72 43.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.917 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.538 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 19.0 mm -128.36 130.78 69.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.094 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -102.51 119.88 39.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.895 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.419 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.69 139.7 20.58 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 121.576 0.703 . . . . 0.0 110.896 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.417 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.9 Cg_endo -69.77 -7.8 21.99 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.692 2.261 . . . . 0.0 112.342 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.9 t -113.92 -37.92 2.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.179 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.436 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.5 m-85 -98.51 -31.61 11.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 86.78 -143.74 19.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.423 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.537 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -97.94 108.8 22.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.878 0.37 . . . . 0.0 111.162 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.538 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 39.7 p90 -135.11 131.95 37.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.905 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.442 ' CD1' ' N ' ' A' ' 30' ' ' TYR . 3.3 m-30 -88.77 124.92 34.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.916 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -111.38 116.41 52.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.095 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.627 ' OD1' ' CE3' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -100.12 103.3 14.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 179.903 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 48.3 m-70 -68.83 -8.44 43.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.851 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.683 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.9 OUTLIER -90.22 -62.81 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.156 179.995 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 7.4 m-80 -82.44 -19.91 38.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.915 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 19.6 mmm-85 66.28 47.39 1.82 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.901 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.422 ' HG3' ' OD2' ' A' ' 32' ' ' ASP . 0.1 OUTLIER -129.76 122.2 28.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.847 179.988 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.3 p -100.2 118.34 36.32 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -148.98 141.34 24.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.95 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' TYR . . . . . 0.537 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -75.26 -24.45 57.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.818 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 -62.62 161.24 12.52 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 50.6 t30 -120.3 102.02 46.17 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.625 0.726 . . . . 0.0 110.883 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo . . . . . 0 C--O 1.231 0.148 0 C-N-CA 122.709 2.273 . . . . 0.0 112.363 179.957 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.558 HD11 ' CD2' ' A' ' 30' ' ' TYR . 10.7 mt . . . . . 0 C--O 1.231 0.108 0 CA-C-O 121.603 0.716 . . . . 0.0 110.879 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.62 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.67 -171.71 0.49 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.606 2.204 . . . . 0.0 112.371 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.46 150.52 48.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.072 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.658 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 85.31 -43.92 3.31 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.755 -0.735 . . . . 0.0 112.46 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.62 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -68.66 141.62 55.31 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.751 0.31 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 23.2 tp10 -153.14 113.58 4.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.907 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.47 142.57 48.58 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.898 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.574 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 32.3 mm -127.38 130.76 70.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.105 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -103.81 117.88 35.38 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.928 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.42 ' O ' ' N ' ' A' ' 27' ' ' GLY . 9.8 t70 -138.17 139.36 25.39 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.511 0.672 . . . . 0.0 110.956 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.404 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 54.2 Cg_endo -69.77 -6.92 19.75 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.614 2.21 . . . . 0.0 112.367 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.2 t -114.21 -37.91 2.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.18 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.427 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.66 -32.31 11.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.47 -144.19 18.26 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.425 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.456 HD12 ' N ' ' A' ' 28' ' ' ILE . 1.9 mp -97.86 108.82 22.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.827 0.346 . . . . 0.0 111.128 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.574 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.3 p90 -135.78 131.19 35.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.933 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.558 ' CD2' HD11 ' A' ' 14' ' ' LEU . 2.9 m-30 -88.88 125.55 34.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.92 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.9 t -111.35 116.72 53.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.098 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.406 ' O ' ' N ' ' A' ' 36' ' ' ARG . 19.4 t0 -95.55 102.58 14.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 72.8 m-70 -67.93 -15.13 63.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.658 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.0 OUTLIER -85.02 -61.4 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 -179.998 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 21.4 m-20 -83.49 -15.41 49.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.902 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.406 ' N ' ' O ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER 62.9 47.99 4.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.848 179.957 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.579 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.1 OUTLIER -130.38 130.89 44.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.833 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 3.0 p -108.13 120.26 41.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.151 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.4 pt20 -150.01 140.71 22.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' TYR . . . . . 0.411 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -74.38 -21.75 59.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.89 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 21.6 mt-10 -67.94 161.41 26.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.844 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 51.8 t30 -117.62 102.07 51.95 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.631 0.729 . . . . 0.0 110.839 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.451 ' HD2' HD21 ' A' ' 14' ' ' LEU . 54.0 Cg_endo . . . . . 0 C--N 1.342 0.228 0 C-N-CA 122.64 2.226 . . . . 0.0 112.363 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.715 HD11 ' CD2' ' A' ' 30' ' ' TYR . 12.5 mt . . . . . 0 C--O 1.232 0.151 0 CA-C-O 121.554 0.692 . . . . 0.0 110.938 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.638 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.71 -173.67 0.75 Allowed 'Trans proline' 0 C--N 1.34 0.094 0 C-N-CA 122.689 2.259 . . . . 0.0 112.373 179.829 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.4 148.77 51.14 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.063 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.72 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 86.64 -43.04 3.19 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.524 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.638 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.7 m95 -68.22 143.88 55.13 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.691 0.281 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -155.45 116.23 3.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.848 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.498 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -73.8 144.25 45.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.891 179.928 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.573 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 43.7 mm -128.11 130.69 69.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.151 179.891 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -104.74 117.82 35.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.0 t70 -138.15 139.69 26.48 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 121.589 0.709 . . . . 0.0 110.878 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.413 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.1 Cg_endo -69.82 -7.36 20.88 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.689 2.259 . . . . 0.0 112.38 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 86.4 t -114.12 -37.95 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.104 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.43 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.45 -31.54 11.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.913 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.84 -143.78 18.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.449 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.598 ' O ' ' CE2' ' A' ' 40' ' ' TYR . 1.7 mp -98.41 110.17 25.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.855 0.359 . . . . 0.0 111.151 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.573 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.1 p90 -136.93 131.69 33.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.98 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.715 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.84 124.34 34.09 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.885 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 t -110.3 115.97 51.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.116 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -95.33 102.72 14.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.813 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -69.16 -17.31 63.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.72 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -82.2 -62.67 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.185 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 18.9 m-20 -81.2 -18.25 46.85 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.931 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.0 mmt85 66.08 47.75 1.86 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.839 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.588 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 5.0 ptpp? -131.95 131.74 42.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.9 p -106.55 118.35 36.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.16 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -149.81 139.61 21.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' TYR . . . . . 0.598 ' CE2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.65 -24.99 58.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.911 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -64.1 158.7 22.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.901 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 54.2 t30 -115.87 102.01 54.02 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.627 0.727 . . . . 0.0 110.854 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.405 ' HD2' HD21 ' A' ' 14' ' ' LEU . 53.6 Cg_endo . . . . . 0 C--N 1.342 0.209 0 C-N-CA 122.747 2.298 . . . . 0.0 112.288 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.52 HD11 ' CD2' ' A' ' 30' ' ' TYR . 13.5 mt . . . . . 0 C--O 1.231 0.109 0 CA-C-O 121.578 0.704 . . . . 0.0 110.915 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.677 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.84 -173.45 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.693 2.262 . . . . 0.0 112.285 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.43 149.92 47.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.123 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.592 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 83.88 -39.25 2.84 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.387 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.677 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 72.6 m95 -74.94 131.91 41.03 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.707 0.289 . . . . 0.0 110.926 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -145.46 112.91 6.23 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.896 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.2 145.65 47.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.908 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.568 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 18.7 mm -130.06 132.05 65.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.126 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -104.24 118.59 37.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.873 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.429 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.0 t70 -139.73 139.86 23.17 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.576 0.703 . . . . 0.0 110.877 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.428 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.5 Cg_endo -69.79 -8.85 24.65 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.687 2.258 . . . . 0.0 112.312 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.5 t -112.92 -37.91 2.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.157 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.8 m-85 -98.28 -32.06 11.74 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.939 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.08 -143.63 18.93 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.588 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.544 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -98.37 108.06 21.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.82 0.343 . . . . 0.0 111.115 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.568 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 27.4 p90 -135.13 131.83 37.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.895 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.52 ' CD2' HD11 ' A' ' 14' ' ' LEU . 2.9 m-30 -88.64 120.1 29.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.915 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.408 ' CG2' ' CE2' ' A' ' 29' ' ' TYR . 21.9 t -102.79 123.17 55.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.122 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.618 ' OD2' ' CZ3' ' A' ' 18' ' ' TRP . 5.0 m-20 -97.9 118.73 35.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.852 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.45 ' C ' HD12 ' A' ' 34' ' ' ILE . 81.1 m-70 -92.31 -4.97 53.16 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.8 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.592 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.8 OUTLIER -96.39 -49.98 11.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.122 -179.994 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.478 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 14.9 m-80 -98.36 -12.36 21.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.9 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 44.0 mmm-85 64.3 46.29 3.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.858 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.478 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 22.8 pttt -126.09 127.48 45.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.941 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -107.63 121.01 43.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.164 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 -150.29 144.92 25.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.885 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' TYR . . . . . 0.544 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 5.1 m-85 -79.12 -28.76 42.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -60.4 159.33 10.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.842 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -114.73 102.01 54.65 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.632 0.729 . . . . 0.0 110.899 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--O 1.232 0.19 0 C-N-CA 122.72 2.28 . . . . 0.0 112.33 179.925 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.572 HD11 ' CD2' ' A' ' 30' ' ' TYR . 9.2 mt . . . . . 0 C--O 1.231 0.085 0 CA-C-O 121.577 0.704 . . . . 0.0 110.917 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.664 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.8 Cg_endo -69.83 -177.41 1.89 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.626 2.217 . . . . 0.0 112.375 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.38 144.78 56.92 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.053 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.646 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 90.75 -35.87 3.76 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.44 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.664 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 70.5 m95 -78.74 132.73 37.06 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.758 0.313 . . . . 0.0 110.938 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -139.23 111.76 7.67 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.42 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -72.11 146.52 47.44 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.482 ' HB ' ' CZ ' ' A' ' 29' ' ' TYR . 29.9 mm -132.86 133.55 58.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.178 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -106.45 118.93 37.94 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.868 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.435 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -138.57 137.98 21.26 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.577 0.703 . . . . 0.0 110.85 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -8.38 23.46 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.657 2.238 . . . . 0.0 112.372 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.7 t -112.83 -38.02 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.095 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.412 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.04 -31.89 11.91 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.16 -147.63 19.72 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.486 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.418 HD12 ' N ' ' A' ' 28' ' ' ILE . 1.8 mp -97.07 108.88 22.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.873 0.368 . . . . 0.0 111.065 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.482 ' CZ ' ' HB ' ' A' ' 21' ' ' ILE . 42.4 p90 -133.41 131.83 40.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.572 ' CD2' HD11 ' A' ' 14' ' ' LEU . 5.7 m-30 -88.6 124.22 33.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.895 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.2 t -106.06 114.9 46.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.148 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.53 ' OD2' ' CE2' ' A' ' 18' ' ' TRP . 35.9 t0 -91.96 102.25 14.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.836 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -71.53 -10.37 59.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.849 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.646 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.8 OUTLIER -92.32 -60.26 2.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.113 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.467 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 5.9 m-80 -81.29 -21.7 39.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.778 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 10.6 mmt85 67.89 47.63 1.09 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.879 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.467 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 16.9 pttt -139.65 121.86 15.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.879 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 3.3 p -93.07 125.67 37.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.166 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -150.58 140.15 21.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.89 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -73.5 -21.15 60.48 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.923 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 52.8 mm-40 -66.03 157.71 30.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.881 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 60.8 t30 -115.76 101.98 54.11 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.603 0.716 . . . . 0.0 110.875 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.409 ' HD2' ' CD2' ' A' ' 14' ' ' LEU . 54.1 Cg_endo . . . . . 0 C--O 1.232 0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.396 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.556 HD11 ' CD2' ' A' ' 30' ' ' TYR . 13.7 mt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 121.661 0.743 . . . . 0.0 110.908 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.669 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.73 -175.87 1.29 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.66 2.24 . . . . 0.0 112.347 179.842 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.87 145.24 56.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.083 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.769 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 89.52 -41.09 3.01 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.531 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.669 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 69.8 m95 -73.18 129.92 39.11 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.763 0.316 . . . . 0.0 110.916 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -138.45 112.36 8.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.917 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.421 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.57 145.49 43.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.909 179.965 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.579 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 26.2 mm -132.12 133.43 60.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.123 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -105.36 119.39 38.96 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.873 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.438 ' O ' ' N ' ' A' ' 27' ' ' GLY . 10.5 t70 -140.06 138.45 19.48 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.567 0.699 . . . . 0.0 110.883 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -9.78 26.95 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.677 2.251 . . . . 0.0 112.341 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.9 t -111.27 -38.0 3.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.095 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.402 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.8 m-85 -98.05 -33.0 11.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.89 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.41 -146.79 19.16 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.479 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.0 mp -97.68 109.76 24.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.845 0.355 . . . . 0.0 111.152 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.579 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 27.1 p90 -134.53 131.63 38.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.556 ' CD2' HD11 ' A' ' 14' ' ' LEU . 4.9 m-30 -88.51 120.77 30.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.942 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.9 t -106.13 115.69 48.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.143 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.414 ' O ' ' N ' ' A' ' 36' ' ' ARG . 8.8 t0 -94.2 101.99 13.99 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.85 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 76.5 m-70 -67.39 -13.92 62.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.878 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.769 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -85.35 -62.86 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.101 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.497 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 5.8 m-80 -83.56 -15.83 47.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.414 ' N ' ' O ' ' A' ' 32' ' ' ASP . 4.8 mmm180 64.25 47.68 3.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.852 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.497 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 21.1 pttt -129.75 136.79 50.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.835 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 22.6 p -113.44 123.04 49.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.108 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 -149.96 138.54 20.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.948 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -72.59 -16.22 61.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.948 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -73.54 159.97 32.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.857 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -116.43 101.93 53.6 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.646 0.736 . . . . 0.0 110.926 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo . . . . . 0 C--N 1.342 0.236 0 C-N-CA 122.687 2.258 . . . . 0.0 112.354 179.945 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.465 HD11 ' CG ' ' A' ' 30' ' ' TYR . 10.8 mt . . . . . 0 C--O 1.23 0.072 0 CA-C-O 121.65 0.738 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.658 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.8 Cg_endo -69.77 -173.61 0.75 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.707 2.271 . . . . 0.0 112.323 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.86 144.52 55.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.102 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.773 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 92.14 -39.14 3.06 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.479 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.658 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 69.1 m95 -74.68 131.31 40.77 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.669 0.271 . . . . 0.0 110.916 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.462 ' OE1' HD11 ' A' ' 21' ' ' ILE . 10.4 tt0 -135.82 111.82 9.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.891 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.526 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -76.11 146.65 39.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.859 -179.983 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.551 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 31.5 mm -133.56 135.52 55.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.137 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 -107.33 117.66 34.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.905 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.43 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.4 t70 -137.71 137.9 22.85 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.638 0.733 . . . . 0.0 110.796 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -8.12 22.8 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.68 2.253 . . . . 0.0 112.333 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 86.5 t -113.17 -38.03 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.182 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.435 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.5 m-85 -97.46 -31.72 12.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.942 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.44 -148.28 20.51 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.0 mp -96.6 108.97 22.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.778 0.323 . . . . 0.0 111.17 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.551 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 37.9 p90 -132.84 131.38 40.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.928 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.465 ' CG ' HD11 ' A' ' 14' ' ' LEU . 4.9 m-30 -88.38 123.6 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.865 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.8 t -107.94 115.08 48.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.146 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 28.3 t0 -91.63 102.02 14.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.844 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -68.22 -16.52 64.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.817 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.773 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.0 OUTLIER -86.87 -61.11 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.117 -179.988 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 -79.74 -16.97 54.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.902 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 64.47 45.78 3.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.848 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 1.4 pttm -131.68 146.2 52.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.881 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.7 p -120.5 122.94 41.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.112 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 -150.53 140.1 21.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.934 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -72.57 -20.75 61.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.901 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 35.0 mp0 -68.36 157.39 35.8 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.866 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -115.36 102.15 54.45 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.659 0.742 . . . . 0.0 110.844 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 C--N 1.341 0.178 0 C-N-CA 122.677 2.251 . . . . 0.0 112.332 179.962 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.453 HD11 ' CD2' ' A' ' 30' ' ' TYR . 17.4 mt . . . . . 0 C--O 1.232 0.15 0 CA-C-O 121.579 0.704 . . . . 0.0 110.954 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.641 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.74 -171.21 0.45 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.719 2.28 . . . . 0.0 112.417 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.95 147.35 53.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.084 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.579 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 88.2 -44.66 3.22 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.47 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.641 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 63.2 m95 -68.38 135.92 52.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.779 0.323 . . . . 0.0 110.903 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -149.52 115.61 5.72 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.551 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -75.79 142.0 42.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 -179.995 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.573 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 38.4 mm -125.34 131.52 72.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.134 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -102.65 117.78 35.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.0 t70 -139.12 139.48 23.37 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.578 0.704 . . . . 0.0 110.884 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 54.6 Cg_endo -69.69 -11.31 30.67 Favored 'Trans proline' 0 N--CA 1.465 -0.183 0 C-N-CA 122.668 2.245 . . . . 0.0 112.437 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.3 t -109.93 -37.98 3.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.155 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.36 -32.85 11.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.9 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.48 -140.78 15.82 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.472 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.605 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.9 mp -102.08 109.4 26.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.808 0.337 . . . . 0.0 111.132 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.573 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 32.6 p90 -135.54 133.96 38.94 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.882 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.478 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.4 m-30 -90.18 126.8 35.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.927 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.2 t -113.21 117.24 54.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.125 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.459 ' O ' ' N ' ' A' ' 36' ' ' ARG . 62.4 t0 -95.14 103.31 15.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 47.7 m-70 -68.6 -16.38 63.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.645 ' CD1' ' N ' ' A' ' 34' ' ' ILE . 0.6 OUTLIER -83.39 -55.49 7.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.121 -179.993 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 63.1 m-20 -93.33 -2.39 54.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.854 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.459 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.5 mpt_? 54.62 47.94 21.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.7 mtmm -113.54 160.8 18.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -145.12 108.3 4.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.14 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -147.88 144.19 27.93 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.919 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' TYR . . . . . 0.605 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.6 m-85 -76.29 -26.54 55.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -63.6 161.42 14.8 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.854 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 44.6 t30 -116.62 101.93 53.44 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.614 0.721 . . . . 0.0 110.933 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.479 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 54.2 Cg_endo . . . . . 0 C--N 1.342 0.198 0 C-N-CA 122.637 2.225 . . . . 0.0 112.377 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.437 HD11 ' CG ' ' A' ' 30' ' ' TYR . 9.6 mt . . . . . 0 C--O 1.231 0.085 0 CA-C-O 121.614 0.721 . . . . 0.0 110.874 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.664 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.79 -170.38 0.39 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.614 2.209 . . . . 0.0 112.311 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.62 140.91 48.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.12 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.618 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 94.62 -32.19 6.24 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.505 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.664 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 67.4 m95 -81.89 147.72 29.15 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.703 0.287 . . . . 0.0 110.896 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.486 ' O ' ' CG ' ' A' ' 19' ' ' GLU . 2.3 pt-20 -152.71 119.57 5.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.888 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.59 141.47 36.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.95 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.578 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 18.2 mm -129.41 132.4 66.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.097 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -106.02 120.6 42.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.933 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.425 ' CG ' ' HD2' ' A' ' 24' ' ' PRO . 10.8 t70 -140.37 139.66 21.21 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.561 0.696 . . . . 0.0 110.888 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.425 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.9 Cg_endo -69.67 -8.18 22.94 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.696 2.264 . . . . 0.0 112.376 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 99.5 t -114.89 -37.9 2.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.123 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.31 -29.2 13.3 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.905 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 82.51 -151.73 29.82 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.508 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 1.9 mp -89.81 110.88 22.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.824 0.345 . . . . 0.0 111.05 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.578 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 46.3 p90 -136.03 130.88 34.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.913 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.437 ' CG ' HD11 ' A' ' 14' ' ' LEU . 5.3 m-30 -88.48 132.79 34.34 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.963 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.4 t -114.62 116.47 52.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.138 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.478 ' OD1' ' CD1' ' A' ' 18' ' ' TRP . 13.3 t0 -98.59 102.03 13.64 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.898 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 -72.07 -11.24 60.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.84 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.618 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.8 OUTLIER -85.83 -57.2 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.129 179.947 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -87.65 -18.36 29.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.895 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 68.02 47.88 1.02 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.87 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.423 ' HE2' ' CH2' ' A' ' 18' ' ' TRP . 8.5 pttm -139.35 130.96 27.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.1 p -104.19 126.15 51.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 -150.63 141.82 23.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.956 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -73.78 -21.63 60.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 30.0 mm-40 -66.41 154.1 41.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.924 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 60.9 t30 -112.3 101.99 53.22 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.597 0.713 . . . . 0.0 110.911 -179.948 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.405 ' HD2' ' CD2' ' A' ' 14' ' ' LEU . 53.1 Cg_endo . . . . . 0 C--N 1.34 0.13 0 C-N-CA 122.672 2.248 . . . . 0.0 112.31 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.585 HD11 ' CD2' ' A' ' 30' ' ' TYR . 11.6 mt . . . . . 0 C--O 1.23 0.053 0 CA-C-O 121.609 0.719 . . . . 0.0 110.956 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.635 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.6 Cg_endo -69.76 -171.78 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.647 2.232 . . . . 0.0 112.368 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.73 149.98 49.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.077 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.744 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 84.94 -40.46 3.0 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.539 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.635 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 58.4 m95 -72.51 140.44 48.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.712 0.291 . . . . 0.0 110.995 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -152.24 115.04 4.6 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.438 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.35 138.6 43.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.576 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 34.9 mm -121.13 131.21 73.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.166 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -103.54 117.94 35.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.854 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.44 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.7 t70 -138.91 137.98 20.55 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.578 0.704 . . . . 0.0 110.88 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 -8.26 23.14 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.665 2.244 . . . . 0.0 112.291 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.5 t -112.86 -37.97 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.169 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' TYR . . . . . 0.418 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -97.94 -31.98 11.9 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.959 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.4 -145.49 18.47 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.561 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.596 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -98.99 108.57 22.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.813 0.339 . . . . 0.0 111.081 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.576 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 31.5 p90 -134.42 131.58 38.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.585 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.6 m-30 -88.75 122.4 32.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.912 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.0 t -108.11 115.62 49.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.146 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 57.1 t0 -94.77 101.99 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.828 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 65.9 m-70 -68.74 -18.76 64.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.862 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.744 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -81.67 -62.73 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.109 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.2 m-80 -80.34 -16.37 54.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.867 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 27.5 mmm180 64.11 47.69 3.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.55 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 11.1 ptpt -133.11 129.44 37.95 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.7 p -105.34 119.46 39.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.198 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -150.29 140.5 22.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.91 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' TYR . . . . . 0.596 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.55 -25.08 59.08 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.884 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -62.06 161.84 10.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.872 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 58.9 t30 -118.44 101.93 50.59 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.581 0.705 . . . . 0.0 110.937 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.41 ' HD2' HD21 ' A' ' 14' ' ' LEU . 53.7 Cg_endo . . . . . 0 C--N 1.341 0.148 0 C-N-CA 122.677 2.251 . . . . 0.0 112.346 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' LEU . . . . . 0.565 HD11 ' CD2' ' A' ' 30' ' ' TYR . 14.3 mt . . . . . 0 C--O 1.231 0.124 0 CA-C-O 121.556 0.693 . . . . 0.0 110.947 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.667 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.5 Cg_endo -69.77 -173.49 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.721 2.281 . . . . 0.0 112.292 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.52 146.91 54.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.035 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.666 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 87.9 -42.14 3.1 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.456 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' TRP . . . . . 0.667 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 70.8 m95 -71.78 122.3 20.45 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.834 0.35 . . . . 0.0 110.911 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.44 ' OE1' HD11 ' A' ' 21' ' ' ILE . 7.5 tt0 -128.3 111.43 13.36 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.507 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -76.17 145.2 40.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.854 179.987 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.57 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 32.8 mm -132.68 133.58 59.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.127 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -106.06 117.99 35.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.912 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.1 t70 -138.36 139.67 25.87 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.64 0.733 . . . . 0.0 110.891 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.42 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.7 Cg_endo -69.71 -11.8 31.67 Favored 'Trans proline' 0 C--O 1.232 0.225 0 C-N-CA 122.704 2.269 . . . . 0.0 112.33 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 94.0 t -109.36 -37.95 3.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.162 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.28 -32.27 11.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.846 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.13 -140.95 16.0 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.439 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 1.9 mp -102.91 108.87 25.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 0.0 111.179 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' TYR . . . . . 0.57 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 25.0 p90 -133.39 131.14 39.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.922 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' TYR . . . . . 0.565 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.27 119.65 28.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.916 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.4 t -101.88 115.57 43.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.098 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.615 ' OD2' ' CZ3' ' A' ' 18' ' ' TRP . 3.8 m-20 -88.87 112.96 23.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' HIS . . . . . 0.451 ' C ' HD12 ' A' ' 34' ' ' ILE . 87.6 m-70 -86.37 -7.07 58.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.946 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.666 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.7 OUTLIER -97.11 -49.13 12.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.097 179.99 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 -96.06 -13.66 23.53 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.85 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ARG . . . . . 0.406 ' HA ' ' O ' ' A' ' 32' ' ' ASP . 25.3 mmt180 65.32 42.49 3.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.851 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' LYS . . . . . 0.558 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 0.1 OUTLIER -121.51 129.86 53.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.877 -179.986 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -111.21 116.1 30.48 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.149 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -145.96 146.39 31.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.935 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -77.96 -30.9 50.59 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.939 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLU . . . . . 0.409 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 4.1 mt-10 -58.25 166.75 1.53 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.845 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 52.7 t30 -120.81 102.0 44.87 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.663 0.744 . . . . 0.0 110.906 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' PRO . . . . . 0.55 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 53.1 Cg_endo . . . . . 0 C--N 1.342 0.223 0 C-N-CA 122.682 2.255 . . . . 0.0 112.271 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 112.588 -0.205 . . . . 0.0 112.588 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 73.8 m -138.31 151.41 47.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.845 0.355 . . . . 0.0 110.904 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.8 m -124.09 154.32 40.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.784 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 123.63 -155.51 17.68 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.529 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.9 t -122.63 161.92 22.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.943 0.401 . . . . 0.0 110.787 -179.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 73.2 m -149.35 173.41 13.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.8 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 56.19 60.5 8.82 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.439 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 58.4 mt -83.43 -47.73 11.09 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.745 0.307 . . . . 0.0 110.856 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.95 117.66 35.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.88 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.2 t -109.42 16.28 22.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.884 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -108.69 13.17 25.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.883 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 37.5 mt -114.4 154.18 28.55 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.875 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -75.69 171.87 13.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.892 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.526 HD21 HD22 ' A' ' 42' ' ' ASN . 13.3 mt -89.41 153.15 48.25 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.557 0.694 . . . . 0.0 110.953 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.611 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.85 -175.55 1.22 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.611 2.208 . . . . 0.0 112.313 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.26 146.76 53.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.09 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.665 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 89.5 -44.26 3.05 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.497 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.611 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -69.7 142.32 53.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.735 0.302 . . . . 0.0 110.904 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -153.29 114.67 4.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.922 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.441 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -72.71 144.26 47.74 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.919 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.576 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 41.9 mm -128.17 130.62 69.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.177 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -104.97 117.86 35.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.859 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -137.84 139.78 27.52 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.624 0.726 . . . . 0.0 110.878 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.415 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.2 Cg_endo -69.83 -7.96 22.39 Favored 'Trans proline' 0 C--O 1.233 0.237 0 C-N-CA 122.646 2.231 . . . . 0.0 112.302 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 96.4 t -113.83 -38.01 2.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.081 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.8 m-85 -98.08 -30.79 12.47 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.941 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.26 -142.91 18.43 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.527 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.557 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.8 mp -99.64 111.46 29.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.848 0.356 . . . . 0.0 111.116 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.576 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 39.2 p90 -137.2 131.54 32.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.978 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.471 ' CD2' HD11 ' A' ' 14' ' ' LEU . 5.5 m-30 -88.98 123.6 33.47 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.925 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.415 ' CG2' ' CE2' ' A' ' 29' ' ' TYR . 10.8 t -110.2 116.57 52.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.148 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.407 ' OD2' ' NE1' ' A' ' 18' ' ' TRP . 51.5 t0 -95.77 106.09 18.17 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.929 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -71.36 -14.27 62.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.819 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.665 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.9 OUTLIER -85.98 -62.34 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.158 179.971 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.425 ' C ' ' HD3' ' A' ' 36' ' ' ARG . 28.0 m-80 -80.65 -13.81 58.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.852 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.425 ' HD3' ' C ' ' A' ' 35' ' ' ASN . 1.8 mpp_? 63.09 46.25 4.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -128.03 154.75 45.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.855 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.7 p -129.45 117.95 21.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.133 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -149.66 141.86 24.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.956 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' TYR . . . . . 0.557 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.81 -25.99 59.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.922 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 -63.06 160.77 14.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.94 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.526 HD22 HD21 ' A' ' 14' ' ' LEU . 9.9 t-20 -115.48 102.02 54.33 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.589 0.709 . . . . 0.0 110.849 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.442 ' HD2' HD21 ' A' ' 14' ' ' LEU . 53.4 Cg_endo -69.8 3.13 2.97 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.705 2.27 . . . . 0.0 112.322 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 7.5 p -52.05 148.2 6.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 124.73 177.94 15.14 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.495 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 85.08 0.63 Allowed 'Trans proline' 0 N--CA 1.466 -0.14 0 C-N-CA 122.684 2.256 . . . . 0.0 112.388 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 27.9 p -143.85 107.45 4.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.861 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 50.8 p -96.37 164.29 12.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.835 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.478 179.989 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.282 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 40.5 p -58.68 -52.02 67.48 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.892 0.377 . . . . 0.0 110.823 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.6 p -74.68 -44.42 50.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.805 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.66 157.14 20.31 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.457 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 91.5 p -111.98 147.45 35.89 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.926 0.393 . . . . 0.0 110.861 -179.766 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.9 m 56.38 42.02 28.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.83 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -126.0 -75.69 0.24 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.464 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.1 mp -86.75 105.72 17.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.851 0.358 . . . . 0.0 110.925 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -130.93 127.55 38.68 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.85 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.7 t -99.97 17.02 22.03 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.91 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 20.7 pt-20 -107.48 15.56 24.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.89 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 50.4 mt -107.1 173.26 6.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.915 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 77.2 mt-10 -107.65 169.36 8.64 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.879 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.613 HD11 ' CD2' ' A' ' 30' ' ' TYR . 11.0 mt -91.09 154.49 45.01 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.603 0.716 . . . . 0.0 110.924 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.63 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.2 Cg_endo -69.7 -172.74 0.6 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.668 2.245 . . . . 0.0 112.349 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.58 148.62 51.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.093 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.695 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 86.91 -41.39 3.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.492 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.63 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.0 m95 -71.3 143.68 50.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.65 0.262 . . . . 0.0 110.956 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 30.3 tp10 -154.3 113.49 3.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.847 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.462 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -72.95 139.8 46.99 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.934 179.888 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.577 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 34.7 mm -122.76 129.12 75.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.164 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -101.97 117.92 35.82 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.896 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.447 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.7 t70 -139.01 139.16 22.57 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.614 0.721 . . . . 0.0 110.836 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -9.81 27.01 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.72 2.28 . . . . 0.0 112.372 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.4 t -111.54 -37.94 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.123 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.413 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -97.79 -32.1 11.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.967 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.27 -144.67 18.66 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.455 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.485 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.0 mp -98.62 109.81 24.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.781 0.325 . . . . 0.0 111.105 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.577 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 36.9 p90 -136.16 130.75 33.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.613 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.78 124.35 34.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.914 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.466 HG22 HG22 ' A' ' 38' ' ' THR . 12.0 t -110.91 115.93 51.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.114 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.406 ' O ' ' N ' ' A' ' 36' ' ' ARG . 13.5 t0 -94.45 101.93 13.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.895 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -67.46 -18.38 65.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.695 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -80.7 -63.35 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.15 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -81.14 -16.72 52.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.818 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.406 ' N ' ' O ' ' A' ' 32' ' ' ASP . 17.7 mmt180 64.89 47.98 2.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.565 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.0 OUTLIER -132.47 129.03 38.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.869 179.976 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.466 HG22 HG22 ' A' ' 31' ' ' VAL . 2.3 p -104.59 120.19 40.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.167 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -150.11 140.91 22.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.932 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' TYR . . . . . 0.485 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.41 -23.77 59.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.908 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 55.7 mm-40 -64.86 158.28 25.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.909 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.54 ' ND2' ' HB3' ' A' ' 44' ' ' SER . 55.8 t30 -115.32 102.0 54.46 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.665 0.745 . . . . 0.0 110.896 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.409 ' HD2' HD21 ' A' ' 14' ' ' LEU . 53.1 Cg_endo -69.7 0.77 5.12 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.713 2.276 . . . . 0.0 112.335 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.54 ' HB3' ' ND2' ' A' ' 42' ' ' ASN . 8.2 t -53.33 167.89 0.18 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.828 -179.788 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 122.43 161.47 11.26 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.46 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 -5.2 15.64 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.717 2.278 . . . . 0.0 112.343 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.9 m -70.22 -55.63 8.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.889 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 30.7 t -60.59 120.39 9.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.868 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.473 179.988 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.5 t -65.59 147.82 52.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.869 0.366 . . . . 0.0 110.889 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.9 t 64.33 42.39 5.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.885 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -83.98 -84.5 0.92 Allowed Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.415 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 94.3 p -58.23 105.99 0.33 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.821 0.343 . . . . 0.0 110.909 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 26.1 p -73.34 126.98 31.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.19 -69.62 1.35 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.5 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 23.6 mt 58.89 41.18 21.72 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.841 0.353 . . . . 0.0 110.899 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -87.63 17.97 4.3 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.86 179.844 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 27.7 p -75.47 5.31 6.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -109.26 17.25 21.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.84 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 17.6 mt -129.45 176.88 7.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.945 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -111.67 170.97 7.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.505 HD11 ' CD2' ' A' ' 30' ' ' TYR . 15.1 mt -90.61 151.93 44.52 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.586 0.708 . . . . 0.0 110.923 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.632 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.3 Cg_endo -69.74 -172.19 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.605 2.203 . . . . 0.0 112.376 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.19 146.63 54.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.071 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.704 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 88.54 -40.7 3.06 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.467 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.632 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -72.64 142.66 48.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.733 0.301 . . . . 0.0 110.895 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -153.4 115.51 4.34 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.882 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.474 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.22 140.99 45.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 -179.967 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.559 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 38.1 mm -123.87 129.73 74.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.163 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.2 mt-10 -103.79 117.88 35.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.871 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.449 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.1 t70 -139.12 139.67 24.0 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.568 0.699 . . . . 0.0 110.905 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.42 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.6 Cg_endo -69.77 -9.48 26.2 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.627 2.218 . . . . 0.0 112.38 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 95.6 t -111.78 -38.04 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.13 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -97.91 -31.49 12.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.959 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.3 -145.73 19.86 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.456 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.598 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.7 mp -97.1 110.01 24.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.821 0.343 . . . . 0.0 111.198 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.559 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 34.9 p90 -137.37 130.62 30.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.901 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.505 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.0 m-30 -89.02 126.85 35.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.931 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.522 HG22 HG22 ' A' ' 38' ' ' THR . 10.6 t -112.67 116.13 51.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.115 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.463 ' O ' ' N ' ' A' ' 36' ' ' ARG . 10.4 t0 -93.56 102.16 14.35 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.821 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 -68.0 -17.14 64.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.889 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.704 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -82.46 -58.17 3.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.127 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -87.34 -14.29 41.16 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.887 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.463 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.2 mpt_? 62.59 47.99 4.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.79 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.469 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.0 OUTLIER -130.93 126.94 37.4 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.941 179.952 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.522 HG22 HG22 ' A' ' 31' ' ' VAL . 1.6 p -102.35 119.34 38.65 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.107 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -149.65 141.83 24.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.961 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' TYR . . . . . 0.598 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 3.0 m-85 -76.02 -24.6 55.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.89 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 25.7 mm-40 -62.93 161.25 13.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.47 HD22 HD21 ' A' ' 14' ' ' LEU . 8.8 t-20 -116.36 102.1 53.61 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.616 0.722 . . . . 0.0 110.867 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.88 3.95 2.53 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.655 2.237 . . . . 0.0 112.316 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.3 p -52.06 147.35 7.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.88 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 134.19 170.81 12.39 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.489 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 95.53 0.56 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.7 2.267 . . . . 0.0 112.349 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.3 m -76.34 -47.17 24.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.842 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.1 t -51.63 -52.42 47.86 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.834 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.43 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.509 179.954 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.9 m -78.46 114.22 17.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.85 0.357 . . . . 0.0 110.852 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.4 m 57.94 42.12 23.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.822 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -88.92 -166.66 42.4 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.504 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 16.3 m -136.03 155.68 49.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.896 0.379 . . . . 0.0 110.828 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.1 t -52.16 -56.74 12.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.898 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 179.12 -174.58 46.58 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.437 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 28.1 mt -135.24 148.21 49.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.863 0.363 . . . . 0.0 110.875 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -121.76 103.35 8.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.892 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 61.0 m -100.94 16.66 24.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.871 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -113.21 16.2 19.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.891 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 34.3 mt -128.73 159.91 34.18 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.919 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -112.9 172.27 7.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.921 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.461 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 11.9 mt -88.71 155.45 50.52 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.619 0.723 . . . . 0.0 110.937 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.629 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.71 -175.82 1.27 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.677 2.251 . . . . 0.0 112.361 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.31 143.37 57.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.113 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.717 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 93.21 -41.49 2.69 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.543 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.629 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 60.4 m95 -72.69 137.75 46.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.721 0.296 . . . . 0.0 110.932 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -151.1 114.46 4.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.92 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.461 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -71.92 145.12 48.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.879 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.568 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 44.6 mm -129.13 131.76 67.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -106.57 117.99 35.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.851 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.424 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.6 t70 -138.54 139.65 25.36 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.608 0.718 . . . . 0.0 110.884 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.412 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.5 Cg_endo -69.74 -7.22 20.48 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.609 2.206 . . . . 0.0 112.362 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 95.2 t -114.49 -38.01 2.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.404 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.9 m-85 -98.29 -31.08 12.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.867 -179.856 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.02 -144.27 19.29 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.416 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.45 HD12 ' N ' ' A' ' 28' ' ' ILE . 1.8 mp -97.15 111.29 26.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.783 0.325 . . . . 0.0 111.145 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.568 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 32.0 p90 -139.18 131.35 28.13 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.935 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.481 ' CD1' ' N ' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.05 128.25 35.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.947 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.9 t -113.06 115.86 50.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -95.62 102.41 14.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.883 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 60.6 m-70 -69.51 -14.4 62.85 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.86 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.717 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.0 OUTLIER -87.16 -60.94 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.132 -179.981 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 21.0 m-20 -82.63 -15.19 53.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 13.1 mmm180 62.38 47.58 5.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.79 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.577 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 4.8 ptpp? -130.48 129.11 42.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.897 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -107.64 121.58 44.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.181 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.4 pt20 -150.05 141.86 23.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.881 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.2 m-85 -72.33 -26.99 62.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.903 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.435 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 6.1 mm-40 -68.99 162.99 25.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.946 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.468 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 1.9 t-20 -122.13 108.66 34.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.661 0.744 . . . . 0.0 110.862 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 42' ' ' ASN . 53.1 Cg_endo -69.78 1.73 4.18 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.698 2.265 . . . . 0.0 112.35 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 83.0 p -51.97 171.06 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.843 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 88.12 -176.4 45.43 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.491 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.86 -17.05 37.34 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.63 2.22 . . . . 0.0 112.335 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 44.5 m 61.16 41.85 13.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.863 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.4 t -71.07 137.66 49.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.844 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.224 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.491 -179.99 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.433 -0.267 . . . . 0.0 112.433 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 42.7 m -90.7 173.31 8.1 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.879 0.371 . . . . 0.0 110.811 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 46.3 t -60.39 153.2 23.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.858 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 71.4 71.63 1.02 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.527 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 60.3 p -70.78 -47.15 61.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.853 0.358 . . . . 0.0 110.872 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.9 m -107.2 141.46 38.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.788 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -134.13 88.14 0.25 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.46 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.1 tp -118.32 142.64 47.31 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.819 0.342 . . . . 0.0 110.917 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -91.55 110.78 22.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 34.7 t -103.9 16.35 26.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.836 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -114.84 16.38 17.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.905 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 24.7 mt -127.58 156.19 42.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.885 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 21.9 mt-10 -89.35 171.21 9.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.846 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.428 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 11.8 mt -93.94 154.77 40.72 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.63 0.729 . . . . 0.0 110.899 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.629 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.3 Cg_endo -69.77 -174.58 0.94 Allowed 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.663 2.242 . . . . 0.0 112.314 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.23 143.74 57.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.071 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.683 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 93.15 -41.64 2.68 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.629 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 60.6 m95 -72.42 137.76 46.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.73 0.3 . . . . 0.0 110.955 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -151.35 117.06 5.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.835 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.525 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -75.53 143.55 42.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.916 179.907 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.567 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 45.0 mm -127.09 131.89 70.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.121 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -104.94 117.69 34.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.848 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.418 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -137.99 138.5 23.62 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.652 0.739 . . . . 0.0 110.899 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -6.62 19.04 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.689 2.259 . . . . 0.0 112.267 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 90.7 t -115.2 -38.02 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.133 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.42 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.8 m-85 -98.1 -31.23 12.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.925 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.04 -145.45 19.23 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.45 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.408 HD12 ' N ' ' A' ' 28' ' ' ILE . 2.0 mp -97.41 111.6 27.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 111.086 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.567 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.7 p90 -138.57 132.83 31.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.896 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.481 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.84 128.52 36.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.945 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.8 t -113.43 115.82 50.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.116 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -94.54 102.12 14.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.892 179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 70.2 m-70 -68.99 -12.86 62.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.683 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.9 OUTLIER -89.0 -60.39 2.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.134 179.958 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -83.01 -18.6 39.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.809 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.6 mmm180 65.67 48.05 2.03 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.577 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 14.9 ptpt -130.53 131.16 44.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -109.25 120.29 42.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.118 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 -149.43 140.89 23.32 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.965 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -71.19 -24.6 62.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.941 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.405 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 8.0 mt-10 -69.76 161.1 30.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.458 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 1.9 t-20 -122.75 105.45 35.4 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.637 0.732 . . . . 0.0 110.913 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.42 ' HD2' ' HA ' ' A' ' 42' ' ' ASN . 54.5 Cg_endo -69.7 3.25 2.85 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.73 2.286 . . . . 0.0 112.391 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 64.9 p -52.41 142.11 18.2 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.896 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -151.54 168.07 30.96 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.478 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 0.02 6.27 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.692 2.261 . . . . 0.0 112.319 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 21.0 m -81.09 -59.08 2.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.892 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.6 t -130.05 116.37 18.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.822 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.473 179.997 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 89.8 p -147.74 106.86 3.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.978 0.418 . . . . 0.0 110.849 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.6 m -72.03 -50.29 29.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.909 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -165.35 117.02 0.73 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.509 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 79.2 p -63.38 104.4 0.61 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.869 0.366 . . . . 0.0 110.854 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.8 p -39.8 -58.05 1.44 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.906 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.66 67.19 0.98 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.47 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 tp -71.46 128.9 37.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.798 0.333 . . . . 0.0 110.935 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 43.0 m-20 -137.71 123.07 19.46 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.879 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.3 p -102.27 16.8 25.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.874 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -117.42 15.48 14.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.939 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 35.0 mt -129.07 160.29 33.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.979 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 -108.73 168.91 9.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.896 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.554 HD11 ' CD2' ' A' ' 30' ' ' TYR . 14.5 mt -83.71 152.62 63.52 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.59 0.71 . . . . 0.0 110.924 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.629 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.1 Cg_endo -69.7 -173.85 0.79 Allowed 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.683 2.255 . . . . 0.0 112.392 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.73 149.29 49.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.098 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.724 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 86.05 -42.4 3.15 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.503 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.629 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.2 m95 -70.39 139.19 51.82 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.685 0.279 . . . . 0.0 110.916 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 29.4 tp10 -149.49 113.87 5.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.846 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.85 144.79 50.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.896 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.582 HG21 ' OH ' ' A' ' 29' ' ' TYR . 33.9 mm -128.27 130.97 69.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.126 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -105.6 118.59 36.97 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.91 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.432 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.14 139.56 21.47 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.669 0.747 . . . . 0.0 110.845 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.407 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.6 Cg_endo -69.74 -8.65 24.14 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.751 2.301 . . . . 0.0 112.336 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 91.3 t -112.68 -38.04 2.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.113 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.417 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.22 -32.45 11.56 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.927 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.4 -144.62 18.55 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.505 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.6 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.9 mp -97.99 109.59 23.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.811 0.338 . . . . 0.0 111.195 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.582 ' OH ' HG21 ' A' ' 21' ' ' ILE . 38.4 p90 -135.34 130.96 35.81 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.95 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.554 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.9 m-30 -88.65 121.44 31.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.981 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.465 HG22 HG22 ' A' ' 38' ' ' THR . 11.7 t -107.96 116.36 51.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.151 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -96.03 102.59 14.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 60.6 m-70 -68.26 -18.14 64.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.902 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.724 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -81.39 -63.42 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -79.22 -18.46 52.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.902 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.478 ' CZ ' ' HA ' ' A' ' 36' ' ' ARG . 0.1 OUTLIER 66.61 47.77 1.56 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 -179.971 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.502 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 6.3 ptpt -134.5 130.72 37.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.876 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.465 HG22 HG22 ' A' ' 31' ' ' VAL . 1.8 p -106.05 119.99 40.63 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.19 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -149.99 141.76 23.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.926 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' TYR . . . . . 0.6 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -75.05 -25.42 58.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.914 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -62.74 158.18 19.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.834 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.495 HD22 HD21 ' A' ' 14' ' ' LEU . 9.2 t-20 -114.28 101.9 54.45 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.522 0.677 . . . . 0.0 110.915 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.426 ' HD2' HD21 ' A' ' 14' ' ' LEU . 53.9 Cg_endo -69.72 3.39 2.78 Favored 'Trans proline' 0 N--CA 1.465 -0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.376 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 14.0 p -51.92 168.61 0.08 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.894 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 120.16 174.8 15.45 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.442 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 102.42 1.02 Allowed 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.736 2.291 . . . . 0.0 112.371 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 98.4 p -63.04 120.75 12.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.837 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 25.2 p -103.96 134.04 47.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.855 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.479 179.985 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.536 -0.226 . . . . 0.0 112.536 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 99.3 p -130.24 122.51 28.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.921 0.391 . . . . 0.0 110.833 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.1 t -140.92 160.27 40.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.88 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -101.0 66.96 0.48 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.46 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.0 m -133.35 114.32 13.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.908 0.385 . . . . 0.0 110.834 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.8 t -60.67 -46.66 89.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.9 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.55 -152.76 5.75 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.536 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 13.2 tp -91.36 125.95 36.28 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.838 0.351 . . . . 0.0 110.923 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -104.93 17.82 23.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.906 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.5 m -77.39 7.97 4.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.837 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -107.25 15.83 24.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.878 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 45.1 mt -116.7 146.86 42.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.87 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -64.24 171.06 3.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.8 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.562 HD11 ' CD2' ' A' ' 30' ' ' TYR . 11.5 mt -98.97 153.42 37.82 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.569 0.699 . . . . 0.0 110.887 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.625 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.7 -171.73 0.5 Allowed 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.69 2.26 . . . . 0.0 112.368 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.23 147.32 52.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.106 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.744 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 88.58 -40.39 3.08 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.483 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.625 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 57.3 m95 -73.3 130.55 40.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.674 0.273 . . . . 0.0 110.887 -179.867 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -137.28 113.29 9.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.883 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.58 144.56 41.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.843 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.543 ' HB ' ' CZ ' ' A' ' 29' ' ' TYR . 29.9 mm -130.62 132.8 64.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.181 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -104.38 120.28 40.87 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.899 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.43 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.69 137.54 17.47 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.668 0.747 . . . . 0.0 110.876 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -7.68 21.66 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.654 2.236 . . . . 0.0 112.416 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.9 t -113.47 -37.95 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.218 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.417 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.14 -31.69 11.98 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.893 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.48 -148.19 20.43 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.435 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.414 HD12 ' N ' ' A' ' 28' ' ' ILE . 1.9 mp -96.39 109.17 22.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.862 0.363 . . . . 0.0 111.122 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.543 ' CZ ' ' HB ' ' A' ' 21' ' ' ILE . 37.9 p90 -133.31 131.07 39.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.562 ' CD2' HD11 ' A' ' 14' ' ' LEU . 4.7 m-30 -88.21 123.59 33.0 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.935 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.6 t -109.44 115.77 50.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.067 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.449 ' O ' ' N ' ' A' ' 36' ' ' ARG . 9.8 t0 -94.64 102.03 13.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 76.1 m-70 -68.55 -16.15 63.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.856 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.744 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -83.27 -58.6 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.176 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -87.42 -14.12 41.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.853 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 32' ' ' ASP . 4.1 mpt_? 62.73 47.47 4.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.919 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.58 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 5.6 ptpt -128.77 130.02 46.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.4 p -107.34 118.56 37.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.136 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.8 pt20 -150.07 142.99 24.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.889 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -75.12 -26.44 59.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.904 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 23.7 mm-40 -62.01 161.17 11.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.532 ' ND2' ' HB3' ' A' ' 44' ' ' SER . 56.4 t30 -116.77 102.28 53.19 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.657 0.741 . . . . 0.0 110.891 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.448 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 53.9 Cg_endo -69.68 -3.27 11.63 Favored 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.706 2.271 . . . . 0.0 112.34 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.532 ' HB3' ' ND2' ' A' ' 42' ' ' ASN . 6.6 t -52.3 157.91 1.31 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 -179.811 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 139.94 164.2 9.8 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.475 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.7 -34.63 14.38 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.725 2.283 . . . . 0.0 112.322 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 86.3 p -119.7 159.32 24.71 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.856 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 22.1 t 66.75 42.1 2.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.828 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.228 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.485 179.986 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.384 0 N-CA-C 112.52 -0.232 . . . . 0.0 112.52 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.7 t -45.89 -57.31 4.46 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.891 0.377 . . . . 0.0 110.842 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 69.3 m -90.6 162.21 15.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.875 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 151.59 56.7 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.516 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 70.2 m -45.85 -54.19 8.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.877 0.37 . . . . 0.0 110.838 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.8 t 53.28 42.03 32.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.869 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -119.86 74.55 0.32 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.471 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -91.89 140.61 29.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.829 0.347 . . . . 0.0 110.914 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -122.44 154.22 38.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.841 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.1 t -85.68 17.23 3.43 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.852 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -111.95 17.67 19.49 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.823 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 30.1 mt -113.31 157.88 21.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.862 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -109.34 173.29 6.39 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.86 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.44 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 14.5 mt -96.68 154.94 38.27 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.577 0.703 . . . . 0.0 110.926 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.643 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.0 Cg_endo -69.72 -175.78 1.26 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.702 2.268 . . . . 0.0 112.321 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.46 144.26 57.16 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.725 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 92.03 -40.82 2.86 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.501 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.643 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 63.8 m95 -73.04 135.27 44.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.769 0.319 . . . . 0.0 110.908 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -149.52 114.98 5.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.889 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.503 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -72.41 143.68 48.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.901 179.944 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.547 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 45.8 mm -127.02 131.67 70.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.125 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -104.84 117.74 34.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.92 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.417 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.9 t70 -139.15 139.13 22.2 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.591 0.71 . . . . 0.0 110.901 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -7.03 20.03 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.659 2.239 . . . . 0.0 112.372 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.6 t -114.5 -37.99 2.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.126 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.412 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.17 -31.81 11.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.94 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.57 -145.85 19.75 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.467 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.0 mp -96.63 108.57 21.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.792 0.33 . . . . 0.0 111.123 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.547 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.3 p90 -135.97 132.1 35.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.476 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.06 125.05 34.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.93 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.9 t -110.5 115.78 50.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.176 179.798 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -95.44 102.04 13.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 66.9 m-70 -68.93 -14.15 62.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.725 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -84.41 -63.26 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.169 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 19.2 m-20 -82.6 -17.24 45.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.916 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 33.4 mmm-85 65.81 47.42 2.08 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.836 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.58 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 4.1 ptpp? -129.81 126.75 38.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.952 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.3 p -104.92 122.11 45.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.185 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 -150.01 140.02 21.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.88 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.2 m-85 -71.1 -26.11 62.9 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.908 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -69.05 160.27 31.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.849 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.454 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 2.0 t-20 -120.23 106.8 40.21 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.618 0.723 . . . . 0.0 110.887 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 42' ' ' ASN . 53.4 Cg_endo -69.81 3.23 2.92 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.743 2.295 . . . . 0.0 112.347 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 42.5 t -52.28 152.62 3.27 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.817 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 148.83 -177.59 26.97 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.454 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 168.46 21.4 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.673 2.249 . . . . 0.0 112.336 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 27.0 t 57.29 42.23 25.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.848 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.4 m -74.79 -44.65 48.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.852 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.505 -179.988 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.427 -0.269 . . . . 0.0 112.427 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.7 p -103.17 155.82 18.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.908 0.385 . . . . 0.0 110.847 -179.729 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 70.0 m -87.82 148.81 24.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.834 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 162.42 -90.27 0.11 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.516 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.5 m -73.91 -37.93 64.49 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.868 0.366 . . . . 0.0 110.881 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.5 m -55.11 156.69 3.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.872 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -45.88 -92.91 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.512 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 26.7 mt 60.25 42.62 14.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.737 0.303 . . . . 0.0 110.959 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -91.95 117.68 30.04 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 38.9 m -100.13 17.61 20.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.824 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -113.71 17.35 18.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.881 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.554 HD13 ' HA2' ' A' ' 45' ' ' GLY . 25.1 mt -128.03 147.53 50.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.881 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -85.9 163.64 17.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.588 HD11 ' CD2' ' A' ' 30' ' ' TYR . 13.3 mt -82.77 153.54 67.54 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-O 121.643 0.735 . . . . 0.0 110.879 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.651 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.68 -173.96 0.8 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.683 2.256 . . . . 0.0 112.367 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.42 149.64 48.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.122 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.756 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 84.52 -41.3 3.01 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.458 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.651 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 57.7 m95 -70.41 140.44 52.05 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.827 0.346 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -152.81 117.96 5.18 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.941 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.05 147.12 40.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.851 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.505 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 31.6 mm -131.01 132.04 63.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.161 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -105.16 117.8 34.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.883 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -138.05 137.47 21.22 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.606 0.717 . . . . 0.0 110.858 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.79 -4.04 13.24 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.651 2.234 . . . . 0.0 112.392 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.6 t -117.19 -38.03 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.123 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.425 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.56 -31.0 12.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.85 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.0 -146.08 18.94 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.436 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.582 ' O ' ' CE2' ' A' ' 40' ' ' TYR . 1.7 mp -98.43 108.3 21.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.849 0.357 . . . . 0.0 111.159 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.518 ' HB3' ' CE1' ' A' ' 40' ' ' TYR . 28.8 p90 -134.41 132.2 39.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.912 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.588 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.0 m-30 -88.65 122.53 32.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.925 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 t -107.78 115.89 49.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.129 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.459 ' O ' ' N ' ' A' ' 36' ' ' ARG . 57.6 t0 -95.15 101.95 13.73 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.861 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -68.57 -18.52 64.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.756 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -82.14 -57.16 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.125 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -87.18 -14.88 39.94 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.874 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.459 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.3 mpt_? 62.23 47.73 5.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.853 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.577 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 5.0 ptpp? -131.5 132.49 44.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.854 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 7.1 p -108.05 118.35 36.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.12 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -150.05 139.14 21.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.919 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' TYR . . . . . 0.582 ' CE2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -74.26 -21.04 59.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.967 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 34.1 mp0 -65.99 156.9 32.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.888 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.57 HD22 ' HB3' ' A' ' 44' ' ' SER . 52.3 t30 -115.52 101.98 54.3 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.644 0.735 . . . . 0.0 110.968 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.41 ' HD2' HD21 ' A' ' 14' ' ' LEU . 53.6 Cg_endo -69.74 -13.03 34.15 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.642 2.228 . . . . 0.0 112.339 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.57 ' HB3' HD22 ' A' ' 42' ' ' ASN . 34.9 t -52.05 155.76 1.78 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.832 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.554 ' HA2' HD13 ' A' ' 12' ' ' LEU . . . 126.07 -172.75 17.86 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.469 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 2.49 3.49 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.679 2.252 . . . . 0.0 112.344 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 93.2 p -71.06 172.56 8.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.894 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 49.5 m -38.82 -49.67 1.64 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.918 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.449 179.985 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 N-CA-C 112.457 -0.257 . . . . 0.0 112.457 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.2 t -62.95 121.73 14.26 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.855 0.36 . . . . 0.0 110.9 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.4 t -157.68 104.54 1.97 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.895 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -65.18 -124.49 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.527 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 70.6 m -77.44 152.27 34.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.891 0.377 . . . . 0.0 110.855 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.4 m -114.15 175.84 5.3 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.784 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.498 ' C ' HD12 ' A' ' 8' ' ' LEU . . . -169.26 122.17 0.99 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.538 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.498 HD12 ' C ' ' A' ' 7' ' ' GLY . 7.0 mp -121.69 168.34 11.91 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.829 0.347 . . . . 0.0 110.956 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -82.41 17.04 1.83 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.842 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 70.4 m -78.13 8.66 4.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -104.49 10.73 35.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.886 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.401 ' CD1' ' C ' ' A' ' 45' ' ' GLY . 46.3 mt -116.27 148.62 40.31 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.943 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -84.68 164.78 18.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.886 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LEU . . . . . . . . . . . . . 12.8 mt -79.93 151.94 73.93 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.579 0.704 . . . . 0.0 110.921 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.644 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.6 Cg_endo -69.77 -169.36 0.32 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.7 2.267 . . . . 0.0 112.326 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.98 153.74 41.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.683 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 82.24 -45.89 3.43 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.418 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.644 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 71.3 m95 -67.67 134.66 51.52 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.732 0.301 . . . . 0.0 110.896 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -149.92 113.99 5.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.02 142.72 43.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.917 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.538 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 19.0 mm -128.36 130.78 69.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.094 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -102.51 119.88 39.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.895 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.419 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.69 139.7 20.58 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 121.576 0.703 . . . . 0.0 110.896 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.417 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.9 Cg_endo -69.77 -7.8 21.99 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.692 2.261 . . . . 0.0 112.342 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.9 t -113.92 -37.92 2.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.179 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.436 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.5 m-85 -98.51 -31.61 11.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 86.78 -143.74 19.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.423 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.537 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -97.94 108.8 22.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.878 0.37 . . . . 0.0 111.162 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.538 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 39.7 p90 -135.11 131.95 37.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.905 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.442 ' CD1' ' N ' ' A' ' 30' ' ' TYR . 3.3 m-30 -88.77 124.92 34.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.916 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -111.38 116.41 52.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.095 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.627 ' OD1' ' CE3' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -100.12 103.3 14.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 179.903 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 48.3 m-70 -68.83 -8.44 43.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.851 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.683 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.9 OUTLIER -90.22 -62.81 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.156 179.995 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 7.4 m-80 -82.44 -19.91 38.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.915 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 19.6 mmm-85 66.28 47.39 1.82 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.901 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.422 ' HG3' ' OD2' ' A' ' 32' ' ' ASP . 0.1 OUTLIER -129.76 122.2 28.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.847 179.988 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.3 p -100.2 118.34 36.32 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -148.98 141.34 24.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.95 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' TYR . . . . . 0.537 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -75.26 -24.45 57.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.818 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 -62.62 161.24 12.52 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.702 HD22 ' HB2' ' A' ' 44' ' ' SER . 50.6 t30 -120.3 102.02 46.17 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.625 0.726 . . . . 0.0 110.883 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.74 -9.37 25.95 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.709 2.273 . . . . 0.0 112.363 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.702 ' HB2' HD22 ' A' ' 42' ' ' ASN . 6.6 m -59.35 146.4 39.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.854 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . 0.401 ' C ' ' CD1' ' A' ' 12' ' ' LEU . . . -168.36 165.57 38.9 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.496 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.83 113.28 3.33 Favored 'Trans proline' 0 N--CA 1.465 -0.205 0 C-N-CA 122.688 2.258 . . . . 0.0 112.346 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 58.0 m -59.86 112.22 1.76 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.802 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.9 m -76.32 -56.43 4.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.849 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.515 -179.982 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.474 -0.25 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 58.3 m -56.64 -41.85 77.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.836 0.351 . . . . 0.0 110.841 -179.686 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.9 t -95.93 -44.46 7.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.851 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -46.85 -87.01 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.501 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 m -60.35 -47.62 85.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.859 0.361 . . . . 0.0 110.806 -179.684 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.6 t 60.48 42.39 14.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.826 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -49.04 134.73 22.64 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.467 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.46 HD13 ' N ' ' A' ' 9' ' ' ASP . 0.8 OUTLIER -144.11 118.51 9.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.883 0.373 . . . . 0.0 110.875 -179.918 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.46 ' N ' HD13 ' A' ' 8' ' ' LEU . 5.5 p-10 -69.26 105.19 2.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.9 t -106.93 13.8 27.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.846 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -109.28 16.9 22.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.964 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 20.2 mt -128.93 146.91 50.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.892 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -78.19 173.67 12.01 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.833 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.558 HD11 ' CD2' ' A' ' 30' ' ' TYR . 10.7 mt -99.78 155.06 36.9 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 121.603 0.716 . . . . 0.0 110.879 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.62 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.67 -171.71 0.49 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.606 2.204 . . . . 0.0 112.371 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.46 150.52 48.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.072 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.658 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 85.31 -43.92 3.31 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.755 -0.735 . . . . 0.0 112.46 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.62 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -68.66 141.62 55.31 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.751 0.31 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 23.2 tp10 -153.14 113.58 4.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.907 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.47 142.57 48.58 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.898 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.574 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 32.3 mm -127.38 130.76 70.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.105 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -103.81 117.88 35.38 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.928 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.42 ' O ' ' N ' ' A' ' 27' ' ' GLY . 9.8 t70 -138.17 139.36 25.39 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.511 0.672 . . . . 0.0 110.956 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.404 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 54.2 Cg_endo -69.77 -6.92 19.75 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.614 2.21 . . . . 0.0 112.367 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.2 t -114.21 -37.91 2.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.18 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.427 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.66 -32.31 11.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.47 -144.19 18.26 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.425 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.456 HD12 ' N ' ' A' ' 28' ' ' ILE . 1.9 mp -97.86 108.82 22.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.827 0.346 . . . . 0.0 111.128 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.574 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.3 p90 -135.78 131.19 35.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.933 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.558 ' CD2' HD11 ' A' ' 14' ' ' LEU . 2.9 m-30 -88.88 125.55 34.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.92 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.9 t -111.35 116.72 53.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.098 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.406 ' O ' ' N ' ' A' ' 36' ' ' ARG . 19.4 t0 -95.55 102.58 14.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 72.8 m-70 -67.93 -15.13 63.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.658 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.0 OUTLIER -85.02 -61.4 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 -179.998 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 21.4 m-20 -83.49 -15.41 49.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.902 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.406 ' N ' ' O ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER 62.9 47.99 4.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.848 179.957 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.579 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.1 OUTLIER -130.38 130.89 44.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.833 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 3.0 p -108.13 120.26 41.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.151 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.4 pt20 -150.01 140.71 22.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' TYR . . . . . 0.411 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -74.38 -21.75 59.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.89 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 21.6 mt-10 -67.94 161.41 26.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.844 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.537 ' ND2' ' HB3' ' A' ' 44' ' ' SER . 51.8 t30 -117.62 102.07 51.95 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.631 0.729 . . . . 0.0 110.839 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.451 ' HD2' HD21 ' A' ' 14' ' ' LEU . 54.0 Cg_endo -69.84 -12.57 33.01 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.64 2.226 . . . . 0.0 112.363 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.537 ' HB3' ' ND2' ' A' ' 42' ' ' ASN . 24.1 t -34.76 -59.44 0.48 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.92 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -52.12 -173.4 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.433 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 2.45 3.54 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.623 2.215 . . . . 0.0 112.308 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 74.7 p -106.58 135.19 48.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.7 t -121.91 152.51 39.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.839 -179.769 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.525 -179.941 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.448 -0.261 . . . . 0.0 112.448 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.7 t -83.64 -51.78 6.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.856 0.36 . . . . 0.0 110.884 -179.736 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.7 p -83.99 169.89 14.52 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.856 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -171.77 157.63 27.96 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.471 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.0 m -112.06 133.34 54.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.822 0.344 . . . . 0.0 110.898 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.2 t -82.56 147.72 28.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.905 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.94 132.37 11.16 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.492 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 7.5 mp -86.13 -59.34 2.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.854 0.359 . . . . 0.0 110.934 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -148.14 108.39 4.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.875 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.9 p -97.06 16.36 19.84 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.767 -179.658 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -117.49 17.7 14.47 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.92 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 32.6 mt -124.81 151.07 45.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.956 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -76.21 171.22 14.88 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.892 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.715 HD11 ' CD2' ' A' ' 30' ' ' TYR . 12.5 mt -94.19 155.19 40.23 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.554 0.692 . . . . 0.0 110.938 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.638 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.71 -173.67 0.75 Allowed 'Trans proline' 0 C--N 1.34 0.094 0 C-N-CA 122.689 2.259 . . . . 0.0 112.373 179.829 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.4 148.77 51.14 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.063 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.72 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 86.64 -43.04 3.19 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.524 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.638 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.7 m95 -68.22 143.88 55.13 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.691 0.281 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -155.45 116.23 3.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.848 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.498 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -73.8 144.25 45.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.891 179.928 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.573 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 43.7 mm -128.11 130.69 69.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.151 179.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -104.74 117.82 35.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.0 t70 -138.15 139.69 26.48 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 121.589 0.709 . . . . 0.0 110.878 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.413 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.1 Cg_endo -69.82 -7.36 20.88 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.689 2.259 . . . . 0.0 112.38 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 86.4 t -114.12 -37.95 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.104 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.43 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.45 -31.54 11.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.913 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.84 -143.78 18.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.449 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.598 ' O ' ' CE2' ' A' ' 40' ' ' TYR . 1.7 mp -98.41 110.17 25.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.855 0.359 . . . . 0.0 111.151 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.573 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.1 p90 -136.93 131.69 33.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.98 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.715 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.84 124.34 34.09 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.885 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 t -110.3 115.97 51.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.116 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -95.33 102.72 14.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.813 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -69.16 -17.31 63.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.72 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -82.2 -62.67 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.185 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 18.9 m-20 -81.2 -18.25 46.85 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.931 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.0 mmt85 66.08 47.75 1.86 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.839 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.588 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 5.0 ptpp? -131.95 131.74 42.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.9 p -106.55 118.35 36.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.16 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -149.81 139.61 21.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' TYR . . . . . 0.598 ' CE2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.65 -24.99 58.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.911 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -64.1 158.7 22.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.901 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.556 HD22 ' CB ' ' A' ' 44' ' ' SER . 54.2 t30 -115.87 102.01 54.02 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.627 0.727 . . . . 0.0 110.854 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.405 ' HD2' HD21 ' A' ' 14' ' ' LEU . 53.6 Cg_endo -69.8 0.0 6.31 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.747 2.298 . . . . 0.0 112.288 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.556 ' CB ' HD22 ' A' ' 42' ' ' ASN . 7.6 t -52.09 161.69 0.57 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.875 -179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.61 175.07 25.33 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.432 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 -178.92 2.54 Favored 'Trans proline' 0 C--O 1.231 0.158 0 C-N-CA 122.663 2.242 . . . . 0.0 112.397 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.3 p 52.63 39.03 27.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.884 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.2 t -57.4 161.09 3.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.916 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.492 -179.945 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.371 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.3 p -48.42 -32.95 8.41 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.864 0.364 . . . . 0.0 110.808 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.8 p -62.43 -50.34 71.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.856 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -40.16 139.66 1.11 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.452 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.1 m -58.46 -46.51 86.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.894 0.378 . . . . 0.0 110.879 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 74.6 m -100.93 109.12 21.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.909 -179.854 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.446 ' H ' ' CB ' ' A' ' 10' ' ' SER . . . -89.43 -174.07 46.03 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.453 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.1 mp -70.22 -48.54 56.59 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.785 0.326 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -98.65 17.96 17.95 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.857 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.446 ' CB ' ' H ' ' A' ' 7' ' ' GLY . 26.5 t -82.32 16.78 1.9 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.855 -179.78 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -104.33 16.24 26.59 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.894 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 38.8 mt -105.5 146.04 30.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -92.59 168.49 11.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.851 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.52 HD11 ' CD2' ' A' ' 30' ' ' TYR . 13.5 mt -94.61 153.77 40.17 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.578 0.704 . . . . 0.0 110.915 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.677 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.84 -173.45 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.693 2.262 . . . . 0.0 112.285 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.43 149.92 47.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.123 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.592 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 83.88 -39.25 2.84 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.387 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.677 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 72.6 m95 -74.94 131.91 41.03 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.707 0.289 . . . . 0.0 110.926 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -145.46 112.91 6.23 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.896 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.2 145.65 47.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.908 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.568 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 18.7 mm -130.06 132.05 65.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.126 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -104.24 118.59 37.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.873 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.429 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.0 t70 -139.73 139.86 23.17 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.576 0.703 . . . . 0.0 110.877 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.428 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.5 Cg_endo -69.79 -8.85 24.65 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.687 2.258 . . . . 0.0 112.312 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.5 t -112.92 -37.91 2.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.157 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.8 m-85 -98.28 -32.06 11.74 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.939 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.08 -143.63 18.93 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.588 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.544 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -98.37 108.06 21.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.82 0.343 . . . . 0.0 111.115 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.568 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 27.4 p90 -135.13 131.83 37.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.895 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.52 ' CD2' HD11 ' A' ' 14' ' ' LEU . 2.9 m-30 -88.64 120.1 29.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.915 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.408 ' CG2' ' CE2' ' A' ' 29' ' ' TYR . 21.9 t -102.79 123.17 55.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.122 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.618 ' OD2' ' CZ3' ' A' ' 18' ' ' TRP . 5.0 m-20 -97.9 118.73 35.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.852 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.45 ' C ' HD12 ' A' ' 34' ' ' ILE . 81.1 m-70 -92.31 -4.97 53.16 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.8 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.592 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.8 OUTLIER -96.39 -49.98 11.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.122 -179.994 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.478 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 14.9 m-80 -98.36 -12.36 21.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.9 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 44.0 mmm-85 64.3 46.29 3.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.858 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.478 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 22.8 pttt -126.09 127.48 45.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.941 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -107.63 121.01 43.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.164 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 -150.29 144.92 25.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.885 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' TYR . . . . . 0.544 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 5.1 m-85 -79.12 -28.76 42.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -60.4 159.33 10.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.842 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.461 ' OD1' ' CB ' ' A' ' 44' ' ' SER . 14.7 t-20 -114.73 102.01 54.65 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.632 0.729 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 3.57 2.71 Favored 'Trans proline' 0 C--O 1.232 0.19 0 C-N-CA 122.72 2.28 . . . . 0.0 112.33 179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.461 ' CB ' ' OD1' ' A' ' 42' ' ' ASN . 8.3 t -52.01 168.73 0.08 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.856 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 156.02 160.09 9.79 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.499 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 127.58 14.83 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.699 2.266 . . . . 0.0 112.4 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.1 t -66.17 -53.67 34.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.854 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' SER . . . . . 0.42 ' O ' ' C ' ' A' ' 49' ' ' GLY . 35.0 p -159.64 157.24 29.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.844 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' A' ' 48' ' ' SER . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.459 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.465 -0.254 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.5 t -156.52 145.71 20.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.947 0.403 . . . . 0.0 110.813 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 76.7 p -77.84 -45.8 23.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.81 -179.796 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 105.26 61.72 0.64 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.507 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.6 m 57.06 42.1 26.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.868 0.366 . . . . 0.0 110.837 -179.701 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.4 m -74.4 -49.86 20.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.896 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 43.33 -112.92 0.6 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.502 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.618 HD23 ' H ' ' A' ' 8' ' ' LEU . 1.7 pt? -94.42 149.45 21.23 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.817 0.342 . . . . 0.0 110.955 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -117.78 103.01 9.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.855 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 73.9 m -92.98 16.04 13.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.895 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -114.65 15.33 17.66 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.886 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 36.5 mt -125.55 161.84 26.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.916 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -90.33 171.43 9.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.919 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.572 HD11 ' CD2' ' A' ' 30' ' ' TYR . 9.2 mt -92.96 154.51 41.82 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.577 0.704 . . . . 0.0 110.917 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.664 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.8 Cg_endo -69.83 -177.41 1.89 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.626 2.217 . . . . 0.0 112.375 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.38 144.78 56.92 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.053 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.646 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 90.75 -35.87 3.76 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.44 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.664 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 70.5 m95 -78.74 132.73 37.06 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.758 0.313 . . . . 0.0 110.938 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -139.23 111.76 7.67 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.42 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -72.11 146.52 47.44 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.482 ' HB ' ' CZ ' ' A' ' 29' ' ' TYR . 29.9 mm -132.86 133.55 58.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.178 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -106.45 118.93 37.94 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.868 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.435 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -138.57 137.98 21.26 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.577 0.703 . . . . 0.0 110.85 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -8.38 23.46 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.657 2.238 . . . . 0.0 112.372 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.7 t -112.83 -38.02 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.095 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.412 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.04 -31.89 11.91 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.16 -147.63 19.72 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.486 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.418 HD12 ' N ' ' A' ' 28' ' ' ILE . 1.8 mp -97.07 108.88 22.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.873 0.368 . . . . 0.0 111.065 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.482 ' CZ ' ' HB ' ' A' ' 21' ' ' ILE . 42.4 p90 -133.41 131.83 40.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.572 ' CD2' HD11 ' A' ' 14' ' ' LEU . 5.7 m-30 -88.6 124.22 33.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.895 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.2 t -106.06 114.9 46.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.148 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.53 ' OD2' ' CE2' ' A' ' 18' ' ' TRP . 35.9 t0 -91.96 102.25 14.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.836 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -71.53 -10.37 59.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.849 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.646 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.8 OUTLIER -92.32 -60.26 2.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.113 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.467 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 5.9 m-80 -81.29 -21.7 39.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.778 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 10.6 mmt85 67.89 47.63 1.09 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.879 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.467 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 16.9 pttt -139.65 121.86 15.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.879 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 3.3 p -93.07 125.67 37.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.166 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -150.58 140.15 21.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.89 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -73.5 -21.15 60.48 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.923 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 52.8 mm-40 -66.03 157.71 30.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.881 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.434 HD22 HD21 ' A' ' 14' ' ' LEU . 9.0 t-20 -115.76 101.98 54.11 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.603 0.716 . . . . 0.0 110.875 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.409 ' HD2' ' CD2' ' A' ' 14' ' ' LEU . 54.1 Cg_endo -69.75 2.87 3.13 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.396 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.2 p -52.62 146.46 10.09 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.86 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 131.55 176.83 14.57 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.485 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 -177.59 1.93 Allowed 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.726 2.284 . . . . 0.0 112.298 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 13.3 t -94.42 146.51 24.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 14.9 t -89.65 113.35 24.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.882 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.527 -179.996 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.273 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.2 t -120.17 112.34 18.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.865 0.364 . . . . 0.0 110.897 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 80.2 p -160.5 153.1 20.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.806 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -96.21 -119.39 3.59 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.5 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 82.6 p -163.49 167.44 21.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.941 0.4 . . . . 0.0 110.846 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 17.1 m -92.68 176.43 6.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.795 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -43.23 119.9 2.56 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.516 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.473 ' HG ' ' N ' ' A' ' 9' ' ' ASP . 1.3 pt? -39.24 -39.38 0.61 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.804 0.335 . . . . 0.0 110.951 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.473 ' N ' ' HG ' ' A' ' 8' ' ' LEU . 4.6 m-20 -128.37 129.34 46.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.87 179.798 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.7 m -94.19 17.02 13.38 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.893 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -108.55 15.68 23.61 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.894 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 25.1 mt -112.71 146.0 39.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.897 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 27.0 mt-10 -85.98 173.34 10.0 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.867 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.556 HD11 ' CD2' ' A' ' 30' ' ' TYR . 13.7 mt -100.63 153.47 37.72 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.661 0.743 . . . . 0.0 110.908 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.669 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.73 -175.87 1.29 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.66 2.24 . . . . 0.0 112.347 179.842 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.87 145.24 56.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.083 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.769 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 89.52 -41.09 3.01 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.531 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.669 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 69.8 m95 -73.18 129.92 39.11 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.763 0.316 . . . . 0.0 110.916 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -138.45 112.36 8.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.917 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.421 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.57 145.49 43.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.909 179.965 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.579 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 26.2 mm -132.12 133.43 60.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.123 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -105.36 119.39 38.96 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.873 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.438 ' O ' ' N ' ' A' ' 27' ' ' GLY . 10.5 t70 -140.06 138.45 19.48 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.567 0.699 . . . . 0.0 110.883 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -9.78 26.95 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.677 2.251 . . . . 0.0 112.341 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.9 t -111.27 -38.0 3.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.095 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.402 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.8 m-85 -98.05 -33.0 11.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.89 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.41 -146.79 19.16 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.479 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.0 mp -97.68 109.76 24.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.845 0.355 . . . . 0.0 111.152 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.579 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 27.1 p90 -134.53 131.63 38.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.556 ' CD2' HD11 ' A' ' 14' ' ' LEU . 4.9 m-30 -88.51 120.77 30.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.942 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.9 t -106.13 115.69 48.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.143 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.414 ' O ' ' N ' ' A' ' 36' ' ' ARG . 8.8 t0 -94.2 101.99 13.99 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.85 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 76.5 m-70 -67.39 -13.92 62.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.878 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.769 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -85.35 -62.86 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.101 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.497 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 5.8 m-80 -83.56 -15.83 47.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.414 ' N ' ' O ' ' A' ' 32' ' ' ASP . 4.8 mmm180 64.25 47.68 3.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.852 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.497 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 21.1 pttt -129.75 136.79 50.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.835 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 22.6 p -113.44 123.04 49.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.108 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 -149.96 138.54 20.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.948 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -72.59 -16.22 61.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.948 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -73.54 159.97 32.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.857 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.407 ' OD1' ' CB ' ' A' ' 44' ' ' SER . 11.9 t-20 -116.43 101.93 53.6 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.646 0.736 . . . . 0.0 110.926 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.72 3.56 2.68 Favored 'Trans proline' 0 C--N 1.342 0.236 0 C-N-CA 122.687 2.258 . . . . 0.0 112.354 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.407 ' CB ' ' OD1' ' A' ' 42' ' ' ASN . 19.5 t -52.1 156.96 1.44 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.855 -179.815 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 129.68 160.21 10.09 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.502 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.62 115.74 4.21 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.71 2.273 . . . . 0.0 112.4 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 64.7 m -81.03 -58.9 2.87 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.905 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.8 m 54.33 42.17 31.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.921 -179.796 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.41 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.441 -179.918 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.453 -0.259 . . . . 0.0 112.453 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 30.0 t -42.46 -44.86 4.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.877 0.37 . . . . 0.0 110.796 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.7 m -79.11 148.88 32.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.862 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -146.93 -153.85 6.02 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.463 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 28.9 t -58.37 151.04 20.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.865 0.364 . . . . 0.0 110.849 -179.699 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 8.9 t -154.97 159.26 40.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.891 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 133.97 158.17 8.49 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.446 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.9 mp -85.06 153.67 22.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.863 0.363 . . . . 0.0 110.865 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -93.3 116.61 29.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.798 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.1 p -81.42 13.37 3.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.855 -179.783 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -112.97 16.48 19.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.832 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 30.0 mt -110.72 154.17 24.25 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.895 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -104.12 166.78 10.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.819 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.465 HD11 ' CG ' ' A' ' 30' ' ' TYR . 10.8 mt -85.06 154.94 60.89 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.65 0.738 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.658 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.8 Cg_endo -69.77 -173.61 0.75 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.707 2.271 . . . . 0.0 112.323 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.86 144.52 55.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.102 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.773 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 92.14 -39.14 3.06 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.479 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.658 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 69.1 m95 -74.68 131.31 40.77 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.669 0.271 . . . . 0.0 110.916 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.462 ' OE1' HD11 ' A' ' 21' ' ' ILE . 10.4 tt0 -135.82 111.82 9.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.891 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.526 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -76.11 146.65 39.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.859 -179.983 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.551 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 31.5 mm -133.56 135.52 55.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.137 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 -107.33 117.66 34.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.905 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.43 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.4 t70 -137.71 137.9 22.85 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.638 0.733 . . . . 0.0 110.796 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -8.12 22.8 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.68 2.253 . . . . 0.0 112.333 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 86.5 t -113.17 -38.03 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.182 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.435 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.5 m-85 -97.46 -31.72 12.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.942 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.44 -148.28 20.51 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.0 mp -96.6 108.97 22.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.778 0.323 . . . . 0.0 111.17 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.551 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 37.9 p90 -132.84 131.38 40.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.928 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.465 ' CG ' HD11 ' A' ' 14' ' ' LEU . 4.9 m-30 -88.38 123.6 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.865 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.8 t -107.94 115.08 48.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.146 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 28.3 t0 -91.63 102.02 14.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.844 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -68.22 -16.52 64.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.817 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.773 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.0 OUTLIER -86.87 -61.11 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.117 -179.988 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 -79.74 -16.97 54.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.902 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 64.47 45.78 3.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.848 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 1.4 pttm -131.68 146.2 52.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.881 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.7 p -120.5 122.94 41.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.112 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 -150.53 140.1 21.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.934 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -72.57 -20.75 61.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.901 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 35.0 mp0 -68.36 157.39 35.8 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.866 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.546 ' ND2' ' HB3' ' A' ' 44' ' ' SER . 60.7 t30 -115.36 102.15 54.45 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.659 0.742 . . . . 0.0 110.844 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.87 3.37 2.86 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.677 2.251 . . . . 0.0 112.332 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.546 ' HB3' ' ND2' ' A' ' 42' ' ' ASN . 34.2 t -52.16 142.67 15.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.838 -179.863 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 129.22 162.77 11.02 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.474 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -16.34 37.65 Favored 'Trans proline' 0 C--O 1.23 0.095 0 C-N-CA 122.702 2.268 . . . . 0.0 112.375 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 67.9 m -46.8 -45.36 19.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.833 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 99.3 p -44.16 -46.84 8.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.785 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.48 -179.939 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.546 -0.222 . . . . 0.0 112.546 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 43.7 t -105.32 149.2 26.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.884 0.374 . . . . 0.0 110.888 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.4 t -75.49 138.11 41.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.815 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.47 104.98 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.526 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 78.6 p -71.98 -49.05 40.53 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.828 0.346 . . . . 0.0 110.885 -179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 77.9 p -128.55 160.61 31.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.879 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -69.45 112.72 4.67 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.478 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.481 HD22 ' HA ' ' A' ' 8' ' ' LEU . 0.6 OUTLIER -87.31 -53.68 4.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.72 0.295 . . . . 0.0 110.866 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -85.61 17.69 3.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.855 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.3 t -76.98 7.32 4.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.824 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -107.57 15.53 24.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.844 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 30.6 mt -125.16 158.01 35.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.914 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -92.67 171.3 9.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.882 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.453 HD11 ' CD2' ' A' ' 30' ' ' TYR . 17.4 mt -98.73 152.29 37.79 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.579 0.704 . . . . 0.0 110.954 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.641 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.74 -171.21 0.45 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.719 2.28 . . . . 0.0 112.417 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.95 147.35 53.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.084 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.579 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 88.2 -44.66 3.22 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.47 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.641 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 63.2 m95 -68.38 135.92 52.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.779 0.323 . . . . 0.0 110.903 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -149.52 115.61 5.72 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.551 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -75.79 142.0 42.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 -179.995 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.573 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 38.4 mm -125.34 131.52 72.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.134 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -102.65 117.78 35.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.0 t70 -139.12 139.48 23.37 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.578 0.704 . . . . 0.0 110.884 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 54.6 Cg_endo -69.69 -11.31 30.67 Favored 'Trans proline' 0 N--CA 1.465 -0.183 0 C-N-CA 122.668 2.245 . . . . 0.0 112.437 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.3 t -109.93 -37.98 3.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.155 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.36 -32.85 11.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.9 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.48 -140.78 15.82 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.472 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.605 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.9 mp -102.08 109.4 26.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.808 0.337 . . . . 0.0 111.132 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.573 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 32.6 p90 -135.54 133.96 38.94 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.882 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.478 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.4 m-30 -90.18 126.8 35.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.927 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.2 t -113.21 117.24 54.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.125 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.459 ' O ' ' N ' ' A' ' 36' ' ' ARG . 62.4 t0 -95.14 103.31 15.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 47.7 m-70 -68.6 -16.38 63.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.645 ' CD1' ' N ' ' A' ' 34' ' ' ILE . 0.6 OUTLIER -83.39 -55.49 7.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.121 -179.993 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 63.1 m-20 -93.33 -2.39 54.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.854 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.459 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.5 mpt_? 54.62 47.94 21.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.7 mtmm -113.54 160.8 18.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -145.12 108.3 4.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.14 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -147.88 144.19 27.93 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.919 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' TYR . . . . . 0.605 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.6 m-85 -76.29 -26.54 55.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -63.6 161.42 14.8 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.854 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 18.7 t-20 -116.62 101.93 53.44 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.614 0.721 . . . . 0.0 110.933 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.479 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 54.2 Cg_endo -69.74 -11.26 30.5 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.637 2.225 . . . . 0.0 112.377 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.463 ' C ' ' O ' ' A' ' 43' ' ' PRO . 8.4 t -33.56 -65.77 0.17 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.85 -179.865 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -63.61 173.1 12.89 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.521 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 83.24 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.69 2.26 . . . . 0.0 112.338 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 28.2 p -108.5 124.8 51.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.84 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 48.9 m -114.89 175.81 5.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.953 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.498 -179.973 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.407 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.4 ' O ' ' C ' ' A' ' 3' ' ' SER . 34.0 t 64.86 42.37 4.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.841 0.353 . . . . 0.0 110.829 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . 0.4 ' C ' ' O ' ' A' ' 2' ' ' SER . 86.3 p -37.48 -41.18 0.43 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.882 -179.787 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 152.61 161.49 10.28 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.546 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 29.6 t -92.83 142.41 27.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.806 0.336 . . . . 0.0 110.924 -179.701 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.4 m -43.41 -50.72 6.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.857 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 132.95 121.03 2.18 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.503 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 54.0 mt -91.2 -45.82 8.43 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.769 0.319 . . . . 0.0 110.907 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.06 17.98 14.41 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.904 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.0 m -82.02 16.27 1.98 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.908 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -112.93 16.36 19.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.899 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 30.5 mt -115.61 167.67 10.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -97.26 168.31 10.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.859 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.437 HD11 ' CG ' ' A' ' 30' ' ' TYR . 9.6 mt -89.19 156.67 48.68 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.614 0.721 . . . . 0.0 110.874 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.664 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.79 -170.38 0.39 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.614 2.209 . . . . 0.0 112.311 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.62 140.91 48.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.12 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.618 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 94.62 -32.19 6.24 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.505 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.664 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 67.4 m95 -81.89 147.72 29.15 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.703 0.287 . . . . 0.0 110.896 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.486 ' O ' ' CG ' ' A' ' 19' ' ' GLU . 2.3 pt-20 -152.71 119.57 5.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.888 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.59 141.47 36.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.95 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.578 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 18.2 mm -129.41 132.4 66.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.097 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -106.02 120.6 42.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.933 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.425 ' CG ' ' HD2' ' A' ' 24' ' ' PRO . 10.8 t70 -140.37 139.66 21.21 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.561 0.696 . . . . 0.0 110.888 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.425 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.9 Cg_endo -69.67 -8.18 22.94 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.696 2.264 . . . . 0.0 112.376 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 99.5 t -114.89 -37.9 2.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.123 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.31 -29.2 13.3 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.905 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 82.51 -151.73 29.82 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.508 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 1.9 mp -89.81 110.88 22.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.824 0.345 . . . . 0.0 111.05 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.578 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 46.3 p90 -136.03 130.88 34.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.913 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.437 ' CG ' HD11 ' A' ' 14' ' ' LEU . 5.3 m-30 -88.48 132.79 34.34 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.963 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.4 t -114.62 116.47 52.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.138 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.478 ' OD1' ' CD1' ' A' ' 18' ' ' TRP . 13.3 t0 -98.59 102.03 13.64 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.898 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 -72.07 -11.24 60.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.84 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.618 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.8 OUTLIER -85.83 -57.2 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.129 179.947 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -87.65 -18.36 29.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.895 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 68.02 47.88 1.02 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.87 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.423 ' HE2' ' CH2' ' A' ' 18' ' ' TRP . 8.5 pttm -139.35 130.96 27.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.1 p -104.19 126.15 51.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 -150.63 141.82 23.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.956 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -73.78 -21.63 60.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 30.0 mm-40 -66.41 154.1 41.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.924 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.537 ' ND2' ' HB3' ' A' ' 44' ' ' SER . 60.9 t30 -112.3 101.99 53.22 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.597 0.713 . . . . 0.0 110.911 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.405 ' HD2' ' CD2' ' A' ' 14' ' ' LEU . 53.1 Cg_endo -69.79 2.2 3.77 Favored 'Trans proline' 0 C--N 1.34 0.13 0 C-N-CA 122.672 2.248 . . . . 0.0 112.31 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.537 ' HB3' ' ND2' ' A' ' 42' ' ' ASN . 30.3 t -52.1 148.49 6.18 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.868 -179.835 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 144.27 165.73 11.11 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.478 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.7 0.7 5.22 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.658 2.239 . . . . 0.0 112.376 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.0 t -108.27 131.68 54.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.834 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 t -109.63 127.74 54.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.905 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.459 179.985 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.521 -0.232 . . . . 0.0 112.521 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.6 m -87.26 -60.92 1.84 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.811 0.339 . . . . 0.0 110.8 -179.703 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.8 m -77.25 -54.95 5.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.33 87.06 1.11 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.512 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 42.4 t -83.11 -46.56 12.63 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.782 0.325 . . . . 0.0 110.796 -179.734 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.4 t -64.29 151.95 42.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.915 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -124.85 -89.19 0.8 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.493 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mt -119.76 121.53 39.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.788 0.328 . . . . 0.0 110.928 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -102.29 171.79 7.27 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.869 179.868 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' SER . . . . . 0.563 ' O ' ' CG ' ' A' ' 11' ' ' GLU . 1.7 t -147.82 178.0 8.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.826 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.563 ' CG ' ' O ' ' A' ' 10' ' ' SER . 2.8 pt-20 54.0 32.05 14.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.905 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.441 ' HG ' ' O ' ' A' ' 10' ' ' SER . 27.3 mt -117.48 162.64 17.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.989 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -111.14 173.99 6.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.919 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.585 HD11 ' CD2' ' A' ' 30' ' ' TYR . 11.6 mt -104.2 154.11 38.48 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.609 0.719 . . . . 0.0 110.956 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.635 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.6 Cg_endo -69.76 -171.78 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.647 2.232 . . . . 0.0 112.368 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.73 149.98 49.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.077 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.744 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 84.94 -40.46 3.0 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.539 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.635 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 58.4 m95 -72.51 140.44 48.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.712 0.291 . . . . 0.0 110.995 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -152.24 115.04 4.6 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.438 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.35 138.6 43.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.576 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 34.9 mm -121.13 131.21 73.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.166 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -103.54 117.94 35.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.854 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.44 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.7 t70 -138.91 137.98 20.55 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.578 0.704 . . . . 0.0 110.88 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 -8.26 23.14 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.665 2.244 . . . . 0.0 112.291 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.5 t -112.86 -37.97 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.169 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' TYR . . . . . 0.418 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -97.94 -31.98 11.9 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.959 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.4 -145.49 18.47 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.561 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.596 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -98.99 108.57 22.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.813 0.339 . . . . 0.0 111.081 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.576 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 31.5 p90 -134.42 131.58 38.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.585 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.6 m-30 -88.75 122.4 32.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.912 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.0 t -108.11 115.62 49.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.146 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 57.1 t0 -94.77 101.99 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.828 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 65.9 m-70 -68.74 -18.76 64.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.862 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.744 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -81.67 -62.73 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.109 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.2 m-80 -80.34 -16.37 54.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.867 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 27.5 mmm180 64.11 47.69 3.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.55 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 11.1 ptpt -133.11 129.44 37.95 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.7 p -105.34 119.46 39.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.198 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -150.29 140.5 22.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.91 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' TYR . . . . . 0.596 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.55 -25.08 59.08 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.884 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -62.06 161.84 10.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.872 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.547 ' ND2' ' HB3' ' A' ' 44' ' ' SER . 58.9 t30 -118.44 101.93 50.59 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.581 0.705 . . . . 0.0 110.937 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.41 ' HD2' HD21 ' A' ' 14' ' ' LEU . 53.7 Cg_endo -69.65 -11.68 31.51 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.677 2.251 . . . . 0.0 112.346 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.547 ' HB3' ' ND2' ' A' ' 42' ' ' ASN . 23.0 t -42.78 -49.61 5.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.832 -179.786 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -47.04 176.24 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.508 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 159.24 54.11 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.708 2.272 . . . . 0.0 112.277 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 69.7 m 62.64 42.68 8.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.88 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 22.6 t -54.24 -59.67 4.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.878 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.484 179.994 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.246 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.9 m -67.09 -46.88 72.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.889 0.376 . . . . 0.0 110.827 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.8 p -122.3 160.39 25.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.791 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -81.79 45.66 3.33 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.532 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 24.3 p -123.24 119.54 30.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.891 0.377 . . . . 0.0 110.835 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.8 m -151.41 150.26 30.25 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.84 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.12 64.18 1.24 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.545 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.8 mt -76.73 -52.62 9.25 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.818 0.342 . . . . 0.0 110.953 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 63.3 m-20 -87.57 130.91 34.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.948 179.738 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.7 p -106.22 14.64 27.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.846 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -116.88 16.52 15.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.863 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 32.2 mt -110.87 148.58 32.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.963 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 27.1 mt-10 -85.67 169.56 13.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.865 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' LEU . . . . . 0.565 HD11 ' CD2' ' A' ' 30' ' ' TYR . 14.3 mt -97.16 154.09 38.25 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.556 0.693 . . . . 0.0 110.947 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.667 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.5 Cg_endo -69.77 -173.49 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.721 2.281 . . . . 0.0 112.292 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.52 146.91 54.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.035 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.666 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 87.9 -42.14 3.1 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.456 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' TRP . . . . . 0.667 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 70.8 m95 -71.78 122.3 20.45 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.834 0.35 . . . . 0.0 110.911 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.44 ' OE1' HD11 ' A' ' 21' ' ' ILE . 7.5 tt0 -128.3 111.43 13.36 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.507 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -76.17 145.2 40.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.854 179.987 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.57 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 32.8 mm -132.68 133.58 59.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.127 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -106.06 117.99 35.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.912 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.1 t70 -138.36 139.67 25.87 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.64 0.733 . . . . 0.0 110.891 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.42 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.7 Cg_endo -69.71 -11.8 31.67 Favored 'Trans proline' 0 C--O 1.232 0.225 0 C-N-CA 122.704 2.269 . . . . 0.0 112.33 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 94.0 t -109.36 -37.95 3.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.162 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.28 -32.27 11.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.846 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.13 -140.95 16.0 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.439 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 1.9 mp -102.91 108.87 25.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 0.0 111.179 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' TYR . . . . . 0.57 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 25.0 p90 -133.39 131.14 39.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.922 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' TYR . . . . . 0.565 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.27 119.65 28.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.916 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.4 t -101.88 115.57 43.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.098 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.615 ' OD2' ' CZ3' ' A' ' 18' ' ' TRP . 3.8 m-20 -88.87 112.96 23.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' HIS . . . . . 0.451 ' C ' HD12 ' A' ' 34' ' ' ILE . 87.6 m-70 -86.37 -7.07 58.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.946 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.666 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.7 OUTLIER -97.11 -49.13 12.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.097 179.99 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 -96.06 -13.66 23.53 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.85 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ARG . . . . . 0.406 ' HA ' ' O ' ' A' ' 32' ' ' ASP . 25.3 mmt180 65.32 42.49 3.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.851 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' LYS . . . . . 0.558 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 0.1 OUTLIER -121.51 129.86 53.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.877 -179.986 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -111.21 116.1 30.48 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.149 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -145.96 146.39 31.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.935 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -77.96 -30.9 50.59 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.939 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLU . . . . . 0.409 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 4.1 mt-10 -58.25 166.75 1.53 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.845 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.417 ' ND2' HD21 ' A' ' 14' ' ' LEU . 12.5 t-20 -120.81 102.0 44.87 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.663 0.744 . . . . 0.0 110.906 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' PRO . . . . . 0.55 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.77 -1.58 8.73 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.682 2.255 . . . . 0.0 112.271 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 7.9 t -52.02 154.47 2.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.88 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 158.52 166.54 17.85 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.533 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.69 2.54 3.41 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.749 2.3 . . . . 0.0 112.345 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 2.5 m -112.77 107.34 15.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.793 -179.77 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 50.1 m -119.2 129.81 55.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.852 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.282 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.507 -179.996 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.526 HD21 HD22 ' A' ' 42' ' ' ASN . 13.3 mt . . . . . 0 C--O 1.23 0.071 0 CA-C-O 121.557 0.694 . . . . 0.0 110.953 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.611 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.85 -175.55 1.22 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.611 2.208 . . . . 0.0 112.313 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.26 146.76 53.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.09 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.665 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 89.5 -44.26 3.05 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.497 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.611 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -69.7 142.32 53.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.735 0.302 . . . . 0.0 110.904 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -153.29 114.67 4.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.922 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.441 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -72.71 144.26 47.74 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.919 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.576 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 41.9 mm -128.17 130.62 69.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.177 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -104.97 117.86 35.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.859 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -137.84 139.78 27.52 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.624 0.726 . . . . 0.0 110.878 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.415 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.2 Cg_endo -69.83 -7.96 22.39 Favored 'Trans proline' 0 C--O 1.233 0.237 0 C-N-CA 122.646 2.231 . . . . 0.0 112.302 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 96.4 t -113.83 -38.01 2.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.081 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.8 m-85 -98.08 -30.79 12.47 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.941 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.26 -142.91 18.43 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.527 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.557 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.8 mp -99.64 111.46 29.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.848 0.356 . . . . 0.0 111.116 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.576 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 39.2 p90 -137.2 131.54 32.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.978 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.471 ' CD2' HD11 ' A' ' 14' ' ' LEU . 5.5 m-30 -88.98 123.6 33.47 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.925 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.415 ' CG2' ' CE2' ' A' ' 29' ' ' TYR . 10.8 t -110.2 116.57 52.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.148 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.407 ' OD2' ' NE1' ' A' ' 18' ' ' TRP . 51.5 t0 -95.77 106.09 18.17 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.929 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -71.36 -14.27 62.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.819 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.665 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.9 OUTLIER -85.98 -62.34 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.158 179.971 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.425 ' C ' ' HD3' ' A' ' 36' ' ' ARG . 28.0 m-80 -80.65 -13.81 58.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.852 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.425 ' HD3' ' C ' ' A' ' 35' ' ' ASN . 1.8 mpp_? 63.09 46.25 4.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -128.03 154.75 45.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.855 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.7 p -129.45 117.95 21.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.133 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.473 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.1 pt20 -149.66 141.86 24.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.956 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . 0.557 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.81 -25.99 59.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.922 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 -63.06 160.77 14.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.94 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.526 HD22 HD21 ' A' ' 14' ' ' LEU . 9.9 t-20 -115.48 102.02 54.33 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.589 0.709 . . . . 0.0 110.849 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.473 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.4 Cg_endo . . . . . 0 C--N 1.341 0.16 0 C-N-CA 122.705 2.27 . . . . 0.0 112.322 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.613 HD11 ' CD2' ' A' ' 30' ' ' TYR . 11.0 mt . . . . . 0 C--O 1.23 0.052 0 CA-C-O 121.603 0.716 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.63 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.2 Cg_endo -69.7 -172.74 0.6 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.668 2.245 . . . . 0.0 112.349 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.58 148.62 51.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.093 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.695 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 86.91 -41.39 3.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.492 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.63 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.0 m95 -71.3 143.68 50.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.65 0.262 . . . . 0.0 110.956 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 30.3 tp10 -154.3 113.49 3.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.847 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.462 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -72.95 139.8 46.99 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.934 179.888 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.577 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 34.7 mm -122.76 129.12 75.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.164 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -101.97 117.92 35.82 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.896 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.447 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.7 t70 -139.01 139.16 22.57 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.614 0.721 . . . . 0.0 110.836 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -9.81 27.01 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.72 2.28 . . . . 0.0 112.372 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.4 t -111.54 -37.94 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.123 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.413 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.7 m-85 -97.79 -32.1 11.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.967 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.27 -144.67 18.66 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.455 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.485 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.0 mp -98.62 109.81 24.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.781 0.325 . . . . 0.0 111.105 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.577 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 36.9 p90 -136.16 130.75 33.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.613 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.78 124.35 34.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.914 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.466 HG22 HG22 ' A' ' 38' ' ' THR . 12.0 t -110.91 115.93 51.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.114 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.406 ' O ' ' N ' ' A' ' 36' ' ' ARG . 13.5 t0 -94.45 101.93 13.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.895 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -67.46 -18.38 65.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.695 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -80.7 -63.35 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.15 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -81.14 -16.72 52.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.818 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.406 ' N ' ' O ' ' A' ' 32' ' ' ASP . 17.7 mmt180 64.89 47.98 2.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.565 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.0 OUTLIER -132.47 129.03 38.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.869 179.976 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.466 HG22 HG22 ' A' ' 31' ' ' VAL . 2.3 p -104.59 120.19 40.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.167 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.437 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.8 pt20 -150.11 140.91 22.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.932 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . 0.485 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.41 -23.77 59.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.908 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 55.7 mm-40 -64.86 158.28 25.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.909 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.444 ' ND2' ' HG ' ' A' ' 14' ' ' LEU . 12.0 t-20 -115.32 102.0 54.46 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.665 0.745 . . . . 0.0 110.896 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.437 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.1 Cg_endo . . . . . 0 C--N 1.342 0.209 0 C-N-CA 122.713 2.276 . . . . 0.0 112.335 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.505 HD11 ' CD2' ' A' ' 30' ' ' TYR . 15.1 mt . . . . . 0 C--O 1.231 0.111 0 CA-C-O 121.586 0.708 . . . . 0.0 110.923 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.632 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.3 Cg_endo -69.74 -172.19 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.605 2.203 . . . . 0.0 112.376 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.19 146.63 54.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.071 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.704 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 88.54 -40.7 3.06 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.467 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.632 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -72.64 142.66 48.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.733 0.301 . . . . 0.0 110.895 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -153.4 115.51 4.34 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.882 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.474 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.22 140.99 45.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 -179.967 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.559 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 38.1 mm -123.87 129.73 74.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.163 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.2 mt-10 -103.79 117.88 35.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.871 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.449 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.1 t70 -139.12 139.67 24.0 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.568 0.699 . . . . 0.0 110.905 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.42 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.6 Cg_endo -69.77 -9.48 26.2 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.627 2.218 . . . . 0.0 112.38 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 95.6 t -111.78 -38.04 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.13 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -97.91 -31.49 12.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.959 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.3 -145.73 19.86 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.456 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.598 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.7 mp -97.1 110.01 24.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.821 0.343 . . . . 0.0 111.198 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.559 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 34.9 p90 -137.37 130.62 30.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.901 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.505 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.0 m-30 -89.02 126.85 35.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.931 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.522 HG22 HG22 ' A' ' 38' ' ' THR . 10.6 t -112.67 116.13 51.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.115 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.463 ' O ' ' N ' ' A' ' 36' ' ' ARG . 10.4 t0 -93.56 102.16 14.35 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.821 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 -68.0 -17.14 64.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.889 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.704 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -82.46 -58.17 3.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.127 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -87.34 -14.29 41.16 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.887 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.463 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.2 mpt_? 62.59 47.99 4.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.79 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.469 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.0 OUTLIER -130.93 126.94 37.4 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.941 179.952 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.522 HG22 HG22 ' A' ' 31' ' ' VAL . 1.6 p -102.35 119.34 38.65 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.107 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.456 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.0 pt20 -149.65 141.83 24.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.961 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . 0.598 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 3.0 m-85 -76.02 -24.6 55.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.89 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 25.7 mm-40 -62.93 161.25 13.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.47 HD22 HD21 ' A' ' 14' ' ' LEU . 8.8 t-20 -116.36 102.1 53.61 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.616 0.722 . . . . 0.0 110.867 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.456 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.3 Cg_endo . . . . . 0 C--N 1.341 0.179 0 C-N-CA 122.655 2.237 . . . . 0.0 112.316 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.461 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 11.9 mt . . . . . 0 C--O 1.231 0.119 0 CA-C-O 121.619 0.723 . . . . 0.0 110.937 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.629 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.71 -175.82 1.27 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.677 2.251 . . . . 0.0 112.361 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.31 143.37 57.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.113 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.717 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 93.21 -41.49 2.69 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.543 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.629 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 60.4 m95 -72.69 137.75 46.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.721 0.296 . . . . 0.0 110.932 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -151.1 114.46 4.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.92 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.461 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -71.92 145.12 48.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.879 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.568 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 44.6 mm -129.13 131.76 67.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -106.57 117.99 35.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.851 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.424 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.6 t70 -138.54 139.65 25.36 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.608 0.718 . . . . 0.0 110.884 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.412 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.5 Cg_endo -69.74 -7.22 20.48 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.609 2.206 . . . . 0.0 112.362 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 95.2 t -114.49 -38.01 2.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.404 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.9 m-85 -98.29 -31.08 12.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.867 -179.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.02 -144.27 19.29 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.416 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.45 ' N ' HD12 ' A' ' 28' ' ' ILE . 1.8 mp -97.15 111.29 26.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.783 0.325 . . . . 0.0 111.145 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.568 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 32.0 p90 -139.18 131.35 28.13 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.935 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.481 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.05 128.25 35.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.947 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.9 t -113.06 115.86 50.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -95.62 102.41 14.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.883 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 60.6 m-70 -69.51 -14.4 62.85 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.86 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.717 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.0 OUTLIER -87.16 -60.94 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.132 -179.981 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 21.0 m-20 -82.63 -15.19 53.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 13.1 mmm180 62.38 47.58 5.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.79 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.577 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 4.8 ptpp? -130.48 129.11 42.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.897 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -107.64 121.58 44.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.181 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.472 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.9 pt20 -150.05 141.86 23.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.881 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.2 m-85 -72.33 -26.99 62.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.903 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.435 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 6.1 mm-40 -68.99 162.99 25.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.946 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.468 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 1.9 t-20 -122.13 108.66 34.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.661 0.744 . . . . 0.0 110.862 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.472 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.1 Cg_endo . . . . . 0 C--N 1.341 0.179 0 C-N-CA 122.698 2.265 . . . . 0.0 112.35 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.428 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 11.8 mt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 121.63 0.729 . . . . 0.0 110.899 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.629 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.3 Cg_endo -69.77 -174.58 0.94 Allowed 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.663 2.242 . . . . 0.0 112.314 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.23 143.74 57.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.071 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.683 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 93.15 -41.64 2.68 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.629 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 60.6 m95 -72.42 137.76 46.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.73 0.3 . . . . 0.0 110.955 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -151.35 117.06 5.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.835 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.525 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -75.53 143.55 42.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.916 179.907 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.567 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 45.0 mm -127.09 131.89 70.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.121 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -104.94 117.69 34.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.848 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.418 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -137.99 138.5 23.62 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.652 0.739 . . . . 0.0 110.899 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -6.62 19.04 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.689 2.259 . . . . 0.0 112.267 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 90.7 t -115.2 -38.02 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.133 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.42 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.8 m-85 -98.1 -31.23 12.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.925 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.04 -145.45 19.23 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.45 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.408 ' N ' HD12 ' A' ' 28' ' ' ILE . 2.0 mp -97.41 111.6 27.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 111.086 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.567 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.7 p90 -138.57 132.83 31.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.896 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.481 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.84 128.52 36.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.945 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.8 t -113.43 115.82 50.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.116 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -94.54 102.12 14.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.892 179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 70.2 m-70 -68.99 -12.86 62.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.683 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.9 OUTLIER -89.0 -60.39 2.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.134 179.958 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -83.01 -18.6 39.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.809 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.6 mmm180 65.67 48.05 2.03 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.577 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 14.9 ptpt -130.53 131.16 44.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -109.25 120.29 42.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.118 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.469 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 6.9 pt20 -149.43 140.89 23.32 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.965 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -71.19 -24.6 62.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.941 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.405 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 8.0 mt-10 -69.76 161.1 30.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.458 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 1.9 t-20 -122.75 105.45 35.4 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.637 0.732 . . . . 0.0 110.913 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.469 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.5 Cg_endo . . . . . 0 C--N 1.341 0.18 0 C-N-CA 122.73 2.286 . . . . 0.0 112.391 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.554 HD11 ' CD2' ' A' ' 30' ' ' TYR . 14.5 mt . . . . . 0 C--O 1.232 0.138 0 CA-C-O 121.59 0.71 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.629 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.1 Cg_endo -69.7 -173.85 0.79 Allowed 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.683 2.255 . . . . 0.0 112.392 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.73 149.29 49.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.098 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.724 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 86.05 -42.4 3.15 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.503 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.629 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.2 m95 -70.39 139.19 51.82 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.685 0.279 . . . . 0.0 110.916 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 29.4 tp10 -149.49 113.87 5.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.846 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.85 144.79 50.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.896 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.582 HG21 ' OH ' ' A' ' 29' ' ' TYR . 33.9 mm -128.27 130.97 69.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.126 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -105.6 118.59 36.97 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.91 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.432 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.14 139.56 21.47 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.669 0.747 . . . . 0.0 110.845 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.407 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.6 Cg_endo -69.74 -8.65 24.14 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.751 2.301 . . . . 0.0 112.336 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 91.3 t -112.68 -38.04 2.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.113 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.417 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.22 -32.45 11.56 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.927 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.4 -144.62 18.55 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.505 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.6 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.9 mp -97.99 109.59 23.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.811 0.338 . . . . 0.0 111.195 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.582 ' OH ' HG21 ' A' ' 21' ' ' ILE . 38.4 p90 -135.34 130.96 35.81 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.95 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.554 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.9 m-30 -88.65 121.44 31.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.981 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.465 HG22 HG22 ' A' ' 38' ' ' THR . 11.7 t -107.96 116.36 51.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.151 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -96.03 102.59 14.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 60.6 m-70 -68.26 -18.14 64.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.902 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.724 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -81.39 -63.42 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -79.22 -18.46 52.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.902 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.478 ' CZ ' ' HA ' ' A' ' 36' ' ' ARG . 0.1 OUTLIER 66.61 47.77 1.56 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 -179.971 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.502 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 6.3 ptpt -134.5 130.72 37.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.876 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.465 HG22 HG22 ' A' ' 31' ' ' VAL . 1.8 p -106.05 119.99 40.63 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.19 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.4 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.7 pt20 -149.99 141.76 23.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.926 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . 0.6 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -75.05 -25.42 58.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.914 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -62.74 158.18 19.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.834 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.495 HD22 HD21 ' A' ' 14' ' ' LEU . 9.2 t-20 -114.28 101.9 54.45 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.522 0.677 . . . . 0.0 110.915 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.426 ' HD2' HD21 ' A' ' 14' ' ' LEU . 53.9 Cg_endo . . . . . 0 N--CA 1.465 -0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.376 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.562 HD11 ' CD2' ' A' ' 30' ' ' TYR . 11.5 mt . . . . . 0 C--O 1.232 0.139 0 CA-C-O 121.569 0.699 . . . . 0.0 110.887 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.625 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.7 -171.73 0.5 Allowed 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.69 2.26 . . . . 0.0 112.368 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.23 147.32 52.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.106 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.744 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 88.58 -40.39 3.08 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.483 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.625 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 57.3 m95 -73.3 130.55 40.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.674 0.273 . . . . 0.0 110.887 -179.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -137.28 113.29 9.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.883 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.58 144.56 41.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.843 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.543 ' HB ' ' CZ ' ' A' ' 29' ' ' TYR . 29.9 mm -130.62 132.8 64.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.181 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -104.38 120.28 40.87 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.899 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.43 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.69 137.54 17.47 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.668 0.747 . . . . 0.0 110.876 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -7.68 21.66 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.654 2.236 . . . . 0.0 112.416 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.9 t -113.47 -37.95 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.218 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.417 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.14 -31.69 11.98 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.893 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.48 -148.19 20.43 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.435 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 28' ' ' ILE . 1.9 mp -96.39 109.17 22.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.862 0.363 . . . . 0.0 111.122 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.543 ' CZ ' ' HB ' ' A' ' 21' ' ' ILE . 37.9 p90 -133.31 131.07 39.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.562 ' CD2' HD11 ' A' ' 14' ' ' LEU . 4.7 m-30 -88.21 123.59 33.0 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.935 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.6 t -109.44 115.77 50.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.067 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.449 ' O ' ' N ' ' A' ' 36' ' ' ARG . 9.8 t0 -94.64 102.03 13.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 76.1 m-70 -68.55 -16.15 63.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.856 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.744 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -83.27 -58.6 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.176 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -87.42 -14.12 41.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.853 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 32' ' ' ASP . 4.1 mpt_? 62.73 47.47 4.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.919 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.58 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 5.6 ptpt -128.77 130.02 46.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.4 p -107.34 118.56 37.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.136 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.42 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 6.2 pt20 -150.07 142.99 24.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.889 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -75.12 -26.44 59.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.904 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 23.7 mm-40 -62.01 161.17 11.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.451 HD22 HD21 ' A' ' 14' ' ' LEU . 12.7 t-20 -116.77 102.28 53.19 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.657 0.741 . . . . 0.0 110.891 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.448 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.154 0 C-N-CA 122.706 2.271 . . . . 0.0 112.34 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.44 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 14.5 mt . . . . . 0 C--O 1.232 0.139 0 CA-C-O 121.577 0.703 . . . . 0.0 110.926 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.643 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.0 Cg_endo -69.72 -175.78 1.26 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.702 2.268 . . . . 0.0 112.321 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.46 144.26 57.16 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.725 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 92.03 -40.82 2.86 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.501 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.643 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 63.8 m95 -73.04 135.27 44.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.769 0.319 . . . . 0.0 110.908 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -149.52 114.98 5.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.889 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.503 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -72.41 143.68 48.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.901 179.944 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.547 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 45.8 mm -127.02 131.67 70.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.125 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -104.84 117.74 34.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.92 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.417 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.9 t70 -139.15 139.13 22.2 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.591 0.71 . . . . 0.0 110.901 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -7.03 20.03 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.659 2.239 . . . . 0.0 112.372 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.6 t -114.5 -37.99 2.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.126 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.412 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.17 -31.81 11.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.94 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.57 -145.85 19.75 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.467 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.0 mp -96.63 108.57 21.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.792 0.33 . . . . 0.0 111.123 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.547 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.3 p90 -135.97 132.1 35.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.476 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.06 125.05 34.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.93 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.9 t -110.5 115.78 50.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.176 179.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -95.44 102.04 13.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 66.9 m-70 -68.93 -14.15 62.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.725 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -84.41 -63.26 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.169 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 19.2 m-20 -82.6 -17.24 45.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.916 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 33.4 mmm-85 65.81 47.42 2.08 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.836 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.58 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 4.1 ptpp? -129.81 126.75 38.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.952 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.3 p -104.92 122.11 45.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.185 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.486 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 8.5 pt20 -150.01 140.02 21.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.88 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.2 m-85 -71.1 -26.11 62.9 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.908 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -69.05 160.27 31.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.849 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.454 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 2.0 t-20 -120.23 106.8 40.21 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.618 0.723 . . . . 0.0 110.887 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.486 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.4 Cg_endo . . . . . 0 C--O 1.231 0.173 0 C-N-CA 122.743 2.295 . . . . 0.0 112.347 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.588 HD11 ' CD2' ' A' ' 30' ' ' TYR . 13.3 mt . . . . . 0 C--O 1.231 0.09 0 CA-C-O 121.643 0.735 . . . . 0.0 110.879 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.651 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.68 -173.96 0.8 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.683 2.256 . . . . 0.0 112.367 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.42 149.64 48.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.122 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.756 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 84.52 -41.3 3.01 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.458 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.651 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 57.7 m95 -70.41 140.44 52.05 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.827 0.346 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -152.81 117.96 5.18 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.941 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.05 147.12 40.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.851 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.505 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 31.6 mm -131.01 132.04 63.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.161 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -105.16 117.8 34.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.883 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -138.05 137.47 21.22 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.606 0.717 . . . . 0.0 110.858 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.79 -4.04 13.24 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.651 2.234 . . . . 0.0 112.392 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.6 t -117.19 -38.03 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.123 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.425 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.56 -31.0 12.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.85 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.0 -146.08 18.94 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.436 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.582 ' O ' ' CE2' ' A' ' 40' ' ' TYR . 1.7 mp -98.43 108.3 21.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.849 0.357 . . . . 0.0 111.159 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.518 ' HB3' ' CE1' ' A' ' 40' ' ' TYR . 28.8 p90 -134.41 132.2 39.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.912 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.588 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.0 m-30 -88.65 122.53 32.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.925 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 t -107.78 115.89 49.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.129 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.459 ' O ' ' N ' ' A' ' 36' ' ' ARG . 57.6 t0 -95.15 101.95 13.73 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.861 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -68.57 -18.52 64.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.756 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -82.14 -57.16 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.125 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -87.18 -14.88 39.94 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.874 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.459 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.3 mpt_? 62.23 47.73 5.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.853 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.577 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 5.0 ptpp? -131.5 132.49 44.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.854 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 7.1 p -108.05 118.35 36.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.12 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -150.05 139.14 21.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.919 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . 0.582 ' CE2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -74.26 -21.04 59.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.967 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 34.1 mp0 -65.99 156.9 32.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.888 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.454 HD22 ' CD2' ' A' ' 14' ' ' LEU . 7.4 t-20 -115.52 101.98 54.3 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.644 0.735 . . . . 0.0 110.968 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.41 ' HD2' HD21 ' A' ' 14' ' ' LEU . 53.6 Cg_endo . . . . . 0 C--N 1.342 0.208 0 C-N-CA 122.642 2.228 . . . . 0.0 112.339 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.569 HD21 HD22 ' A' ' 42' ' ' ASN . 12.8 mt . . . . . 0 C--O 1.232 0.173 0 CA-C-O 121.579 0.704 . . . . 0.0 110.921 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.644 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.6 Cg_endo -69.77 -169.36 0.32 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.7 2.267 . . . . 0.0 112.326 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.98 153.74 41.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.683 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 82.24 -45.89 3.43 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.418 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.644 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 71.3 m95 -67.67 134.66 51.52 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.732 0.301 . . . . 0.0 110.896 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -149.92 113.99 5.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.02 142.72 43.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.917 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.538 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 19.0 mm -128.36 130.78 69.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.094 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -102.51 119.88 39.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.895 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.419 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.69 139.7 20.58 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 121.576 0.703 . . . . 0.0 110.896 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.417 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.9 Cg_endo -69.77 -7.8 21.99 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.692 2.261 . . . . 0.0 112.342 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.9 t -113.92 -37.92 2.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.179 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.436 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.5 m-85 -98.51 -31.61 11.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 86.78 -143.74 19.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.423 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.537 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -97.94 108.8 22.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.878 0.37 . . . . 0.0 111.162 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.538 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 39.7 p90 -135.11 131.95 37.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.905 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.442 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 3.3 m-30 -88.77 124.92 34.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.916 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -111.38 116.41 52.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.095 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.627 ' OD1' ' CE3' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -100.12 103.3 14.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 179.903 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 48.3 m-70 -68.83 -8.44 43.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.851 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.683 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.9 OUTLIER -90.22 -62.81 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.156 179.995 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 7.4 m-80 -82.44 -19.91 38.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.915 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 19.6 mmm-85 66.28 47.39 1.82 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.901 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.422 ' HG3' ' OD2' ' A' ' 32' ' ' ASP . 0.1 OUTLIER -129.76 122.2 28.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.847 179.988 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.3 p -100.2 118.34 36.32 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.421 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 6.7 pt20 -148.98 141.34 24.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.95 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . 0.537 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -75.26 -24.45 57.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 -62.62 161.24 12.52 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.569 HD22 HD21 ' A' ' 14' ' ' LEU . 13.6 t-20 -120.3 102.02 46.17 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.625 0.726 . . . . 0.0 110.883 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.421 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.2 Cg_endo . . . . . 0 C--O 1.231 0.148 0 C-N-CA 122.709 2.273 . . . . 0.0 112.363 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.558 HD11 ' CD2' ' A' ' 30' ' ' TYR . 10.7 mt . . . . . 0 C--O 1.231 0.108 0 CA-C-O 121.603 0.716 . . . . 0.0 110.879 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.62 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.67 -171.71 0.49 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.606 2.204 . . . . 0.0 112.371 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.46 150.52 48.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.072 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.658 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 85.31 -43.92 3.31 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.755 -0.735 . . . . 0.0 112.46 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.62 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -68.66 141.62 55.31 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.751 0.31 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 23.2 tp10 -153.14 113.58 4.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.907 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.47 142.57 48.58 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.898 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.574 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 32.3 mm -127.38 130.76 70.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.105 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -103.81 117.88 35.38 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.928 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.42 ' O ' ' N ' ' A' ' 27' ' ' GLY . 9.8 t70 -138.17 139.36 25.39 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.511 0.672 . . . . 0.0 110.956 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.404 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 54.2 Cg_endo -69.77 -6.92 19.75 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.614 2.21 . . . . 0.0 112.367 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.2 t -114.21 -37.91 2.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.18 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.427 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.66 -32.31 11.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.47 -144.19 18.26 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.425 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.456 ' N ' HD12 ' A' ' 28' ' ' ILE . 1.9 mp -97.86 108.82 22.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.827 0.346 . . . . 0.0 111.128 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.574 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.3 p90 -135.78 131.19 35.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.933 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.558 ' CD2' HD11 ' A' ' 14' ' ' LEU . 2.9 m-30 -88.88 125.55 34.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.92 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.9 t -111.35 116.72 53.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.098 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.406 ' O ' ' N ' ' A' ' 36' ' ' ARG . 19.4 t0 -95.55 102.58 14.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 72.8 m-70 -67.93 -15.13 63.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.658 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.0 OUTLIER -85.02 -61.4 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 -179.998 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 21.4 m-20 -83.49 -15.41 49.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.902 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.406 ' N ' ' O ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER 62.9 47.99 4.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.848 179.957 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.579 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.1 OUTLIER -130.38 130.89 44.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.833 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 3.0 p -108.13 120.26 41.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.151 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.474 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 8.2 pt20 -150.01 140.71 22.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . 0.411 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -74.38 -21.75 59.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.89 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.402 ' HB2' ' NE2' ' A' ' 39' ' ' GLN . 21.6 mt-10 -67.94 161.41 26.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.844 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.533 HD22 HD21 ' A' ' 14' ' ' LEU . 12.0 t-20 -117.62 102.07 51.95 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.631 0.729 . . . . 0.0 110.839 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.474 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.0 Cg_endo . . . . . 0 C--N 1.342 0.228 0 C-N-CA 122.64 2.226 . . . . 0.0 112.363 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.715 HD11 ' CD2' ' A' ' 30' ' ' TYR . 12.5 mt . . . . . 0 C--O 1.232 0.151 0 CA-C-O 121.554 0.692 . . . . 0.0 110.938 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.638 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.71 -173.67 0.75 Allowed 'Trans proline' 0 C--N 1.34 0.094 0 C-N-CA 122.689 2.259 . . . . 0.0 112.373 179.829 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.4 148.77 51.14 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.063 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.72 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 86.64 -43.04 3.19 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.524 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.638 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.7 m95 -68.22 143.88 55.13 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.691 0.281 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -155.45 116.23 3.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.848 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.498 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -73.8 144.25 45.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.891 179.928 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.573 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 43.7 mm -128.11 130.69 69.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.151 179.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -104.74 117.82 35.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.0 t70 -138.15 139.69 26.48 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 121.589 0.709 . . . . 0.0 110.878 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.413 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.1 Cg_endo -69.82 -7.36 20.88 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.689 2.259 . . . . 0.0 112.38 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 86.4 t -114.12 -37.95 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.104 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.43 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.45 -31.54 11.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.913 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.84 -143.78 18.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.449 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.598 ' O ' ' CE2' ' A' ' 40' ' ' TYR . 1.7 mp -98.41 110.17 25.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.855 0.359 . . . . 0.0 111.151 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.573 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.1 p90 -136.93 131.69 33.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.98 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.715 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.84 124.34 34.09 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.885 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 t -110.3 115.97 51.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.116 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -95.33 102.72 14.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.813 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -69.16 -17.31 63.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.72 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -82.2 -62.67 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.185 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 18.9 m-20 -81.2 -18.25 46.85 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.931 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.0 mmt85 66.08 47.75 1.86 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.839 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.588 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 5.0 ptpp? -131.95 131.74 42.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.9 p -106.55 118.35 36.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.16 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.463 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 9.0 pt20 -149.81 139.61 21.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . 0.598 ' CE2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.65 -24.99 58.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.911 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -64.1 158.7 22.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.901 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.443 ' ND2' ' HG ' ' A' ' 14' ' ' LEU . 12.7 t-20 -115.87 102.01 54.02 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.627 0.727 . . . . 0.0 110.854 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.463 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.6 Cg_endo . . . . . 0 C--N 1.342 0.209 0 C-N-CA 122.747 2.298 . . . . 0.0 112.288 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.52 HD11 ' CD2' ' A' ' 30' ' ' TYR . 13.5 mt . . . . . 0 C--O 1.231 0.109 0 CA-C-O 121.578 0.704 . . . . 0.0 110.915 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.677 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.84 -173.45 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.693 2.262 . . . . 0.0 112.285 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.43 149.92 47.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.123 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.592 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 83.88 -39.25 2.84 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.387 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.677 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 72.6 m95 -74.94 131.91 41.03 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.707 0.289 . . . . 0.0 110.926 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -145.46 112.91 6.23 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.896 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.2 145.65 47.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.908 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.568 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 18.7 mm -130.06 132.05 65.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.126 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -104.24 118.59 37.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.873 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.429 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.0 t70 -139.73 139.86 23.17 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.576 0.703 . . . . 0.0 110.877 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.428 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.5 Cg_endo -69.79 -8.85 24.65 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.687 2.258 . . . . 0.0 112.312 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.5 t -112.92 -37.91 2.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.157 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.8 m-85 -98.28 -32.06 11.74 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.939 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.08 -143.63 18.93 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.588 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.544 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -98.37 108.06 21.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.82 0.343 . . . . 0.0 111.115 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.568 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 27.4 p90 -135.13 131.83 37.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.895 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.52 ' CD2' HD11 ' A' ' 14' ' ' LEU . 2.9 m-30 -88.64 120.1 29.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.915 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.408 ' CG2' ' CE2' ' A' ' 29' ' ' TYR . 21.9 t -102.79 123.17 55.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.122 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.618 ' OD2' ' CZ3' ' A' ' 18' ' ' TRP . 5.0 m-20 -97.9 118.73 35.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.852 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.45 ' C ' HD12 ' A' ' 34' ' ' ILE . 81.1 m-70 -92.31 -4.97 53.16 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.8 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.592 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.8 OUTLIER -96.39 -49.98 11.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.122 -179.994 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.478 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 14.9 m-80 -98.36 -12.36 21.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.9 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 44.0 mmm-85 64.3 46.29 3.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.858 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.478 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 22.8 pttt -126.09 127.48 45.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.941 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -107.63 121.01 43.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.164 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.464 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 8.7 pt20 -150.29 144.92 25.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.885 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . 0.544 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 5.1 m-85 -79.12 -28.76 42.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -60.4 159.33 10.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.842 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 14.7 t-20 -114.73 102.01 54.65 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.632 0.729 . . . . 0.0 110.899 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.464 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.0 Cg_endo . . . . . 0 C--O 1.232 0.19 0 C-N-CA 122.72 2.28 . . . . 0.0 112.33 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.572 HD11 ' CD2' ' A' ' 30' ' ' TYR . 9.2 mt . . . . . 0 C--O 1.231 0.085 0 CA-C-O 121.577 0.704 . . . . 0.0 110.917 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.664 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.8 Cg_endo -69.83 -177.41 1.89 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.626 2.217 . . . . 0.0 112.375 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.38 144.78 56.92 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.053 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.646 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 90.75 -35.87 3.76 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.44 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.664 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 70.5 m95 -78.74 132.73 37.06 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.758 0.313 . . . . 0.0 110.938 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -139.23 111.76 7.67 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.42 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -72.11 146.52 47.44 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.482 ' HB ' ' CZ ' ' A' ' 29' ' ' TYR . 29.9 mm -132.86 133.55 58.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.178 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -106.45 118.93 37.94 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.868 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.435 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -138.57 137.98 21.26 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.577 0.703 . . . . 0.0 110.85 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -8.38 23.46 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.657 2.238 . . . . 0.0 112.372 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.7 t -112.83 -38.02 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.095 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.412 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.04 -31.89 11.91 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.16 -147.63 19.72 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.486 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.418 HD12 ' N ' ' A' ' 28' ' ' ILE . 1.8 mp -97.07 108.88 22.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.873 0.368 . . . . 0.0 111.065 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.482 ' CZ ' ' HB ' ' A' ' 21' ' ' ILE . 42.4 p90 -133.41 131.83 40.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.572 ' CD2' HD11 ' A' ' 14' ' ' LEU . 5.7 m-30 -88.6 124.22 33.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.895 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.2 t -106.06 114.9 46.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.148 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.53 ' OD2' ' CE2' ' A' ' 18' ' ' TRP . 35.9 t0 -91.96 102.25 14.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.836 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -71.53 -10.37 59.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.849 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.646 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.8 OUTLIER -92.32 -60.26 2.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.113 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.467 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 5.9 m-80 -81.29 -21.7 39.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.778 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 10.6 mmt85 67.89 47.63 1.09 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.879 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.467 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 16.9 pttt -139.65 121.86 15.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.879 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 3.3 p -93.07 125.67 37.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.166 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.438 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 5.7 pt20 -150.58 140.15 21.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.89 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -73.5 -21.15 60.48 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.923 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 52.8 mm-40 -66.03 157.71 30.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.881 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.434 HD22 HD21 ' A' ' 14' ' ' LEU . 9.0 t-20 -115.76 101.98 54.11 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.603 0.716 . . . . 0.0 110.875 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.438 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.1 Cg_endo . . . . . 0 C--O 1.232 0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.396 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.556 HD11 ' CD2' ' A' ' 30' ' ' TYR . 13.7 mt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 121.661 0.743 . . . . 0.0 110.908 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.669 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.73 -175.87 1.29 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.66 2.24 . . . . 0.0 112.347 179.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.87 145.24 56.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.083 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.769 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 89.52 -41.09 3.01 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.531 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.669 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 69.8 m95 -73.18 129.92 39.11 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.763 0.316 . . . . 0.0 110.916 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -138.45 112.36 8.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.917 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.421 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.57 145.49 43.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.909 179.965 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.579 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 26.2 mm -132.12 133.43 60.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.123 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -105.36 119.39 38.96 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.873 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.438 ' O ' ' N ' ' A' ' 27' ' ' GLY . 10.5 t70 -140.06 138.45 19.48 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.567 0.699 . . . . 0.0 110.883 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -9.78 26.95 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.677 2.251 . . . . 0.0 112.341 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.9 t -111.27 -38.0 3.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.095 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.402 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.8 m-85 -98.05 -33.0 11.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.89 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.41 -146.79 19.16 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.479 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.0 mp -97.68 109.76 24.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.845 0.355 . . . . 0.0 111.152 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.579 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 27.1 p90 -134.53 131.63 38.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.556 ' CD2' HD11 ' A' ' 14' ' ' LEU . 4.9 m-30 -88.51 120.77 30.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.942 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.9 t -106.13 115.69 48.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.143 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.414 ' O ' ' N ' ' A' ' 36' ' ' ARG . 8.8 t0 -94.2 101.99 13.99 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.85 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 76.5 m-70 -67.39 -13.92 62.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.878 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.769 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -85.35 -62.86 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.101 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.497 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 5.8 m-80 -83.56 -15.83 47.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.414 ' N ' ' O ' ' A' ' 32' ' ' ASP . 4.8 mmm180 64.25 47.68 3.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.852 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.497 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 21.1 pttt -129.75 136.79 50.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.835 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 22.6 p -113.44 123.04 49.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.108 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.469 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 8.1 pt20 -149.96 138.54 20.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.948 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -72.59 -16.22 61.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.948 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -73.54 159.97 32.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.857 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 -116.43 101.93 53.6 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.646 0.736 . . . . 0.0 110.926 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.469 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.5 Cg_endo . . . . . 0 C--N 1.342 0.236 0 C-N-CA 122.687 2.258 . . . . 0.0 112.354 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.572 HD21 HD22 ' A' ' 42' ' ' ASN . 10.8 mt . . . . . 0 C--O 1.23 0.072 0 CA-C-O 121.65 0.738 . . . . 0.0 110.855 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.658 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.8 Cg_endo -69.77 -173.61 0.75 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.707 2.271 . . . . 0.0 112.323 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.86 144.52 55.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.102 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.773 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 92.14 -39.14 3.06 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.479 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.658 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 69.1 m95 -74.68 131.31 40.77 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.669 0.271 . . . . 0.0 110.916 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.462 ' OE1' HD11 ' A' ' 21' ' ' ILE . 10.4 tt0 -135.82 111.82 9.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.891 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.526 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -76.11 146.65 39.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.859 -179.983 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.551 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 31.5 mm -133.56 135.52 55.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.137 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 -107.33 117.66 34.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.905 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.43 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.4 t70 -137.71 137.9 22.85 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.638 0.733 . . . . 0.0 110.796 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -8.12 22.8 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.68 2.253 . . . . 0.0 112.333 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 86.5 t -113.17 -38.03 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.182 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.435 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.5 m-85 -97.46 -31.72 12.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.942 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.44 -148.28 20.51 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.0 mp -96.6 108.97 22.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.778 0.323 . . . . 0.0 111.17 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.551 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 37.9 p90 -132.84 131.38 40.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.928 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.465 ' CG ' HD11 ' A' ' 14' ' ' LEU . 4.9 m-30 -88.38 123.6 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.865 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.8 t -107.94 115.08 48.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.146 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 28.3 t0 -91.63 102.02 14.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.844 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -68.22 -16.52 64.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.817 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.773 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.0 OUTLIER -86.87 -61.11 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.117 -179.988 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 -79.74 -16.97 54.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.902 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 64.47 45.78 3.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.848 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 1.4 pttm -131.68 146.2 52.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.881 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.7 p -120.5 122.94 41.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.112 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.453 ' NE2' ' HB2' ' A' ' 41' ' ' GLU . 6.7 pt20 -150.53 140.1 21.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.934 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -72.57 -20.75 61.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.901 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.453 ' HB2' ' NE2' ' A' ' 39' ' ' GLN . 35.0 mp0 -68.36 157.39 35.8 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.866 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.572 HD22 HD21 ' A' ' 14' ' ' LEU . 8.9 t-20 -115.36 102.15 54.45 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.659 0.742 . . . . 0.0 110.844 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.431 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.5 Cg_endo . . . . . 0 C--N 1.341 0.178 0 C-N-CA 122.677 2.251 . . . . 0.0 112.332 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.453 HD11 ' CD2' ' A' ' 30' ' ' TYR . 17.4 mt . . . . . 0 C--O 1.232 0.15 0 CA-C-O 121.579 0.704 . . . . 0.0 110.954 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.641 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.74 -171.21 0.45 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.719 2.28 . . . . 0.0 112.417 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.95 147.35 53.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.084 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.579 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 88.2 -44.66 3.22 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.47 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.641 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 63.2 m95 -68.38 135.92 52.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.779 0.323 . . . . 0.0 110.903 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -149.52 115.61 5.72 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.551 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -75.79 142.0 42.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 -179.995 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.573 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 38.4 mm -125.34 131.52 72.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.134 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -102.65 117.78 35.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.0 t70 -139.12 139.48 23.37 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.578 0.704 . . . . 0.0 110.884 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 54.6 Cg_endo -69.69 -11.31 30.67 Favored 'Trans proline' 0 N--CA 1.465 -0.183 0 C-N-CA 122.668 2.245 . . . . 0.0 112.437 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.3 t -109.93 -37.98 3.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.155 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.36 -32.85 11.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.9 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.48 -140.78 15.82 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.472 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.605 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.9 mp -102.08 109.4 26.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.808 0.337 . . . . 0.0 111.132 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.573 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 32.6 p90 -135.54 133.96 38.94 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.882 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.478 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.4 m-30 -90.18 126.8 35.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.927 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.2 t -113.21 117.24 54.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.125 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.459 ' O ' ' N ' ' A' ' 36' ' ' ARG . 62.4 t0 -95.14 103.31 15.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 47.7 m-70 -68.6 -16.38 63.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.645 ' N ' ' CD1' ' A' ' 34' ' ' ILE . 0.6 OUTLIER -83.39 -55.49 7.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.121 -179.993 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 63.1 m-20 -93.33 -2.39 54.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.854 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.459 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.5 mpt_? 54.62 47.94 21.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.7 mtmm -113.54 160.8 18.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -145.12 108.3 4.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.14 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.453 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 9.4 pt20 -147.88 144.19 27.93 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.919 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . 0.605 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.6 m-85 -76.29 -26.54 55.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -63.6 161.42 14.8 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.854 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 18.7 t-20 -116.62 101.93 53.44 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.614 0.721 . . . . 0.0 110.933 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.479 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 54.2 Cg_endo . . . . . 0 C--N 1.342 0.198 0 C-N-CA 122.637 2.225 . . . . 0.0 112.377 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.471 HD21 HD22 ' A' ' 42' ' ' ASN . 9.6 mt . . . . . 0 C--O 1.231 0.085 0 CA-C-O 121.614 0.721 . . . . 0.0 110.874 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.664 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.79 -170.38 0.39 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.614 2.209 . . . . 0.0 112.311 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.62 140.91 48.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.12 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.618 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 94.62 -32.19 6.24 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.505 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.664 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 67.4 m95 -81.89 147.72 29.15 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.703 0.287 . . . . 0.0 110.896 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.486 ' CG ' ' O ' ' A' ' 19' ' ' GLU . 2.3 pt-20 -152.71 119.57 5.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.888 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.59 141.47 36.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.95 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.578 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 18.2 mm -129.41 132.4 66.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.097 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -106.02 120.6 42.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.933 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.425 ' CG ' ' HD2' ' A' ' 24' ' ' PRO . 10.8 t70 -140.37 139.66 21.21 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.561 0.696 . . . . 0.0 110.888 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.425 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.9 Cg_endo -69.67 -8.18 22.94 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.696 2.264 . . . . 0.0 112.376 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 99.5 t -114.89 -37.9 2.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.123 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.31 -29.2 13.3 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.905 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 82.51 -151.73 29.82 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.508 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 1.9 mp -89.81 110.88 22.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.824 0.345 . . . . 0.0 111.05 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.578 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 46.3 p90 -136.03 130.88 34.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.913 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.437 ' CG ' HD11 ' A' ' 14' ' ' LEU . 5.3 m-30 -88.48 132.79 34.34 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.963 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.4 t -114.62 116.47 52.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.138 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.478 ' OD1' ' CD1' ' A' ' 18' ' ' TRP . 13.3 t0 -98.59 102.03 13.64 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.898 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 -72.07 -11.24 60.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.84 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.618 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.8 OUTLIER -85.83 -57.2 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.129 179.947 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -87.65 -18.36 29.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.895 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 68.02 47.88 1.02 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.87 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.423 ' HE2' ' CH2' ' A' ' 18' ' ' TRP . 8.5 pttm -139.35 130.96 27.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.1 p -104.19 126.15 51.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.407 ' NE2' ' HB2' ' A' ' 41' ' ' GLU . 5.3 pt20 -150.63 141.82 23.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.956 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -73.78 -21.63 60.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.407 ' HB2' ' NE2' ' A' ' 39' ' ' GLN . 30.0 mm-40 -66.41 154.1 41.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.924 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.471 HD22 HD21 ' A' ' 14' ' ' LEU . 9.0 t-20 -112.3 101.99 53.22 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.597 0.713 . . . . 0.0 110.911 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.405 ' HD2' ' CD2' ' A' ' 14' ' ' LEU . 53.1 Cg_endo . . . . . 0 C--N 1.34 0.13 0 C-N-CA 122.672 2.248 . . . . 0.0 112.31 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.585 HD11 ' CD2' ' A' ' 30' ' ' TYR . 11.6 mt . . . . . 0 C--O 1.23 0.053 0 CA-C-O 121.609 0.719 . . . . 0.0 110.956 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.635 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.6 Cg_endo -69.76 -171.78 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.647 2.232 . . . . 0.0 112.368 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.73 149.98 49.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.077 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.744 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 84.94 -40.46 3.0 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.539 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.635 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 58.4 m95 -72.51 140.44 48.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.712 0.291 . . . . 0.0 110.995 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -152.24 115.04 4.6 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.438 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.35 138.6 43.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.576 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 34.9 mm -121.13 131.21 73.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.166 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -103.54 117.94 35.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.854 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.44 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.7 t70 -138.91 137.98 20.55 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.578 0.704 . . . . 0.0 110.88 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 -8.26 23.14 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.665 2.244 . . . . 0.0 112.291 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.5 t -112.86 -37.97 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.169 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . 0.418 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.7 m-85 -97.94 -31.98 11.9 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.959 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.4 -145.49 18.47 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.561 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.596 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -98.99 108.57 22.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.813 0.339 . . . . 0.0 111.081 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.576 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 31.5 p90 -134.42 131.58 38.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.585 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.6 m-30 -88.75 122.4 32.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.912 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.0 t -108.11 115.62 49.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.146 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 57.1 t0 -94.77 101.99 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.828 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 65.9 m-70 -68.74 -18.76 64.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.862 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.744 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -81.67 -62.73 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.109 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.2 m-80 -80.34 -16.37 54.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.867 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 27.5 mmm180 64.11 47.69 3.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.55 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 11.1 ptpt -133.11 129.44 37.95 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.7 p -105.34 119.46 39.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.198 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.427 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.4 pt20 -150.29 140.5 22.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.91 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . 0.596 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.55 -25.08 59.08 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.884 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -62.06 161.84 10.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.872 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.463 HD22 HD21 ' A' ' 14' ' ' LEU . 10.8 t-20 -118.44 101.93 50.59 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.581 0.705 . . . . 0.0 110.937 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.427 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.7 Cg_endo . . . . . 0 C--N 1.341 0.148 0 C-N-CA 122.677 2.251 . . . . 0.0 112.346 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' LEU . . . . . 0.565 HD11 ' CD2' ' A' ' 30' ' ' TYR . 14.3 mt . . . . . 0 C--O 1.231 0.124 0 CA-C-O 121.556 0.693 . . . . 0.0 110.947 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.667 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.5 Cg_endo -69.77 -173.49 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.721 2.281 . . . . 0.0 112.292 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.52 146.91 54.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.035 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.666 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 87.9 -42.14 3.1 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.456 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' TRP . . . . . 0.667 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 70.8 m95 -71.78 122.3 20.45 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.834 0.35 . . . . 0.0 110.911 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.44 ' OE1' HD11 ' A' ' 21' ' ' ILE . 7.5 tt0 -128.3 111.43 13.36 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.507 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -76.17 145.2 40.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.854 179.987 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.57 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 32.8 mm -132.68 133.58 59.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.127 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -106.06 117.99 35.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.912 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.1 t70 -138.36 139.67 25.87 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.64 0.733 . . . . 0.0 110.891 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.42 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.7 Cg_endo -69.71 -11.8 31.67 Favored 'Trans proline' 0 C--O 1.232 0.225 0 C-N-CA 122.704 2.269 . . . . 0.0 112.33 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 94.0 t -109.36 -37.95 3.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.162 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.28 -32.27 11.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.846 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.13 -140.95 16.0 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.439 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 1.9 mp -102.91 108.87 25.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 0.0 111.179 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' TYR . . . . . 0.57 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 25.0 p90 -133.39 131.14 39.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.922 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' TYR . . . . . 0.565 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.27 119.65 28.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.916 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.4 t -101.88 115.57 43.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.098 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.615 ' OD2' ' CZ3' ' A' ' 18' ' ' TRP . 3.8 m-20 -88.87 112.96 23.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' HIS . . . . . 0.451 ' C ' HD12 ' A' ' 34' ' ' ILE . 87.6 m-70 -86.37 -7.07 58.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.946 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.666 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.7 OUTLIER -97.11 -49.13 12.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.097 179.99 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 -96.06 -13.66 23.53 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.85 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ARG . . . . . 0.406 ' HA ' ' O ' ' A' ' 32' ' ' ASP . 25.3 mmt180 65.32 42.49 3.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.851 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . 0.558 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 0.1 OUTLIER -121.51 129.86 53.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.877 -179.986 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -111.21 116.1 30.48 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.149 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . 0.453 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 6.8 pt20 -145.96 146.39 31.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.935 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -77.96 -30.9 50.59 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.939 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLU . . . . . 0.409 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 4.1 mt-10 -58.25 166.75 1.53 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.845 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.417 ' ND2' HD21 ' A' ' 14' ' ' LEU . 12.5 t-20 -120.81 102.0 44.87 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.663 0.744 . . . . 0.0 110.906 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' PRO . . . . . 0.55 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 53.1 Cg_endo . . . . . 0 C--N 1.342 0.223 0 C-N-CA 122.682 2.255 . . . . 0.0 112.271 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 N-CA-C 112.588 -0.205 . . . . 0.0 112.588 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 73.8 m -138.31 151.41 47.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.845 0.355 . . . . 0.0 110.904 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.8 m -124.09 154.32 40.14 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.784 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 123.63 -155.51 17.68 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.529 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.9 t -122.63 161.92 22.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.943 0.401 . . . . 0.0 110.787 -179.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 73.2 m -149.35 173.41 13.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.8 -179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 56.19 60.5 8.82 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.439 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 58.4 mt -83.43 -47.73 11.09 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.745 0.307 . . . . 0.0 110.856 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.95 117.66 35.28 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.88 179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.2 t -109.42 16.28 22.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.884 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -108.69 13.17 25.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.883 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 37.5 mt -114.4 154.18 28.55 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.875 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -75.69 171.87 13.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.892 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.526 HD21 HD22 ' A' ' 42' ' ' ASN . 13.3 mt -89.41 153.15 48.25 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.557 0.694 . . . . 0.0 110.953 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.611 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.85 -175.55 1.22 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.611 2.208 . . . . 0.0 112.313 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.26 146.76 53.81 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.09 179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.665 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 89.5 -44.26 3.05 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.497 -179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.611 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -69.7 142.32 53.36 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.735 0.302 . . . . 0.0 110.904 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -153.29 114.67 4.19 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.922 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.441 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -72.71 144.26 47.74 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.919 179.984 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.576 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 41.9 mm -128.17 130.62 69.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.177 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.6 mt-10 -104.97 117.86 35.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.859 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -137.84 139.78 27.52 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-O 121.624 0.726 . . . . 0.0 110.878 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.415 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.2 Cg_endo -69.83 -7.96 22.39 Favored 'Trans proline' 0 C--O 1.233 0.237 0 C-N-CA 122.646 2.231 . . . . 0.0 112.302 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 96.4 t -113.83 -38.01 2.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.081 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.8 m-85 -98.08 -30.79 12.47 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.941 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.26 -142.91 18.43 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.527 -179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.557 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.8 mp -99.64 111.46 29.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.848 0.356 . . . . 0.0 111.116 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.576 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 39.2 p90 -137.2 131.54 32.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.978 -179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.471 ' CD2' HD11 ' A' ' 14' ' ' LEU . 5.5 m-30 -88.98 123.6 33.47 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.925 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.415 ' CG2' ' CE2' ' A' ' 29' ' ' TYR . 10.8 t -110.2 116.57 52.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.148 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.407 ' OD2' ' NE1' ' A' ' 18' ' ' TRP . 51.5 t0 -95.77 106.09 18.17 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.929 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 63.3 m-70 -71.36 -14.27 62.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.819 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.665 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.9 OUTLIER -85.98 -62.34 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.158 179.971 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.425 ' C ' ' HD3' ' A' ' 36' ' ' ARG . 28.0 m-80 -80.65 -13.81 58.71 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.852 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.425 ' HD3' ' C ' ' A' ' 35' ' ' ASN . 1.8 mpp_? 63.09 46.25 4.78 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.882 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -128.03 154.75 45.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.855 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.7 p -129.45 117.95 21.36 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.133 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.473 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.1 pt20 -149.66 141.86 24.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.956 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . 0.557 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.81 -25.99 59.42 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.922 -179.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 16.5 mt-10 -63.06 160.77 14.48 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.94 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.526 HD22 HD21 ' A' ' 14' ' ' LEU . 9.9 t-20 -115.48 102.02 54.33 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.589 0.709 . . . . 0.0 110.849 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.473 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.4 Cg_endo -69.8 3.13 2.97 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.705 2.27 . . . . 0.0 112.322 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 7.5 p -52.05 148.2 6.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.874 -179.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 124.73 177.94 15.14 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.495 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 85.08 0.63 Allowed 'Trans proline' 0 N--CA 1.466 -0.14 0 C-N-CA 122.684 2.256 . . . . 0.0 112.388 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 27.9 p -143.85 107.45 4.62 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.861 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 50.8 p -96.37 164.29 12.71 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.835 -179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.363 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.478 179.989 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.282 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 40.5 p -58.68 -52.02 67.48 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.892 0.377 . . . . 0.0 110.823 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.6 p -74.68 -44.42 50.29 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.805 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -126.66 157.14 20.31 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.457 -179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 91.5 p -111.98 147.45 35.89 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.926 0.393 . . . . 0.0 110.861 -179.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.9 m 56.38 42.02 28.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.83 -179.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -126.0 -75.69 0.24 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.464 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.1 mp -86.75 105.72 17.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.851 0.358 . . . . 0.0 110.925 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -130.93 127.55 38.68 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.85 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.7 t -99.97 17.02 22.03 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.91 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 20.7 pt-20 -107.48 15.56 24.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.89 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 50.4 mt -107.1 173.26 6.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.915 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 77.2 mt-10 -107.65 169.36 8.64 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.879 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.613 HD11 ' CD2' ' A' ' 30' ' ' TYR . 11.0 mt -91.09 154.49 45.01 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.603 0.716 . . . . 0.0 110.924 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.63 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.2 Cg_endo -69.7 -172.74 0.6 Allowed 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.668 2.245 . . . . 0.0 112.349 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.58 148.62 51.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.093 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.695 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 86.91 -41.39 3.1 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.492 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.63 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.0 m95 -71.3 143.68 50.23 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.65 0.262 . . . . 0.0 110.956 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 30.3 tp10 -154.3 113.49 3.71 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.847 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.462 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -72.95 139.8 46.99 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.934 179.888 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.577 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 34.7 mm -122.76 129.12 75.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.164 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -101.97 117.92 35.82 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.896 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.447 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.7 t70 -139.01 139.16 22.57 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-O 121.614 0.721 . . . . 0.0 110.836 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -9.81 27.01 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.72 2.28 . . . . 0.0 112.372 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.4 t -111.54 -37.94 3.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.123 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.413 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.7 m-85 -97.79 -32.1 11.89 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.967 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.27 -144.67 18.66 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.455 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.485 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.0 mp -98.62 109.81 24.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.781 0.325 . . . . 0.0 111.105 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.577 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 36.9 p90 -136.16 130.75 33.72 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.941 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.613 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.78 124.35 34.07 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.914 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.466 HG22 HG22 ' A' ' 38' ' ' THR . 12.0 t -110.91 115.93 51.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.114 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.406 ' O ' ' N ' ' A' ' 36' ' ' ARG . 13.5 t0 -94.45 101.93 13.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.895 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 71.1 m-70 -67.46 -18.38 65.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.89 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.695 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -80.7 -63.35 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.15 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -81.14 -16.72 52.17 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.818 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.406 ' N ' ' O ' ' A' ' 32' ' ' ASP . 17.7 mmt180 64.89 47.98 2.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.914 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.565 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.0 OUTLIER -132.47 129.03 38.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.869 179.976 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.466 HG22 HG22 ' A' ' 31' ' ' VAL . 2.3 p -104.59 120.19 40.72 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.167 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.437 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.8 pt20 -150.11 140.91 22.74 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.932 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . 0.485 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.41 -23.77 59.0 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.908 -179.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 55.7 mm-40 -64.86 158.28 25.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.909 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.444 ' ND2' ' HG ' ' A' ' 14' ' ' LEU . 12.0 t-20 -115.32 102.0 54.46 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.665 0.745 . . . . 0.0 110.896 -179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.437 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.1 Cg_endo -69.7 0.77 5.12 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.713 2.276 . . . . 0.0 112.335 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.2 t -53.33 167.89 0.18 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.828 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 122.43 161.47 11.26 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.642 -0.79 . . . . 0.0 112.46 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.75 -5.2 15.64 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.717 2.278 . . . . 0.0 112.343 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.9 m -70.22 -55.63 8.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.889 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 30.7 t -60.59 120.39 9.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.868 -179.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.473 179.988 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.5 t -65.59 147.82 52.77 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.869 0.366 . . . . 0.0 110.889 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.9 t 64.33 42.39 5.31 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.885 -179.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -83.98 -84.5 0.92 Allowed Glycine 0 N--CA 1.452 -0.256 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.415 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 94.3 p -58.23 105.99 0.33 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.821 0.343 . . . . 0.0 110.909 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 26.1 p -73.34 126.98 31.38 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.885 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -85.19 -69.62 1.35 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.5 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 23.6 mt 58.89 41.18 21.72 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.841 0.353 . . . . 0.0 110.899 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -87.63 17.97 4.3 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.86 179.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 27.7 p -75.47 5.31 6.0 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -109.26 17.25 21.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.84 -179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 17.6 mt -129.45 176.88 7.61 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.945 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 10.6 mt-10 -111.67 170.97 7.77 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.942 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.505 HD11 ' CD2' ' A' ' 30' ' ' TYR . 15.1 mt -90.61 151.93 44.52 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.586 0.708 . . . . 0.0 110.923 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.632 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.3 Cg_endo -69.74 -172.19 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.605 2.203 . . . . 0.0 112.376 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.19 146.63 54.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.071 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.704 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 88.54 -40.7 3.06 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.467 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.632 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -72.64 142.66 48.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.733 0.301 . . . . 0.0 110.895 -179.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -153.4 115.51 4.34 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.882 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.474 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.22 140.99 45.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.863 -179.967 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.559 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 38.1 mm -123.87 129.73 74.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.163 179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.2 mt-10 -103.79 117.88 35.39 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.871 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.449 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.1 t70 -139.12 139.67 24.0 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.568 0.699 . . . . 0.0 110.905 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.42 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.6 Cg_endo -69.77 -9.48 26.2 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.627 2.218 . . . . 0.0 112.38 -179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 95.6 t -111.78 -38.04 3.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.13 179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -97.91 -31.49 12.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.959 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.3 -145.73 19.86 Favored Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.456 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.598 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.7 mp -97.1 110.01 24.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.821 0.343 . . . . 0.0 111.198 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.559 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 34.9 p90 -137.37 130.62 30.9 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.901 -179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.505 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.0 m-30 -89.02 126.85 35.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.931 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.522 HG22 HG22 ' A' ' 38' ' ' THR . 10.6 t -112.67 116.13 51.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.115 179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.463 ' O ' ' N ' ' A' ' 36' ' ' ARG . 10.4 t0 -93.56 102.16 14.35 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.821 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 59.1 m-70 -68.0 -17.14 64.34 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.889 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.704 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -82.46 -58.17 3.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.127 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -87.34 -14.29 41.16 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.887 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.463 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.2 mpt_? 62.59 47.99 4.62 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.79 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.469 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.0 OUTLIER -130.93 126.94 37.4 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.941 179.952 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.522 HG22 HG22 ' A' ' 31' ' ' VAL . 1.6 p -102.35 119.34 38.65 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.107 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.456 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.0 pt20 -149.65 141.83 24.06 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.961 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . 0.598 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 3.0 m-85 -76.02 -24.6 55.25 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.89 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 25.7 mm-40 -62.93 161.25 13.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.94 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.47 HD22 HD21 ' A' ' 14' ' ' LEU . 8.8 t-20 -116.36 102.1 53.61 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.616 0.722 . . . . 0.0 110.867 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.456 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.3 Cg_endo -69.88 3.95 2.53 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.655 2.237 . . . . 0.0 112.316 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.3 p -52.06 147.35 7.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.88 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 134.19 170.81 12.39 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.489 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 95.53 0.56 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.7 2.267 . . . . 0.0 112.349 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.3 m -76.34 -47.17 24.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.842 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 1.1 t -51.63 -52.42 47.86 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.834 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.43 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.509 179.954 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.9 m -78.46 114.22 17.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.85 0.357 . . . . 0.0 110.852 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.4 m 57.94 42.12 23.42 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.822 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -88.92 -166.66 42.4 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.504 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 16.3 m -136.03 155.68 49.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.896 0.379 . . . . 0.0 110.828 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 23.1 t -52.16 -56.74 12.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.898 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 179.12 -174.58 46.58 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.437 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 28.1 mt -135.24 148.21 49.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.863 0.363 . . . . 0.0 110.875 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -121.76 103.35 8.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.892 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 61.0 m -100.94 16.66 24.51 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.871 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -113.21 16.2 19.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.891 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 34.3 mt -128.73 159.91 34.18 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.919 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -112.9 172.27 7.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.921 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.461 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 11.9 mt -88.71 155.45 50.52 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.619 0.723 . . . . 0.0 110.937 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.629 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.71 -175.82 1.27 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.677 2.251 . . . . 0.0 112.361 179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.31 143.37 57.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.113 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.717 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 93.21 -41.49 2.69 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.543 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.629 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 60.4 m95 -72.69 137.75 46.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.721 0.296 . . . . 0.0 110.932 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -151.1 114.46 4.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.92 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.461 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -71.92 145.12 48.68 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.879 179.996 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.568 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 44.6 mm -129.13 131.76 67.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.093 179.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -106.57 117.99 35.49 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.851 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.424 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.6 t70 -138.54 139.65 25.36 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.608 0.718 . . . . 0.0 110.884 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.412 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.5 Cg_endo -69.74 -7.22 20.48 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.609 2.206 . . . . 0.0 112.362 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 95.2 t -114.49 -38.01 2.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.11 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.404 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.9 m-85 -98.29 -31.08 12.24 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.867 -179.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.02 -144.27 19.29 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.416 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.45 ' N ' HD12 ' A' ' 28' ' ' ILE . 1.8 mp -97.15 111.29 26.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.783 0.325 . . . . 0.0 111.145 -179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.568 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 32.0 p90 -139.18 131.35 28.13 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.935 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.481 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.05 128.25 35.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.947 -179.9 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.9 t -113.06 115.86 50.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.129 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -95.62 102.41 14.21 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.883 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 60.6 m-70 -69.51 -14.4 62.85 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.86 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.717 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.0 OUTLIER -87.16 -60.94 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.132 -179.981 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 21.0 m-20 -82.63 -15.19 53.02 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 13.1 mmm180 62.38 47.58 5.16 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.79 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.577 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 4.8 ptpp? -130.48 129.11 42.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.897 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -107.64 121.58 44.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.181 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.472 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.9 pt20 -150.05 141.86 23.72 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.881 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.2 m-85 -72.33 -26.99 62.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.903 -179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.435 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 6.1 mm-40 -68.99 162.99 25.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.946 179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.468 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 1.9 t-20 -122.13 108.66 34.08 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.661 0.744 . . . . 0.0 110.862 -179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.472 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.1 Cg_endo -69.78 1.73 4.18 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.698 2.265 . . . . 0.0 112.35 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 83.0 p -51.97 171.06 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.843 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 88.12 -176.4 45.43 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.491 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.86 -17.05 37.34 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.63 2.22 . . . . 0.0 112.335 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 44.5 m 61.16 41.85 13.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.863 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.4 t -71.07 137.66 49.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.844 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.224 0 C-N-CA 120.642 -0.789 . . . . 0.0 112.491 -179.99 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.433 -0.267 . . . . 0.0 112.433 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 42.7 m -90.7 173.31 8.1 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.879 0.371 . . . . 0.0 110.811 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 46.3 t -60.39 153.2 23.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.858 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 71.4 71.63 1.02 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.527 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 60.3 p -70.78 -47.15 61.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.853 0.358 . . . . 0.0 110.872 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.9 m -107.2 141.46 38.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.788 -179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -134.13 88.14 0.25 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.46 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.1 tp -118.32 142.64 47.31 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.819 0.342 . . . . 0.0 110.917 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -91.55 110.78 22.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.892 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 34.7 t -103.9 16.35 26.54 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.836 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -114.84 16.38 17.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.905 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 24.7 mt -127.58 156.19 42.64 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.885 -179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 21.9 mt-10 -89.35 171.21 9.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.846 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.428 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 11.8 mt -93.94 154.77 40.72 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.63 0.729 . . . . 0.0 110.899 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.629 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.3 Cg_endo -69.77 -174.58 0.94 Allowed 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.663 2.242 . . . . 0.0 112.314 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.23 143.74 57.05 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.071 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.683 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 93.15 -41.64 2.68 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.512 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.629 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 60.6 m95 -72.42 137.76 46.7 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.73 0.3 . . . . 0.0 110.955 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 8.5 tp10 -151.35 117.06 5.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.835 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.525 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -75.53 143.55 42.42 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.916 179.907 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.567 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 45.0 mm -127.09 131.89 70.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.121 179.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -104.94 117.69 34.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.848 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.418 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -137.99 138.5 23.62 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.652 0.739 . . . . 0.0 110.899 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -6.62 19.04 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.689 2.259 . . . . 0.0 112.267 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 90.7 t -115.2 -38.02 2.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.133 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.42 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.8 m-85 -98.1 -31.23 12.23 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.925 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.04 -145.45 19.23 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.45 179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.408 ' N ' HD12 ' A' ' 28' ' ' ILE . 2.0 mp -97.41 111.6 27.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 111.086 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.567 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.7 p90 -138.57 132.83 31.69 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.896 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.481 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.84 128.52 36.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.945 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.8 t -113.43 115.82 50.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.116 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -94.54 102.12 14.04 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.892 179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 70.2 m-70 -68.99 -12.86 62.07 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.894 180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.683 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.9 OUTLIER -89.0 -60.39 2.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.134 179.958 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -83.01 -18.6 39.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.809 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.6 mmm180 65.67 48.05 2.03 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.879 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.577 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 14.9 ptpt -130.53 131.16 44.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.861 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -109.25 120.29 42.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.118 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.469 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 6.9 pt20 -149.43 140.89 23.32 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.965 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -71.19 -24.6 62.26 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.941 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.405 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 8.0 mt-10 -69.76 161.1 30.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.864 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.458 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 1.9 t-20 -122.75 105.45 35.4 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.637 0.732 . . . . 0.0 110.913 -179.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.469 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.5 Cg_endo -69.7 3.25 2.85 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.73 2.286 . . . . 0.0 112.391 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 64.9 p -52.41 142.11 18.2 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.896 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -151.54 168.07 30.96 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.478 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 0.02 6.27 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.692 2.261 . . . . 0.0 112.319 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 21.0 m -81.09 -59.08 2.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.892 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 6.6 t -130.05 116.37 18.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.822 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.336 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.473 179.997 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.466 -0.254 . . . . 0.0 112.466 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 89.8 p -147.74 106.86 3.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.978 0.418 . . . . 0.0 110.849 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.6 m -72.03 -50.29 29.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.909 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -165.35 117.02 0.73 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.509 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 79.2 p -63.38 104.4 0.61 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.869 0.366 . . . . 0.0 110.854 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.8 p -39.8 -58.05 1.44 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.906 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 95.66 67.19 0.98 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.47 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 tp -71.46 128.9 37.35 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.798 0.333 . . . . 0.0 110.935 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 43.0 m-20 -137.71 123.07 19.46 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.879 179.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.3 p -102.27 16.8 25.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.874 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -117.42 15.48 14.73 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.939 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 35.0 mt -129.07 160.29 33.26 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.979 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 29.3 mt-10 -108.73 168.91 9.01 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.896 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.554 HD11 ' CD2' ' A' ' 30' ' ' TYR . 14.5 mt -83.71 152.62 63.52 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.59 0.71 . . . . 0.0 110.924 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.629 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.1 Cg_endo -69.7 -173.85 0.79 Allowed 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.683 2.255 . . . . 0.0 112.392 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.73 149.29 49.45 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.098 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.724 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 86.05 -42.4 3.15 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.503 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.629 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.2 m95 -70.39 139.19 51.82 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.685 0.279 . . . . 0.0 110.916 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 29.4 tp10 -149.49 113.87 5.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.846 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -70.85 144.79 50.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.896 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.582 HG21 ' OH ' ' A' ' 29' ' ' TYR . 33.9 mm -128.27 130.97 69.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.126 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -105.6 118.59 36.97 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.91 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.432 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.14 139.56 21.47 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.669 0.747 . . . . 0.0 110.845 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.407 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.6 Cg_endo -69.74 -8.65 24.14 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.751 2.301 . . . . 0.0 112.336 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 91.3 t -112.68 -38.04 2.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.113 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.417 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.22 -32.45 11.56 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.927 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.4 -144.62 18.55 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.505 -179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.6 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.9 mp -97.99 109.59 23.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.811 0.338 . . . . 0.0 111.195 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.582 ' OH ' HG21 ' A' ' 21' ' ' ILE . 38.4 p90 -135.34 130.96 35.81 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.95 -179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.554 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.9 m-30 -88.65 121.44 31.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.981 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.465 HG22 HG22 ' A' ' 38' ' ' THR . 11.7 t -107.96 116.36 51.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.151 179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -96.03 102.59 14.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.871 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 60.6 m-70 -68.26 -18.14 64.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.902 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.724 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -81.39 -63.42 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.126 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 2.9 m-80 -79.22 -18.46 52.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.902 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.478 ' CZ ' ' HA ' ' A' ' 36' ' ' ARG . 0.1 OUTLIER 66.61 47.77 1.56 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.875 -179.971 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.502 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 6.3 ptpt -134.5 130.72 37.09 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.876 179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.465 HG22 HG22 ' A' ' 31' ' ' VAL . 1.8 p -106.05 119.99 40.63 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.19 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.4 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.7 pt20 -149.99 141.76 23.68 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.926 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . 0.6 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -75.05 -25.42 58.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.914 -179.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 10.8 mt-10 -62.74 158.18 19.26 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.834 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.495 HD22 HD21 ' A' ' 14' ' ' LEU . 9.2 t-20 -114.28 101.9 54.45 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.522 0.677 . . . . 0.0 110.915 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.426 ' HD2' HD21 ' A' ' 14' ' ' LEU . 53.9 Cg_endo -69.72 3.39 2.78 Favored 'Trans proline' 0 N--CA 1.465 -0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.376 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 14.0 p -51.92 168.61 0.08 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.894 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 120.16 174.8 15.45 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.442 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 102.42 1.02 Allowed 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.736 2.291 . . . . 0.0 112.371 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 98.4 p -63.04 120.75 12.02 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.837 -179.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 25.2 p -103.96 134.04 47.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.855 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.27 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.479 179.985 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 N-CA-C 112.536 -0.226 . . . . 0.0 112.536 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 99.3 p -130.24 122.51 28.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.921 0.391 . . . . 0.0 110.833 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.1 t -140.92 160.27 40.42 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.88 -179.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -101.0 66.96 0.48 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.46 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 5.0 m -133.35 114.32 13.58 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.908 0.385 . . . . 0.0 110.834 -179.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.8 t -60.67 -46.66 89.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.9 -179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.55 -152.76 5.75 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.536 179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 13.2 tp -91.36 125.95 36.28 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.838 0.351 . . . . 0.0 110.923 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -104.93 17.82 23.45 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.906 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 3.5 m -77.39 7.97 4.73 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.837 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -107.25 15.83 24.66 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.878 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 45.1 mt -116.7 146.86 42.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.87 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 -64.24 171.06 3.26 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.8 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.562 HD11 ' CD2' ' A' ' 30' ' ' TYR . 11.5 mt -98.97 153.42 37.82 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.569 0.699 . . . . 0.0 110.887 -179.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.625 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.7 -171.73 0.5 Allowed 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.69 2.26 . . . . 0.0 112.368 179.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.23 147.32 52.39 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.106 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.744 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 88.58 -40.39 3.08 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.483 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.625 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 57.3 m95 -73.3 130.55 40.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.674 0.273 . . . . 0.0 110.887 -179.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -137.28 113.29 9.78 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.883 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.58 144.56 41.77 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.843 179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.543 ' HB ' ' CZ ' ' A' ' 29' ' ' TYR . 29.9 mm -130.62 132.8 64.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.181 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -104.38 120.28 40.87 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.899 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.43 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.69 137.54 17.47 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.668 0.747 . . . . 0.0 110.876 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -7.68 21.66 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.654 2.236 . . . . 0.0 112.416 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.9 t -113.47 -37.95 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.218 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.417 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.14 -31.69 11.98 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.893 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.48 -148.19 20.43 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.435 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.414 ' N ' HD12 ' A' ' 28' ' ' ILE . 1.9 mp -96.39 109.17 22.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-O 120.862 0.363 . . . . 0.0 111.122 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.543 ' CZ ' ' HB ' ' A' ' 21' ' ' ILE . 37.9 p90 -133.31 131.07 39.73 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.912 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.562 ' CD2' HD11 ' A' ' 14' ' ' LEU . 4.7 m-30 -88.21 123.59 33.0 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.935 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.6 t -109.44 115.77 50.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.067 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.449 ' O ' ' N ' ' A' ' 36' ' ' ARG . 9.8 t0 -94.64 102.03 13.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.849 179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 76.1 m-70 -68.55 -16.15 63.77 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.856 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.744 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -83.27 -58.6 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.176 179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -87.42 -14.12 41.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.853 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 32' ' ' ASP . 4.1 mpt_? 62.73 47.47 4.68 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.919 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.58 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 5.6 ptpt -128.77 130.02 46.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.897 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.4 p -107.34 118.56 37.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.136 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.42 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 6.2 pt20 -150.07 142.99 24.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.889 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -75.12 -26.44 59.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.904 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 23.7 mm-40 -62.01 161.17 11.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.907 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.451 HD22 HD21 ' A' ' 14' ' ' LEU . 12.7 t-20 -116.77 102.28 53.19 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.657 0.741 . . . . 0.0 110.891 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.448 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 53.9 Cg_endo -69.68 -3.27 11.63 Favored 'Trans proline' 0 C--O 1.231 0.154 0 C-N-CA 122.706 2.271 . . . . 0.0 112.34 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 6.6 t -52.3 157.91 1.31 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.883 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 139.94 164.2 9.8 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.475 -179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.7 -34.63 14.38 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.725 2.283 . . . . 0.0 112.322 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 86.3 p -119.7 159.32 24.71 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.856 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 22.1 t 66.75 42.1 2.73 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.828 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.228 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.485 179.986 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.384 0 N-CA-C 112.52 -0.232 . . . . 0.0 112.52 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.7 t -45.89 -57.31 4.46 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.891 0.377 . . . . 0.0 110.842 -179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 69.3 m -90.6 162.21 15.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.875 -179.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 151.59 56.7 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.516 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 70.2 m -45.85 -54.19 8.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.877 0.37 . . . . 0.0 110.838 -179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.8 t 53.28 42.03 32.1 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.869 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -119.86 74.55 0.32 Allowed Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.471 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -91.89 140.61 29.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.829 0.347 . . . . 0.0 110.914 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -122.44 154.22 38.06 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.841 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.1 t -85.68 17.23 3.43 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.852 -179.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -111.95 17.67 19.49 Favored 'General case' 0 C--O 1.233 0.226 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.823 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 30.1 mt -113.31 157.88 21.26 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.862 -179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -109.34 173.29 6.39 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.86 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.44 ' CD2' ' OD1' ' A' ' 42' ' ' ASN . 14.5 mt -96.68 154.94 38.27 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.577 0.703 . . . . 0.0 110.926 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.643 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.0 Cg_endo -69.72 -175.78 1.26 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.702 2.268 . . . . 0.0 112.321 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.46 144.26 57.16 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.725 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 92.03 -40.82 2.86 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.501 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.643 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 63.8 m95 -73.04 135.27 44.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.769 0.319 . . . . 0.0 110.908 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.5 tp10 -149.52 114.98 5.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.889 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.503 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -72.41 143.68 48.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.901 179.944 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.547 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 45.8 mm -127.02 131.67 70.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.125 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -104.84 117.74 34.8 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.92 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.417 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.9 t70 -139.15 139.13 22.2 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.591 0.71 . . . . 0.0 110.901 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -7.03 20.03 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.659 2.239 . . . . 0.0 112.372 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.6 t -114.5 -37.99 2.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.126 179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.412 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.17 -31.81 11.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.94 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.57 -145.85 19.75 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.467 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.0 mp -96.63 108.57 21.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.792 0.33 . . . . 0.0 111.123 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.547 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.3 p90 -135.97 132.1 35.94 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.902 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.476 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.2 m-30 -89.06 125.05 34.84 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.93 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.9 t -110.5 115.78 50.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.176 179.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -95.44 102.04 13.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.858 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 66.9 m-70 -68.93 -14.15 62.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.725 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -84.41 -63.26 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.169 179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 19.2 m-20 -82.6 -17.24 45.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.916 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 33.4 mmm-85 65.81 47.42 2.08 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.836 -179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.58 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 4.1 ptpp? -129.81 126.75 38.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.952 179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.3 p -104.92 122.11 45.13 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.185 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.486 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 8.5 pt20 -150.01 140.02 21.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.88 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.2 m-85 -71.1 -26.11 62.9 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.908 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 10.8 mm-40 -69.05 160.27 31.32 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.849 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.454 ' ND2' ' CE2' ' A' ' 30' ' ' TYR . 2.0 t-20 -120.23 106.8 40.21 Favored Pre-proline 0 C--N 1.33 -0.273 0 CA-C-O 121.618 0.723 . . . . 0.0 110.887 -179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.486 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.4 Cg_endo -69.81 3.23 2.92 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.743 2.295 . . . . 0.0 112.347 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 42.5 t -52.28 152.62 3.27 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.817 -179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 148.83 -177.59 26.97 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.454 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 168.46 21.4 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.673 2.249 . . . . 0.0 112.336 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 27.0 t 57.29 42.23 25.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.848 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 3.4 m -74.79 -44.65 48.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.852 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.505 -179.988 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 N-CA-C 112.427 -0.269 . . . . 0.0 112.427 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.7 p -103.17 155.82 18.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.908 0.385 . . . . 0.0 110.847 -179.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 70.0 m -87.82 148.81 24.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.834 -179.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 162.42 -90.27 0.11 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.516 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 6.5 m -73.91 -37.93 64.49 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.868 0.366 . . . . 0.0 110.881 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 57.5 m -55.11 156.69 3.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.872 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -45.88 -92.91 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.512 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 26.7 mt 60.25 42.62 14.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.737 0.303 . . . . 0.0 110.959 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -91.95 117.68 30.04 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 38.9 m -100.13 17.61 20.74 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.824 -179.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -113.71 17.35 18.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.881 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.554 HD13 ' HA2' ' A' ' 45' ' ' GLY . 25.1 mt -128.03 147.53 50.51 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.881 -179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -85.9 163.64 17.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.883 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.588 HD11 ' CD2' ' A' ' 30' ' ' TYR . 13.3 mt -82.77 153.54 67.54 Favored Pre-proline 0 C--N 1.328 -0.369 0 CA-C-O 121.643 0.735 . . . . 0.0 110.879 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.651 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.68 -173.96 0.8 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.683 2.256 . . . . 0.0 112.367 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.42 149.64 48.03 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.122 179.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.756 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 84.52 -41.3 3.01 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.821 -0.704 . . . . 0.0 112.458 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.651 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 57.7 m95 -70.41 140.44 52.05 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.827 0.346 . . . . 0.0 110.846 -179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 17.8 tp10 -152.81 117.96 5.18 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.941 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.05 147.12 40.95 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.851 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.505 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 31.6 mm -131.01 132.04 63.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.161 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -105.16 117.8 34.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.883 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 8.9 t70 -138.05 137.47 21.22 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.606 0.717 . . . . 0.0 110.858 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.79 -4.04 13.24 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.651 2.234 . . . . 0.0 112.392 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.6 t -117.19 -38.03 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.123 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.425 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.56 -31.0 12.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.85 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.0 -146.08 18.94 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.436 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.582 ' O ' ' CE2' ' A' ' 40' ' ' TYR . 1.7 mp -98.43 108.3 21.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.849 0.357 . . . . 0.0 111.159 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.518 ' HB3' ' CE1' ' A' ' 40' ' ' TYR . 28.8 p90 -134.41 132.2 39.1 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.912 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.588 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.0 m-30 -88.65 122.53 32.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.925 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 t -107.78 115.89 49.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.129 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.459 ' O ' ' N ' ' A' ' 36' ' ' ARG . 57.6 t0 -95.15 101.95 13.73 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.861 179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 66.6 m-70 -68.57 -18.52 64.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.756 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -82.14 -57.16 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.125 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -87.18 -14.88 39.94 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.874 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.459 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.3 mpt_? 62.23 47.73 5.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.853 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.577 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 5.0 ptpp? -131.5 132.49 44.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.854 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 7.1 p -108.05 118.35 36.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.12 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 8.9 pt20 -150.05 139.14 21.12 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.919 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . 0.582 ' CE2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -74.26 -21.04 59.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.967 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 34.1 mp0 -65.99 156.9 32.28 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.888 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.454 HD22 ' CD2' ' A' ' 14' ' ' LEU . 7.4 t-20 -115.52 101.98 54.3 Favored Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 121.644 0.735 . . . . 0.0 110.968 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.41 ' HD2' HD21 ' A' ' 14' ' ' LEU . 53.6 Cg_endo -69.74 -13.03 34.15 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.642 2.228 . . . . 0.0 112.339 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 34.9 t -52.05 155.76 1.78 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.832 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.554 ' HA2' HD13 ' A' ' 12' ' ' LEU . . . 126.07 -172.75 17.86 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.674 -0.774 . . . . 0.0 112.469 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 2.49 3.49 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.679 2.252 . . . . 0.0 112.344 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 93.2 p -71.06 172.56 8.91 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.894 -179.875 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 49.5 m -38.82 -49.67 1.64 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.918 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.449 179.985 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 N-CA-C 112.457 -0.257 . . . . 0.0 112.457 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.2 t -62.95 121.73 14.26 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.855 0.36 . . . . 0.0 110.9 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 23.4 t -157.68 104.54 1.97 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.895 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -65.18 -124.49 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.527 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 70.6 m -77.44 152.27 34.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.891 0.377 . . . . 0.0 110.855 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.4 m -114.15 175.84 5.3 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.784 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.498 ' C ' HD12 ' A' ' 8' ' ' LEU . . . -169.26 122.17 0.99 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.538 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.498 HD12 ' C ' ' A' ' 7' ' ' GLY . 7.0 mp -121.69 168.34 11.91 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.829 0.347 . . . . 0.0 110.956 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -82.41 17.04 1.83 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.842 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 70.4 m -78.13 8.66 4.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.876 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -104.49 10.73 35.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.886 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.401 ' CD1' ' C ' ' A' ' 45' ' ' GLY . 46.3 mt -116.27 148.62 40.31 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.943 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -84.68 164.78 18.4 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.886 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.569 HD21 HD22 ' A' ' 42' ' ' ASN . 12.8 mt -79.93 151.94 73.93 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-O 121.579 0.704 . . . . 0.0 110.921 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.644 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.6 Cg_endo -69.77 -169.36 0.32 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.7 2.267 . . . . 0.0 112.326 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.98 153.74 41.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.105 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.683 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 82.24 -45.89 3.43 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.418 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.644 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 71.3 m95 -67.67 134.66 51.52 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.732 0.301 . . . . 0.0 110.896 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -149.92 113.99 5.13 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.02 142.72 43.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.917 179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.538 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 19.0 mm -128.36 130.78 69.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.094 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -102.51 119.88 39.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.895 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.419 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.5 t70 -140.69 139.7 20.58 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-O 121.576 0.703 . . . . 0.0 110.896 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.417 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.9 Cg_endo -69.77 -7.8 21.99 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.692 2.261 . . . . 0.0 112.342 -179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.9 t -113.92 -37.92 2.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.179 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.436 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.5 m-85 -98.51 -31.61 11.89 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.903 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 86.78 -143.74 19.22 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.423 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.537 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -97.94 108.8 22.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.878 0.37 . . . . 0.0 111.162 -179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.538 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 39.7 p90 -135.11 131.95 37.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.905 -179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.442 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 3.3 m-30 -88.77 124.92 34.6 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.916 -179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.0 t -111.38 116.41 52.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.095 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.627 ' OD1' ' CE3' ' A' ' 18' ' ' TRP . 0.8 OUTLIER -100.12 103.3 14.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.905 179.903 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 48.3 m-70 -68.83 -8.44 43.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.851 -179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.683 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.9 OUTLIER -90.22 -62.81 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.156 179.995 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 7.4 m-80 -82.44 -19.91 38.03 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.915 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 19.6 mmm-85 66.28 47.39 1.82 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.901 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.422 ' HG3' ' OD2' ' A' ' 32' ' ' ASP . 0.1 OUTLIER -129.76 122.2 28.36 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.847 179.988 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.3 p -100.2 118.34 36.32 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.421 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 6.7 pt20 -148.98 141.34 24.15 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.95 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . 0.537 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -75.26 -24.45 57.61 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.916 -179.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 -62.62 161.24 12.52 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.569 HD22 HD21 ' A' ' 14' ' ' LEU . 13.6 t-20 -120.3 102.02 46.17 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.625 0.726 . . . . 0.0 110.883 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.421 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.2 Cg_endo -69.74 -9.37 25.95 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.709 2.273 . . . . 0.0 112.363 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 6.6 m -59.35 146.4 39.88 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.854 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . 0.401 ' C ' ' CD1' ' A' ' 12' ' ' LEU . . . -168.36 165.57 38.9 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.496 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -69.83 113.28 3.33 Favored 'Trans proline' 0 N--CA 1.465 -0.205 0 C-N-CA 122.688 2.258 . . . . 0.0 112.346 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 58.0 m -59.86 112.22 1.76 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.802 -179.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 4.9 m -76.32 -56.43 4.64 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.849 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.324 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.515 -179.982 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.322 0 N-CA-C 112.474 -0.25 . . . . 0.0 112.474 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 58.3 m -56.64 -41.85 77.87 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.836 0.351 . . . . 0.0 110.841 -179.686 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 11.9 t -95.93 -44.46 7.36 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.851 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -46.85 -87.01 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.501 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.1 m -60.35 -47.62 85.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.859 0.361 . . . . 0.0 110.806 -179.684 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.6 t 60.48 42.39 14.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.826 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -49.04 134.73 22.64 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.467 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.46 HD13 ' N ' ' A' ' 9' ' ' ASP . 0.8 OUTLIER -144.11 118.51 9.65 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.883 0.373 . . . . 0.0 110.875 -179.918 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.46 ' N ' HD13 ' A' ' 8' ' ' LEU . 5.5 p-10 -69.26 105.19 2.44 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.867 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.9 t -106.93 13.8 27.27 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.846 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -109.28 16.9 22.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.964 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 20.2 mt -128.93 146.91 50.83 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.892 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -78.19 173.67 12.01 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.833 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.558 HD11 ' CD2' ' A' ' 30' ' ' TYR . 10.7 mt -99.78 155.06 36.9 Favored Pre-proline 0 C--N 1.33 -0.259 0 CA-C-O 121.603 0.716 . . . . 0.0 110.879 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.62 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.67 -171.71 0.49 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.606 2.204 . . . . 0.0 112.371 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.46 150.52 48.82 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.072 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.658 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 85.31 -43.92 3.31 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.755 -0.735 . . . . 0.0 112.46 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.62 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.6 m95 -68.66 141.62 55.31 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.751 0.31 . . . . 0.0 110.897 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 23.2 tp10 -153.14 113.58 4.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.907 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.47 142.57 48.58 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.898 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.574 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 32.3 mm -127.38 130.76 70.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.105 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 mt-10 -103.81 117.88 35.38 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.928 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.42 ' O ' ' N ' ' A' ' 27' ' ' GLY . 9.8 t70 -138.17 139.36 25.39 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.511 0.672 . . . . 0.0 110.956 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.404 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 54.2 Cg_endo -69.77 -6.92 19.75 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.614 2.21 . . . . 0.0 112.367 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 88.2 t -114.21 -37.91 2.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.18 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.427 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.66 -32.31 11.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.91 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.47 -144.19 18.26 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.812 -0.709 . . . . 0.0 112.425 179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.456 ' N ' HD12 ' A' ' 28' ' ' ILE . 1.9 mp -97.86 108.82 22.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.827 0.346 . . . . 0.0 111.128 -179.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.574 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.3 p90 -135.78 131.19 35.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.933 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.558 ' CD2' HD11 ' A' ' 14' ' ' LEU . 2.9 m-30 -88.88 125.55 34.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.92 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.9 t -111.35 116.72 53.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.098 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.406 ' O ' ' N ' ' A' ' 36' ' ' ARG . 19.4 t0 -95.55 102.58 14.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.887 179.86 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 72.8 m-70 -67.93 -15.13 63.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.835 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.658 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.0 OUTLIER -85.02 -61.4 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.109 -179.998 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 21.4 m-20 -83.49 -15.41 49.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.902 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.406 ' N ' ' O ' ' A' ' 32' ' ' ASP . 0.0 OUTLIER 62.9 47.99 4.17 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.848 179.957 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.579 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 0.1 OUTLIER -130.38 130.89 44.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.833 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 3.0 p -108.13 120.26 41.83 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.151 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.474 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 8.2 pt20 -150.01 140.71 22.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . 0.411 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.8 m-85 -74.38 -21.75 59.51 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.89 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.402 ' HB2' ' NE2' ' A' ' 39' ' ' GLN . 21.6 mt-10 -67.94 161.41 26.55 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.844 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.533 HD22 HD21 ' A' ' 14' ' ' LEU . 12.0 t-20 -117.62 102.07 51.95 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.631 0.729 . . . . 0.0 110.839 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.474 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.0 Cg_endo -69.84 -12.57 33.01 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.64 2.226 . . . . 0.0 112.363 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.449 ' C ' ' O ' ' A' ' 43' ' ' PRO . 24.1 t -34.76 -59.44 0.48 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.92 -179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -52.12 -173.4 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.433 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 2.45 3.54 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.623 2.215 . . . . 0.0 112.308 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 74.7 p -106.58 135.19 48.52 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.878 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.7 t -121.91 152.51 39.56 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.839 -179.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.525 -179.941 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 N-CA-C 112.448 -0.261 . . . . 0.0 112.448 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.7 t -83.64 -51.78 6.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.856 0.36 . . . . 0.0 110.884 -179.736 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.7 p -83.99 169.89 14.52 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.097 -0.502 . . . . 0.0 110.856 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -171.77 157.63 27.96 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.471 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.0 m -112.06 133.34 54.28 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.822 0.344 . . . . 0.0 110.898 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 3.2 t -82.56 147.72 28.46 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.905 -179.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -80.94 132.37 11.16 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.492 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 7.5 mp -86.13 -59.34 2.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.854 0.359 . . . . 0.0 110.934 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -148.14 108.39 4.1 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.875 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.9 p -97.06 16.36 19.84 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.767 -179.658 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -117.49 17.7 14.47 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.92 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 32.6 mt -124.81 151.07 45.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.956 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -76.21 171.22 14.88 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.892 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.715 HD11 ' CD2' ' A' ' 30' ' ' TYR . 12.5 mt -94.19 155.19 40.23 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.554 0.692 . . . . 0.0 110.938 -179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.638 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.5 Cg_endo -69.71 -173.67 0.75 Allowed 'Trans proline' 0 C--N 1.34 0.094 0 C-N-CA 122.689 2.259 . . . . 0.0 112.373 179.829 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.4 148.77 51.14 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.063 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.72 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 86.64 -43.04 3.19 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.524 -179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.638 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 56.7 m95 -68.22 143.88 55.13 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.691 0.281 . . . . 0.0 110.904 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -155.45 116.23 3.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.848 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.498 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -73.8 144.25 45.64 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.891 179.928 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.573 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 43.7 mm -128.11 130.69 69.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.151 179.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 mt-10 -104.74 117.82 35.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.934 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.428 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.0 t70 -138.15 139.69 26.48 Favored Pre-proline 0 C--N 1.327 -0.373 0 CA-C-O 121.589 0.709 . . . . 0.0 110.878 -180.0 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.413 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.1 Cg_endo -69.82 -7.36 20.88 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.689 2.259 . . . . 0.0 112.38 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 86.4 t -114.12 -37.95 2.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.104 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.43 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.6 m-85 -98.45 -31.54 11.94 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.913 -179.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.84 -143.78 18.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.449 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.598 ' O ' ' CE2' ' A' ' 40' ' ' TYR . 1.7 mp -98.41 110.17 25.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.855 0.359 . . . . 0.0 111.151 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.573 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 33.1 p90 -136.93 131.69 33.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.98 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.715 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.84 124.34 34.09 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.885 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 t -110.3 115.97 51.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.116 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 12.9 t0 -95.33 102.72 14.55 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.813 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 64.1 m-70 -69.16 -17.31 63.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.9 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.72 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -82.2 -62.67 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.185 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 18.9 m-20 -81.2 -18.25 46.85 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.931 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 14.0 mmt85 66.08 47.75 1.86 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.839 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.588 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 5.0 ptpp? -131.95 131.74 42.9 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.9 p -106.55 118.35 36.43 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.16 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.463 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 9.0 pt20 -149.81 139.61 21.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.934 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . 0.598 ' CE2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.65 -24.99 58.9 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.911 -179.81 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -64.1 158.7 22.08 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.901 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.443 ' ND2' ' HG ' ' A' ' 14' ' ' LEU . 12.7 t-20 -115.87 102.01 54.02 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.627 0.727 . . . . 0.0 110.854 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.463 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.6 Cg_endo -69.8 0.0 6.31 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.747 2.298 . . . . 0.0 112.288 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 7.6 t -52.09 161.69 0.57 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.875 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 154.61 175.07 25.33 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.432 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 -178.92 2.54 Favored 'Trans proline' 0 C--O 1.231 0.158 0 C-N-CA 122.663 2.242 . . . . 0.0 112.397 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.3 p 52.63 39.03 27.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.884 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 13.2 t -57.4 161.09 3.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.916 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.299 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.492 -179.945 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.371 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.3 p -48.42 -32.95 8.41 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.864 0.364 . . . . 0.0 110.808 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 35.8 p -62.43 -50.34 71.89 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.856 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -40.16 139.66 1.11 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.783 -0.723 . . . . 0.0 112.452 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 2.1 m -58.46 -46.51 86.45 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.894 0.378 . . . . 0.0 110.879 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 74.6 m -100.93 109.12 21.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.909 -179.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.446 ' H ' ' CB ' ' A' ' 10' ' ' SER . . . -89.43 -174.07 46.03 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.453 -179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.1 mp -70.22 -48.54 56.59 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.785 0.326 . . . . 0.0 110.876 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -98.65 17.96 17.95 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.857 179.883 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.446 ' CB ' ' H ' ' A' ' 7' ' ' GLY . 26.5 t -82.32 16.78 1.9 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.855 -179.78 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -104.33 16.24 26.59 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.894 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 38.8 mt -105.5 146.04 30.09 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.866 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -92.59 168.49 11.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.851 179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.52 HD11 ' CD2' ' A' ' 30' ' ' TYR . 13.5 mt -94.61 153.77 40.17 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.578 0.704 . . . . 0.0 110.915 -179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.677 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.84 -173.45 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.693 2.262 . . . . 0.0 112.285 179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.43 149.92 47.48 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.123 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.592 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 83.88 -39.25 2.84 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.387 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.677 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 72.6 m95 -74.94 131.91 41.03 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.707 0.289 . . . . 0.0 110.926 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -145.46 112.91 6.23 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.896 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.2 145.65 47.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.908 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.568 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 18.7 mm -130.06 132.05 65.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.126 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -104.24 118.59 37.0 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.873 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.429 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.0 t70 -139.73 139.86 23.17 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.576 0.703 . . . . 0.0 110.877 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.428 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.5 Cg_endo -69.79 -8.85 24.65 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.687 2.258 . . . . 0.0 112.312 -179.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.5 t -112.92 -37.91 2.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.157 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.8 m-85 -98.28 -32.06 11.74 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.939 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 87.08 -143.63 18.93 Favored Glycine 0 N--CA 1.45 -0.398 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.588 -179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.544 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -98.37 108.06 21.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.82 0.343 . . . . 0.0 111.115 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.568 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 27.4 p90 -135.13 131.83 37.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.895 -180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.52 ' CD2' HD11 ' A' ' 14' ' ' LEU . 2.9 m-30 -88.64 120.1 29.72 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.915 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.408 ' CG2' ' CE2' ' A' ' 29' ' ' TYR . 21.9 t -102.79 123.17 55.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.122 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.618 ' OD2' ' CZ3' ' A' ' 18' ' ' TRP . 5.0 m-20 -97.9 118.73 35.13 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.852 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.45 ' C ' HD12 ' A' ' 34' ' ' ILE . 81.1 m-70 -92.31 -4.97 53.16 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.8 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.592 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.8 OUTLIER -96.39 -49.98 11.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.122 -179.994 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.478 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 14.9 m-80 -98.36 -12.36 21.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.9 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 44.0 mmm-85 64.3 46.29 3.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.858 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.478 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 22.8 pttt -126.09 127.48 45.86 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.941 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -107.63 121.01 43.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.164 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.464 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 8.7 pt20 -150.29 144.92 25.86 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.885 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . 0.544 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 5.1 m-85 -79.12 -28.76 42.94 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.965 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -60.4 159.33 10.38 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.842 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.461 ' OD1' ' CB ' ' A' ' 44' ' ' SER . 14.7 t-20 -114.73 102.01 54.65 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.632 0.729 . . . . 0.0 110.899 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.464 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.0 Cg_endo -69.79 3.57 2.71 Favored 'Trans proline' 0 C--O 1.232 0.19 0 C-N-CA 122.72 2.28 . . . . 0.0 112.33 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.461 ' CB ' ' OD1' ' A' ' 42' ' ' ASN . 8.3 t -52.01 168.73 0.08 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.856 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 156.02 160.09 9.79 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.499 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 127.58 14.83 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.699 2.266 . . . . 0.0 112.4 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 6.1 t -66.17 -53.67 34.68 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.854 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . 0.42 ' O ' ' C ' ' A' ' 49' ' ' GLY . 35.0 p -159.64 157.24 29.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.844 -179.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' A' ' 48' ' ' SER . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.459 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.302 0 N-CA-C 112.465 -0.254 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.5 t -156.52 145.71 20.46 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.947 0.403 . . . . 0.0 110.813 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 76.7 p -77.84 -45.8 23.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.81 -179.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 105.26 61.72 0.64 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.507 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 3.6 m 57.06 42.1 26.42 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.868 0.366 . . . . 0.0 110.837 -179.701 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 28.4 m -74.4 -49.86 20.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.896 -179.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 43.33 -112.92 0.6 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.502 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.618 HD23 ' H ' ' A' ' 8' ' ' LEU . 1.7 pt? -94.42 149.45 21.23 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.817 0.342 . . . . 0.0 110.955 -179.939 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -117.78 103.01 9.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.855 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 73.9 m -92.98 16.04 13.59 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.895 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -114.65 15.33 17.66 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.886 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 36.5 mt -125.55 161.84 26.27 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.916 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -90.33 171.43 9.47 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.919 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.572 HD11 ' CD2' ' A' ' 30' ' ' TYR . 9.2 mt -92.96 154.51 41.82 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.577 0.704 . . . . 0.0 110.917 -179.933 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.664 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.8 Cg_endo -69.83 -177.41 1.89 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.626 2.217 . . . . 0.0 112.375 179.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.38 144.78 56.92 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.053 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.646 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 90.75 -35.87 3.76 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.44 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.664 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 70.5 m95 -78.74 132.73 37.06 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.758 0.313 . . . . 0.0 110.938 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -139.23 111.76 7.67 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.873 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.42 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -72.11 146.52 47.44 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.894 179.982 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.482 ' HB ' ' CZ ' ' A' ' 29' ' ' TYR . 29.9 mm -132.86 133.55 58.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.178 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.9 mt-10 -106.45 118.93 37.94 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.868 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.435 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.2 t70 -138.57 137.98 21.26 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.577 0.703 . . . . 0.0 110.85 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -8.38 23.46 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.657 2.238 . . . . 0.0 112.372 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.7 t -112.83 -38.02 2.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.095 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.412 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.7 m-85 -98.04 -31.89 11.91 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.904 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.16 -147.63 19.72 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.486 179.974 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.418 ' N ' HD12 ' A' ' 28' ' ' ILE . 1.8 mp -97.07 108.88 22.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.873 0.368 . . . . 0.0 111.065 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.482 ' CZ ' ' HB ' ' A' ' 21' ' ' ILE . 42.4 p90 -133.41 131.83 40.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.572 ' CD2' HD11 ' A' ' 14' ' ' LEU . 5.7 m-30 -88.6 124.22 33.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.895 -179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.2 t -106.06 114.9 46.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.148 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.53 ' OD2' ' CE2' ' A' ' 18' ' ' TRP . 35.9 t0 -91.96 102.25 14.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.836 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -71.53 -10.37 59.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.849 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.646 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.8 OUTLIER -92.32 -60.26 2.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.113 179.953 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.467 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 5.9 m-80 -81.29 -21.7 39.14 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.778 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 10.6 mmt85 67.89 47.63 1.09 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.879 -179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.467 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 16.9 pttt -139.65 121.86 15.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.879 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 3.3 p -93.07 125.67 37.78 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.166 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.438 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 5.7 pt20 -150.58 140.15 21.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.89 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 3.6 m-85 -73.5 -21.15 60.48 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.923 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 52.8 mm-40 -66.03 157.71 30.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.881 -179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.434 HD22 HD21 ' A' ' 14' ' ' LEU . 9.0 t-20 -115.76 101.98 54.11 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.603 0.716 . . . . 0.0 110.875 -179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.438 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.1 Cg_endo -69.75 2.87 3.13 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.665 2.243 . . . . 0.0 112.396 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.2 p -52.62 146.46 10.09 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.86 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 131.55 176.83 14.57 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.485 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 -177.59 1.93 Allowed 'Trans proline' 0 C--O 1.231 0.149 0 C-N-CA 122.726 2.284 . . . . 0.0 112.298 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 13.3 t -94.42 146.51 24.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.832 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 14.9 t -89.65 113.35 24.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.882 -179.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.527 -179.996 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.273 0 N-CA-C 112.481 -0.248 . . . . 0.0 112.481 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 5.2 t -120.17 112.34 18.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.865 0.364 . . . . 0.0 110.897 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 80.2 p -160.5 153.1 20.91 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.806 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -96.21 -119.39 3.59 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.5 179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 82.6 p -163.49 167.44 21.48 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.941 0.4 . . . . 0.0 110.846 -179.745 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 17.1 m -92.68 176.43 6.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.795 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -43.23 119.9 2.56 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.516 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.473 ' HG ' ' N ' ' A' ' 9' ' ' ASP . 1.3 pt? -39.24 -39.38 0.61 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.804 0.335 . . . . 0.0 110.951 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.473 ' N ' ' HG ' ' A' ' 8' ' ' LEU . 4.6 m-20 -128.37 129.34 46.09 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.87 179.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.7 m -94.19 17.02 13.38 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.893 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -108.55 15.68 23.61 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.894 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 25.1 mt -112.71 146.0 39.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.897 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 27.0 mt-10 -85.98 173.34 10.0 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.867 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.556 HD11 ' CD2' ' A' ' 30' ' ' TYR . 13.7 mt -100.63 153.47 37.72 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.661 0.743 . . . . 0.0 110.908 -180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.669 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.73 -175.87 1.29 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.66 2.24 . . . . 0.0 112.347 179.842 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.87 145.24 56.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.083 179.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.769 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 89.52 -41.09 3.01 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.531 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.669 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 69.8 m95 -73.18 129.92 39.11 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.763 0.316 . . . . 0.0 110.916 -179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -138.45 112.36 8.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.917 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.421 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.57 145.49 43.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.909 179.965 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.579 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 26.2 mm -132.12 133.43 60.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.123 179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -105.36 119.39 38.96 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.873 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.438 ' O ' ' N ' ' A' ' 27' ' ' GLY . 10.5 t70 -140.06 138.45 19.48 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.567 0.699 . . . . 0.0 110.883 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 -9.78 26.95 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.677 2.251 . . . . 0.0 112.341 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.9 t -111.27 -38.0 3.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.095 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.402 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.8 m-85 -98.05 -33.0 11.34 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.89 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.41 -146.79 19.16 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.479 179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.0 mp -97.68 109.76 24.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.845 0.355 . . . . 0.0 111.152 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.579 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 27.1 p90 -134.53 131.63 38.2 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.879 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.556 ' CD2' HD11 ' A' ' 14' ' ' LEU . 4.9 m-30 -88.51 120.77 30.21 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.942 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.9 t -106.13 115.69 48.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.143 179.894 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.414 ' O ' ' N ' ' A' ' 36' ' ' ARG . 8.8 t0 -94.2 101.99 13.99 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.85 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 76.5 m-70 -67.39 -13.92 62.45 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.878 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.769 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -85.35 -62.86 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.101 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.497 ' CB ' ' HE2' ' A' ' 37' ' ' LYS . 5.8 m-80 -83.56 -15.83 47.72 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.414 ' N ' ' O ' ' A' ' 32' ' ' ASP . 4.8 mmm180 64.25 47.68 3.11 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.852 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.497 ' HE2' ' CB ' ' A' ' 35' ' ' ASN . 21.1 pttt -129.75 136.79 50.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.835 -179.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 22.6 p -113.44 123.04 49.12 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.108 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.469 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 8.1 pt20 -149.96 138.54 20.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.948 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.7 m-85 -72.59 -16.22 61.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.948 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -73.54 159.97 32.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.857 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.407 ' OD1' ' CB ' ' A' ' 44' ' ' SER . 11.9 t-20 -116.43 101.93 53.6 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.646 0.736 . . . . 0.0 110.926 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.469 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 54.5 Cg_endo -69.72 3.56 2.68 Favored 'Trans proline' 0 C--N 1.342 0.236 0 C-N-CA 122.687 2.258 . . . . 0.0 112.354 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.407 ' CB ' ' OD1' ' A' ' 42' ' ' ASN . 19.5 t -52.1 156.96 1.44 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.855 -179.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 129.68 160.21 10.09 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.502 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.62 115.74 4.21 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.71 2.273 . . . . 0.0 112.4 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 64.7 m -81.03 -58.9 2.87 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.905 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 5.8 m 54.33 42.17 31.59 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.921 -179.796 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.41 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.441 -179.918 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.453 -0.259 . . . . 0.0 112.453 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 30.0 t -42.46 -44.86 4.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.877 0.37 . . . . 0.0 110.796 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.7 m -79.11 148.88 32.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.862 -179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -146.93 -153.85 6.02 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.463 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 28.9 t -58.37 151.04 20.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.865 0.364 . . . . 0.0 110.849 -179.699 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 8.9 t -154.97 159.26 40.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.891 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 133.97 158.17 8.49 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.446 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.9 mp -85.06 153.67 22.57 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.863 0.363 . . . . 0.0 110.865 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -93.3 116.61 29.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.798 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.1 p -81.42 13.37 3.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.855 -179.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -112.97 16.48 19.37 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.832 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 30.0 mt -110.72 154.17 24.25 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.895 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -104.12 166.78 10.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.819 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.572 HD21 HD22 ' A' ' 42' ' ' ASN . 10.8 mt -85.06 154.94 60.89 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.65 0.738 . . . . 0.0 110.855 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.658 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.8 Cg_endo -69.77 -173.61 0.75 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.707 2.271 . . . . 0.0 112.323 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -67.86 144.52 55.26 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.102 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.773 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 92.14 -39.14 3.06 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.479 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.658 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 69.1 m95 -74.68 131.31 40.77 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.669 0.271 . . . . 0.0 110.916 -179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.462 ' OE1' HD11 ' A' ' 21' ' ' ILE . 10.4 tt0 -135.82 111.82 9.58 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.891 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.526 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -76.11 146.65 39.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.859 -179.983 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.551 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 31.5 mm -133.56 135.52 55.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.137 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.4 mt-10 -107.33 117.66 34.68 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.905 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.43 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.4 t70 -137.71 137.9 22.85 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.638 0.733 . . . . 0.0 110.796 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -8.12 22.8 Favored 'Trans proline' 0 C--N 1.342 0.22 0 C-N-CA 122.68 2.253 . . . . 0.0 112.333 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 86.5 t -113.17 -38.03 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.182 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.435 ' CD1' ' N ' ' A' ' 26' ' ' TYR . 1.5 m-85 -97.46 -31.72 12.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.942 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 88.44 -148.28 20.51 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.501 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 2.0 mp -96.6 108.97 22.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.778 0.323 . . . . 0.0 111.17 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.551 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 37.9 p90 -132.84 131.38 40.94 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.928 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.465 ' CG ' HD11 ' A' ' 14' ' ' LEU . 4.9 m-30 -88.38 123.6 33.11 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.865 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.8 t -107.94 115.08 48.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.146 179.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 28.3 t0 -91.63 102.02 14.65 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.844 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -68.22 -16.52 64.01 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.817 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.773 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.0 OUTLIER -86.87 -61.11 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.117 -179.988 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 -79.74 -16.97 54.6 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.902 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 21.2 mmt180 64.47 45.78 3.57 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.848 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 1.4 pttm -131.68 146.2 52.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.881 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.7 p -120.5 122.94 41.72 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.112 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.453 ' NE2' ' HB2' ' A' ' 41' ' ' GLU . 6.7 pt20 -150.53 140.1 21.57 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.934 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.8 m-85 -72.57 -20.75 61.26 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.901 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.453 ' HB2' ' NE2' ' A' ' 39' ' ' GLN . 35.0 mp0 -68.36 157.39 35.8 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.866 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.572 HD22 HD21 ' A' ' 14' ' ' LEU . 8.9 t-20 -115.36 102.15 54.45 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.659 0.742 . . . . 0.0 110.844 -179.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.431 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.5 Cg_endo -69.87 3.37 2.86 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.677 2.251 . . . . 0.0 112.332 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 34.2 t -52.16 142.67 15.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.838 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 129.22 162.77 11.02 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.474 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -16.34 37.65 Favored 'Trans proline' 0 C--O 1.23 0.095 0 C-N-CA 122.702 2.268 . . . . 0.0 112.375 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 67.9 m -46.8 -45.36 19.94 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.833 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 99.3 p -44.16 -46.84 8.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.785 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.48 -179.939 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.546 -0.222 . . . . 0.0 112.546 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 43.7 t -105.32 149.2 26.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.884 0.374 . . . . 0.0 110.888 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.4 t -75.49 138.11 41.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.815 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.47 104.98 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.526 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 78.6 p -71.98 -49.05 40.53 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.828 0.346 . . . . 0.0 110.885 -179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 77.9 p -128.55 160.61 31.82 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.879 -179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -69.45 112.72 4.67 Favored Glycine 0 N--CA 1.45 -0.393 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.478 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.481 ' HA ' HD22 ' A' ' 8' ' ' LEU . 0.6 OUTLIER -87.31 -53.68 4.71 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.72 0.295 . . . . 0.0 110.866 -179.879 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.6 p30 -85.61 17.69 3.17 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.855 179.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.3 t -76.98 7.32 4.99 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.824 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -107.57 15.53 24.67 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.844 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 30.6 mt -125.16 158.01 35.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.914 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 16.4 mt-10 -92.67 171.3 9.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.882 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.453 HD11 ' CD2' ' A' ' 30' ' ' TYR . 17.4 mt -98.73 152.29 37.79 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.579 0.704 . . . . 0.0 110.954 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.641 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.7 Cg_endo -69.74 -171.21 0.45 Allowed 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.719 2.28 . . . . 0.0 112.417 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.95 147.35 53.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.084 179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.579 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 88.2 -44.66 3.22 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.47 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.641 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 63.2 m95 -68.38 135.92 52.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.779 0.323 . . . . 0.0 110.903 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -149.52 115.61 5.72 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.897 -179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.551 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -75.79 142.0 42.4 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.92 -179.995 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.573 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 38.4 mm -125.34 131.52 72.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.134 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -102.65 117.78 35.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.874 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.453 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.0 t70 -139.12 139.48 23.37 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.578 0.704 . . . . 0.0 110.884 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.411 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 54.6 Cg_endo -69.69 -11.31 30.67 Favored 'Trans proline' 0 N--CA 1.465 -0.183 0 C-N-CA 122.668 2.245 . . . . 0.0 112.437 179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 93.3 t -109.93 -37.98 3.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.155 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.36 -32.85 11.31 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.9 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.453 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.48 -140.78 15.82 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.472 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.605 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 1.9 mp -102.08 109.4 26.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.808 0.337 . . . . 0.0 111.132 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.573 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 32.6 p90 -135.54 133.96 38.94 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.882 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.478 ' N ' ' CD1' ' A' ' 30' ' ' TYR . 2.4 m-30 -90.18 126.8 35.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.927 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.2 t -113.21 117.24 54.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.462 . . . . 0.0 111.125 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.459 ' O ' ' N ' ' A' ' 36' ' ' ARG . 62.4 t0 -95.14 103.31 15.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.856 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 47.7 m-70 -68.6 -16.38 63.83 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.899 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.645 ' CD1' ' N ' ' A' ' 34' ' ' ILE . 0.6 OUTLIER -83.39 -55.49 7.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.121 -179.993 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 63.1 m-20 -93.33 -2.39 54.91 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.854 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.459 ' N ' ' O ' ' A' ' 32' ' ' ASP . 3.5 mpt_? 54.62 47.94 21.47 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 8.7 mtmm -113.54 160.8 18.13 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.919 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -145.12 108.3 4.57 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.14 179.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.453 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 9.4 pt20 -147.88 144.19 27.93 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.919 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . 0.605 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.6 m-85 -76.29 -26.54 55.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.912 -179.832 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -63.6 161.42 14.8 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.854 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 18.7 t-20 -116.62 101.93 53.44 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.614 0.721 . . . . 0.0 110.933 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.479 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 54.2 Cg_endo -69.74 -11.26 30.5 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.637 2.225 . . . . 0.0 112.377 179.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.463 ' C ' ' O ' ' A' ' 43' ' ' PRO . 8.4 t -33.56 -65.77 0.17 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.85 -179.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -63.61 173.1 12.89 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.521 -179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 83.24 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.69 2.26 . . . . 0.0 112.338 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 28.2 p -108.5 124.8 51.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.84 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 48.9 m -114.89 175.81 5.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.953 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.344 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.498 -179.973 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.407 0 N-CA-C 112.501 -0.24 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.4 ' O ' ' C ' ' A' ' 3' ' ' SER . 34.0 t 64.86 42.37 4.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.841 0.353 . . . . 0.0 110.829 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . 0.4 ' C ' ' O ' ' A' ' 2' ' ' SER . 86.3 p -37.48 -41.18 0.43 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.882 -179.787 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 152.61 161.49 10.28 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.546 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 29.6 t -92.83 142.41 27.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.806 0.336 . . . . 0.0 110.924 -179.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 40.4 m -43.41 -50.72 6.81 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.857 -179.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 132.95 121.03 2.18 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.503 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 54.0 mt -91.2 -45.82 8.43 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.769 0.319 . . . . 0.0 110.907 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -96.06 17.98 14.41 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.904 179.841 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 10.0 m -82.02 16.27 1.98 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.908 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -112.93 16.36 19.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.899 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 30.5 mt -115.61 167.67 10.69 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.905 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -97.26 168.31 10.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.859 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.471 HD21 HD22 ' A' ' 42' ' ' ASN . 9.6 mt -89.19 156.67 48.68 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.614 0.721 . . . . 0.0 110.874 -179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.664 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.79 -170.38 0.39 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.614 2.209 . . . . 0.0 112.311 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.62 140.91 48.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.12 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.618 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 94.62 -32.19 6.24 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.505 -179.909 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.664 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 67.4 m95 -81.89 147.72 29.15 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.703 0.287 . . . . 0.0 110.896 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.486 ' O ' ' CG ' ' A' ' 19' ' ' GLU . 2.3 pt-20 -152.71 119.57 5.76 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.888 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.59 141.47 36.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.95 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.578 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 18.2 mm -129.41 132.4 66.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.097 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -106.02 120.6 42.19 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.933 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.425 ' CG ' ' HD2' ' A' ' 24' ' ' PRO . 10.8 t70 -140.37 139.66 21.21 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.561 0.696 . . . . 0.0 110.888 -179.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.425 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.9 Cg_endo -69.67 -8.18 22.94 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.696 2.264 . . . . 0.0 112.376 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 99.5 t -114.89 -37.9 2.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.123 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.31 -29.2 13.3 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.905 -179.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 82.51 -151.73 29.82 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.508 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 1.9 mp -89.81 110.88 22.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-O 120.824 0.345 . . . . 0.0 111.05 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.578 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 46.3 p90 -136.03 130.88 34.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.913 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.437 ' CG ' HD11 ' A' ' 14' ' ' LEU . 5.3 m-30 -88.48 132.79 34.34 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.963 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.4 t -114.62 116.47 52.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.138 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.478 ' OD1' ' CD1' ' A' ' 18' ' ' TRP . 13.3 t0 -98.59 102.03 13.64 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.898 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 51.9 m-70 -72.07 -11.24 60.66 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.84 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.618 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.8 OUTLIER -85.83 -57.2 4.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.129 179.947 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.5 m-80 -87.65 -18.36 29.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.895 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 68.02 47.88 1.02 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.87 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.423 ' HE2' ' CH2' ' A' ' 18' ' ' TRP . 8.5 pttm -139.35 130.96 27.24 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.923 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.1 p -104.19 126.15 51.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.126 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.407 ' NE2' ' HB2' ' A' ' 41' ' ' GLU . 5.3 pt20 -150.63 141.82 23.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.956 179.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 2.9 m-85 -73.78 -21.63 60.1 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.938 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.407 ' HB2' ' NE2' ' A' ' 39' ' ' GLN . 30.0 mm-40 -66.41 154.1 41.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.924 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.471 HD22 HD21 ' A' ' 14' ' ' LEU . 9.0 t-20 -112.3 101.99 53.22 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.597 0.713 . . . . 0.0 110.911 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.405 ' HD2' ' CD2' ' A' ' 14' ' ' LEU . 53.1 Cg_endo -69.79 2.2 3.77 Favored 'Trans proline' 0 C--N 1.34 0.13 0 C-N-CA 122.672 2.248 . . . . 0.0 112.31 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 30.3 t -52.1 148.49 6.18 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.868 -179.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 144.27 165.73 11.11 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.478 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.7 0.7 5.22 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.658 2.239 . . . . 0.0 112.376 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.0 t -108.27 131.68 54.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.834 -179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 2.8 t -109.63 127.74 54.75 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.905 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.459 179.985 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.521 -0.232 . . . . 0.0 112.521 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.6 m -87.26 -60.92 1.84 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.811 0.339 . . . . 0.0 110.8 -179.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.8 m -77.25 -54.95 5.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.911 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -78.33 87.06 1.11 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.512 179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 42.4 t -83.11 -46.56 12.63 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.782 0.325 . . . . 0.0 110.796 -179.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 46.4 t -64.29 151.95 42.38 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.915 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -124.85 -89.19 0.8 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.493 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.0 mt -119.76 121.53 39.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.788 0.328 . . . . 0.0 110.928 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -102.29 171.79 7.27 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.869 179.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . 0.563 ' O ' ' CG ' ' A' ' 11' ' ' GLU . 1.7 t -147.82 178.0 8.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.826 -179.754 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.563 ' CG ' ' O ' ' A' ' 10' ' ' SER . 2.8 pt-20 54.0 32.05 14.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.905 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.441 ' HG ' ' O ' ' A' ' 10' ' ' SER . 27.3 mt -117.48 162.64 17.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.989 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -111.14 173.99 6.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.919 179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.585 HD11 ' CD2' ' A' ' 30' ' ' TYR . 11.6 mt -104.2 154.11 38.48 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.609 0.719 . . . . 0.0 110.956 179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.635 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 54.6 Cg_endo -69.76 -171.78 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.647 2.232 . . . . 0.0 112.368 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.73 149.98 49.76 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.077 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.744 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 84.94 -40.46 3.0 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.539 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.635 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 58.4 m95 -72.51 140.44 48.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.712 0.291 . . . . 0.0 110.995 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -152.24 115.04 4.6 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.922 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.438 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.35 138.6 43.55 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.887 -179.991 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.576 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 34.9 mm -121.13 131.21 73.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.166 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -103.54 117.94 35.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.854 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.44 ' O ' ' N ' ' A' ' 27' ' ' GLY . 12.7 t70 -138.91 137.98 20.55 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.578 0.704 . . . . 0.0 110.88 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.72 -8.26 23.14 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.665 2.244 . . . . 0.0 112.291 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 92.5 t -112.86 -37.97 2.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.169 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . 0.418 ' N ' ' CD1' ' A' ' 26' ' ' TYR . 1.7 m-85 -97.94 -31.98 11.9 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.959 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.44 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.4 -145.49 18.47 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.561 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.596 ' O ' ' CD2' ' A' ' 40' ' ' TYR . 2.1 mp -98.99 108.57 22.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.813 0.339 . . . . 0.0 111.081 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.576 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 31.5 p90 -134.42 131.58 38.35 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.907 179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.585 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.6 m-30 -88.75 122.4 32.12 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.912 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.0 t -108.11 115.62 49.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.146 179.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 57.1 t0 -94.77 101.99 13.84 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.828 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . . . . . . . . . 65.9 m-70 -68.74 -18.76 64.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.862 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.744 HD13 ' CA ' ' A' ' 17' ' ' GLY . 1.1 mp -81.67 -62.73 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.109 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 14.2 m-80 -80.34 -16.37 54.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.867 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . . . . . . . . . 27.5 mmm180 64.11 47.69 3.23 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 -179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.55 ' HD2' ' CH2' ' A' ' 18' ' ' TRP . 11.1 ptpt -133.11 129.44 37.95 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.908 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.7 p -105.34 119.46 39.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.198 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.427 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 7.4 pt20 -150.29 140.5 22.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.91 -179.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . 0.596 ' CD2' ' O ' ' A' ' 28' ' ' ILE . 2.9 m-85 -74.55 -25.08 59.08 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.884 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . . . . . . . . . 15.9 mt-10 -62.06 161.84 10.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.872 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.463 HD22 HD21 ' A' ' 14' ' ' LEU . 10.8 t-20 -118.44 101.93 50.59 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.581 0.705 . . . . 0.0 110.937 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.427 ' HD3' ' NE2' ' A' ' 39' ' ' GLN . 53.7 Cg_endo -69.65 -11.68 31.51 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.677 2.251 . . . . 0.0 112.346 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 23.0 t -42.78 -49.61 5.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.832 -179.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -47.04 176.24 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.795 -0.717 . . . . 0.0 112.508 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.79 159.24 54.11 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.708 2.272 . . . . 0.0 112.277 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 69.7 m 62.64 42.68 8.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.88 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 22.6 t -54.24 -59.67 4.36 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.878 -179.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.312 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.484 179.994 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.246 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.9 m -67.09 -46.88 72.9 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.889 0.376 . . . . 0.0 110.827 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 57.8 p -122.3 160.39 25.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.791 -179.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -81.79 45.66 3.33 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.532 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 24.3 p -123.24 119.54 30.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.891 0.377 . . . . 0.0 110.835 -179.695 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.8 m -151.41 150.26 30.25 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.84 -179.814 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 90.12 64.18 1.24 Allowed Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.545 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.8 mt -76.73 -52.62 9.25 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.818 0.342 . . . . 0.0 110.953 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 63.3 m-20 -87.57 130.91 34.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.948 179.738 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 23.7 p -106.22 14.64 27.3 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.846 -179.688 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -116.88 16.52 15.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.863 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 32.2 mt -110.87 148.58 32.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.963 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 27.1 mt-10 -85.67 169.56 13.35 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.865 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' LEU . . . . . 0.565 HD11 ' CD2' ' A' ' 30' ' ' TYR . 14.3 mt -97.16 154.09 38.25 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.556 0.693 . . . . 0.0 110.947 179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.667 ' HG2' ' CD1' ' A' ' 18' ' ' TRP . 53.5 Cg_endo -69.77 -173.49 0.73 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.721 2.281 . . . . 0.0 112.292 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -65.52 146.91 54.26 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.035 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.666 ' CA ' HD13 ' A' ' 34' ' ' ILE . . . 87.9 -42.14 3.1 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.456 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' TRP . . . . . 0.667 ' CD1' ' HG2' ' A' ' 15' ' ' PRO . 70.8 m95 -71.78 122.3 20.45 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.834 0.35 . . . . 0.0 110.911 -179.871 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.44 ' OE1' HD11 ' A' ' 21' ' ' ILE . 7.5 tt0 -128.3 111.43 13.36 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.885 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.507 ' O ' HD13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -76.17 145.2 40.06 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.854 179.987 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.57 ' HB ' ' CE1' ' A' ' 29' ' ' TYR . 32.8 mm -132.68 133.58 59.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.127 179.872 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -106.06 117.99 35.45 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.912 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.464 ' O ' ' N ' ' A' ' 27' ' ' GLY . 11.1 t70 -138.36 139.67 25.87 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-O 121.64 0.733 . . . . 0.0 110.891 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.42 ' HD2' ' CG ' ' A' ' 23' ' ' ASP . 53.7 Cg_endo -69.71 -11.8 31.67 Favored 'Trans proline' 0 C--O 1.232 0.225 0 C-N-CA 122.704 2.269 . . . . 0.0 112.33 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 94.0 t -109.36 -37.95 3.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.266 -0.425 . . . . 0.0 111.162 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' TYR . . . . . . . . . . . . . 1.9 m-85 -98.28 -32.27 11.63 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.846 -179.879 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 23' ' ' ASP . . . 89.13 -140.95 16.0 Favored Glycine 0 N--CA 1.452 -0.248 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.439 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 1.9 mp -102.91 108.87 25.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.848 0.356 . . . . 0.0 111.179 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' TYR . . . . . 0.57 ' CE1' ' HB ' ' A' ' 21' ' ' ILE . 25.0 p90 -133.39 131.14 39.68 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.922 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' TYR . . . . . 0.565 ' CD2' HD11 ' A' ' 14' ' ' LEU . 3.8 m-30 -88.27 119.65 28.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.916 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.4 t -101.88 115.57 43.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.098 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.615 ' OD2' ' CZ3' ' A' ' 18' ' ' TRP . 3.8 m-20 -88.87 112.96 23.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.871 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' HIS . . . . . 0.451 ' C ' HD12 ' A' ' 34' ' ' ILE . 87.6 m-70 -86.37 -7.07 58.75 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.946 -179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.666 HD13 ' CA ' ' A' ' 17' ' ' GLY . 0.7 OUTLIER -97.11 -49.13 12.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.097 179.99 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 -96.06 -13.66 23.53 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.85 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ARG . . . . . 0.406 ' HA ' ' O ' ' A' ' 32' ' ' ASP . 25.3 mmt180 65.32 42.49 3.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.851 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . 0.558 ' HD2' ' CZ2' ' A' ' 18' ' ' TRP . 0.1 OUTLIER -121.51 129.86 53.18 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.877 -179.986 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -111.21 116.1 30.48 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.149 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . 0.453 ' NE2' ' HD3' ' A' ' 43' ' ' PRO . 6.8 pt20 -145.96 146.39 31.01 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.935 -179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 4.7 m-85 -77.96 -30.9 50.59 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.939 -179.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLU . . . . . 0.409 ' O ' ' CD2' ' A' ' 30' ' ' TYR . 4.1 mt-10 -58.25 166.75 1.53 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.845 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.417 ' ND2' HD21 ' A' ' 14' ' ' LEU . 12.5 t-20 -120.81 102.0 44.87 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.663 0.744 . . . . 0.0 110.906 -179.937 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' PRO . . . . . 0.55 ' HG3' ' CH2' ' A' ' 18' ' ' TRP . 53.1 Cg_endo -69.77 -1.58 8.73 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.682 2.255 . . . . 0.0 112.271 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 7.9 t -52.02 154.47 2.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.88 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 158.52 166.54 17.85 Favored Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 120.805 -0.712 . . . . 0.0 112.533 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.69 2.54 3.41 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.749 2.3 . . . . 0.0 112.345 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 2.5 m -112.77 107.34 15.93 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.793 -179.77 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 50.1 m -119.2 129.81 55.17 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.852 -179.838 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.282 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.507 -179.996 . . . . . . . . 0 0 . 1 stop_ save_